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ABSTRACT
Along with the many health benefits of regular physical activity, there is also the 
risk of injury. Around 30-50% of all sporting injuries involve damage to tendons 
and in long-distance runners the lifetime risk of developing Achilles tendinopathy 
exceeds 50%. Patellar tendinopathy (PT) is likewise common among sporting 
populations, with prevalence rates higher than 30% in both volleyball and 
basketball players.
The main aims of this thesis were to investigate whether novel genetic variants 
(copy number variation (CNV) and single nucleotide polymorphisms (SNPs)) in 
candidate genes were associated with Achilles tendon pathology (ATP) and to 
investigate whether DNA methylation status was altered in patellar 
tendinopathy, within the promoter regions of candidate genes.
Copy number variation was investigated in the ADAM8, CASP8, COL4A1, 
COL5A1, MMP23B, MMP3 and TNC genes across all ATP cohorts. The British and 
South African ATP cohorts were genotyped for the CASP3 rsl049253 and 
TNFRSF1A rs4149577 single nucleotide polymorphisms. These studies were 
carried out using fluorescence based TaqMan qPCR. DNA methylation was 
measured in the ADAMT54, MMP11 and TIMP1 genes by Pyrosequencing, using 
DNA isolated from healthy and tendinopathic patellar tendon tissue.
On the whole, the genetic association studies on copy number variation within 
this thesis showed that CNV within the loci we investigated does not appear to 
be a risk factor for ATP. Nevertheless, significant differences in discrete copy 
number were reported within the COL5A1 gene between the AUS CON and ATP
XIX
groups (p = 0.012 using the Hs00180523_cn assay) and within the COL4A1 
gene between the combined CON and ATP groups (p = 0.014 using the 
Hs00739915_cn assay). There was also a significant difference in copy number 
within the MMP3 gene between the AUS CON and ATP groups (p = 0.035 using 
the Hs02908568_cn). However, these significant findings were not replicated 
when data were analysed as continuous copy number, therefore further 
investigation would be needed to replicate these findings in other cohorts. 
Similarly, the genetic association studies on the single nucleotide polymorphisms 
TNFRSF1A rs4149577 and CASP3 rsl049253 found no associations with ATP 
within combined and individual South African and UK cohorts.
The DNA methylation studies within this thesis showed that the methylation 
status of the promoter regions of the ADAMTS4, MMP11 and TIMP1 genes was 
altered at certain CpG sites in patellar tendinopathy compared to controls. There 
were significant differences in methylation status reported between the CON and 
PT groups for CpG site 3 of the ADAMT54 gene (p = 0.016), CpG site 4 of the 
MMP11 gene (p = 0.045) and CpG site 2 of the TIMP1 gene (p = 0.012).
The results from this thesis provide evidence that copy number variation within 
the genes studied may not be as important in the risk of developing ATP. This 
thesis has also excluded two SNP variants as risk factors for ATP in the cohorts 
investigated. The preliminary studies on DNA methylation status within the 
ADAMT54, MMP11 and TIMP1 genes suggest that DNA methylation within these 
genes may be an important risk factor for patellar tendinopathy.
xx
CHAPTER 1: LITERATURE REVIEW
1.1 INTRODUCTION
Tendon pathology is a multifactorial disorder prevalent among sporting 
populations (Meeuwisse 1994; Maffulli et al. 2003). The increased stress exerted 
on tendons during exercise can lead to damage in both professional and 
recreational athletes, due to repetitive mechanical loading (Maffulli et al. 2003; 
Xu and Murrell 2008; Collins and Raleigh 2009). A variety of risk factors are known 
to predispose to Achilles tendon pathology (ATP) and research has identified that 
genetics plays a prominent role in an individual's susceptibility (Raleigh and Collins
2012) .
1.2 TENDON ANATOMY AND PHYSIOLOGY
In general, a tendon is considered a connective tissues that connects muscle to 
bone (Benjamin et al. 2008). Tendons transmit the force generated by muscle to 
bone and therefore facilitate joint movement (Xu and Murrell 2008; Birch 2007). 
The release and storage of elastic strain energy is another function of tendons, 
which helps to aid locomotion (Birch 2007). Tendons have two junctional regions, 
known as the myotendinous junction and the osteotendinous junction (Reinking 
2012). Tendons exhibit high mechanical strength, optimal elasticity and good 
flexibility to allow movement at the joint, while limiting muscle damage by acting 
as a buffer to absorb external forces (Sharma and Maffulli 2005; Sakabe and Sakai 
2011) .
Typically tendons consists of fibroblasts called tenocytes (tendon cells) intermixed 
with a highly organised extracellular matrix (ECM) abundant in collagen (Cook et
1
al. 2002; Sakabe and Sakai 2011). Tenocytes are flat, spindle shaped cells that 
are sparsely distributed among the tendon (Cook et al. 2002). These tenocytes 
are responsible for the synthesis of all ECM components, namely the ground 
substance and collagen, and constitute around 90-95% of the cellular component 
of tendons (Khan et al. 1999; Sharma and Maffulli 2005). Collagen is a principle 
structural protein component of tendons, with type I collagen being the most 
prevalent (Mokone et al. 2006). However, numerous other collagen types are 
present, including type II, III, V, VI, IX, and XI (Benjamin et al. 2008). The main 
role of collagen within the tendon is to resist tension yet allowing a level of 
compliance and this is believed to be possible due to its hierarchical architecture 
(Benjamin et al. 2008). Collagen is arranged in hierarchical levels of increasing 
complexity, starting with the smallest unit, the collagen fibril (Khan et al. 1999; 
Karousou et al. 2008) (Figure 1.1). The fibrils combine to form fibres, which 
make up fascicles (Karousou et al. 2008). More specifically, triple-helix 
polypeptide chains of tropocollagen form microfibrils and microfibrils combine to 
form fibrils (Benjamin et al. 2008). Fibrils then assemble into fibres (primary 
bundles), fascicles (secondary bundles), tertiary bundles and ultimately the 
tendon itself (Sharma and Maffulli 2005). Collagens such as type III and V form 
heterotypic fibres with type I collagen (Mokone et al. 2006).
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Figure 1.1 The structural organisation of collagen in tendon. Image adapted from 
Khan et al. (1999).
A thin connective tissue layer called the endotenon is present between the 
fascicles and fibre bundles, functioning to facilitate sliding between the fascicles 
(Benjamin et al. 2008) (Figure 1.1). This role is essential as it enables tendons 
to change shape as their associated muscles contract, as well as transmit tension 
with the changing angles of a joint when it moves. The epitenon, of which the 
endotenon is an extension of, is a further loose connective tissue sheath that 
covers the entire tendon and provides vascular, lymphatic and nerve supply (Khan 
et al. 1999). In comparison to skeletal muscle, oxygen supply to tendons is said 
to be over 7 times lower (Sharma and Maffulli 2005) due to poorer vascularity 
(Young et al. 2005). The lower metabolic rate is beneficial for tendons to maintain 
tension and support loads for long periods, however, it can result in a slower 
healing in response to injury (Young et al. 2005; Sharma and Maffulli 2005).
In addition to tenocytes and collagen, the ECM consists of elastin, water and a 
complex network of protein molecules (Figure 1.2) (Karousou et al. 2008; 
Reinking 2012). These are often described as the ground substance and their 
presence is minimal in normal tendon (Cook et al. 2002). The ground substance 
of the ECM contains proteoglycans, glycoproteins, glycosaminoglycans and other 
specialised proteins including enzymes (Sharma and Maffulli 2005; Xu and Murrell 
2008). Proteoglycans are glycosylated proteins (protein-polysaccharide 
complexes) that have both structural and signalling roles within the tendon 
(Figure 1.2) (Xu and Murrell 2008). They are hydrophilic proteins that aid cell 
migration and the diffusion of water-soluble molecules (Sharma and Maffulli 
2005). Their hydrophilic nature enables them to trap water, affecting the 
viscoelastic properties of tendon and assisting the tendon to resist compressive 
forces (Xu and Murrell 2008). Indeed, proteoglycans have a number of vital 
functions within the cell that include water retention, ion transport, nutrient 
diffusion and the mediation of cell-matrix interactions (Xu and Murrell 2008). They 
consist of a protein core with attached glycosaminoglycan (GAG) sidechains and 
tendons contain a range of different proteoglycans (Birch 2007). Proteoglycans 
found in tendons include decorin, biglycan, fibromodulin, versican, lumican and 
the large aggregating proteoglycan aggrecan (Birch 2007; Rees et al. 2000). 
Proteoglycans, such as aggrecan, can form complexes with other proteoglycans 
and collagen (Xu and Murrell 2008). Proteoglycans have been shown to interact 
with collagen fibres and regulate collagen fibril diameter through their roles in 
collagen fibril formation and maturation (Birch 2007; Xu and Murrell 2008).
Proteoglycan Proteoglycan
ECM
C E LL
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Figure 1.2 Schematic overview of the tendon ECM showing the network of 
connected molecules, including collagen and proteoglycans, surrounding and 
supporting the cell (tenocyte).
Tenascin-C is a large hexametric glycoprotein component of the ECM and part of 
the tenascin family (Figure 1.3) (Midwood et al. 2011). It has been implicated in 
a number of cellular processes including cell migration, proliferation and apoptosis 
(Minear et al. 2011). Tenascin-C expression is distinct and tightly controlled, with 
little or no expression in healthy adult tissues (Midwood et al. 2011). Expression 
is up-regulated in tissues undergoing mechanical loading and during wound 
healing, while is down-regulated after tissue repair (Sharma and Maffulli 2005;
Midwood et al. 2011). In addition, tenascin-C also has elastic properties and roles
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in collagen fibre alignment and orientation, highlighting its structural role in 
tendon (Sharma and Maffulli 2005).
Matrix metalloproteinases (MMPs) are a large family of over 20 enzymes involved 
in degradation and remodelling of the ECM (Karousou et al. 2008; Posthumus et 
al. 2011). They are zinc-containing enzymes, known to degrade a range of 
collagenous and non-collagenous ECM components as well as being involved in 
the activation of other MMPs (Posthumus et al. 2011; Raleigh et al. 2009). MMPs, 
along with their inhibitors, tissue inhibitor of metalloproteinases (TIMPs), play an 
important role in tendon homeostasis (Xu and Murrell 2008). Matrix 
metalloproteinase 3 (MMP3) (Figure 1.3) is one member of this family MMP3, 
which can degrade collagenous and non-collagenous ECM proteins (Somerville et 
al. 2003; Visse and Nagase 2003).
Growth differentiation factors (GDFs) are part of the transforming growth factor 
beta (TGF-p) superfamily with important functions in tissue growth and 
homeostasis, including tendon tissue (Posthumus et al. 2010). GDF5 (Figure 1.3) 
is involved in the growth, repair and maintenance of bone and cartilage, as well 
as musculoskeletal soft tissues including tendon (Foster et al. 2012). In relation 
to cartilage, GDF-5 functions in chondrogenesis (cartilage development), 
chondrocyte proliferation and the maintenance and repair of synovial joints 
(Reynard et al. 2011).
Collagen type III (major fibrillar collagen)
COL3A1
Growth dilTcrentiation factor ? (disulfide- 
linked homodimcr)
Collagen i>pc I (major 
fibnllar collagen)
COL!At. COI.IA2
mam
Collagen type V  (minor 
fibrillar collagen)
COLS AI. COL5A2 Matrix metalloproteinase 3 
(/inc dependent cn/>mc)
MMP3
Tcnascin C 
(hcxamcnc 
glycoprotein)
TNC
Figure 1.3 Diagram showing the general structural ECM components of tendon, 
consisting of major and minor fibrillar collagens and associated proteins including 
tenascin C and matrix metalloproteinase 3 (MMP3). Adapted from Collins and
Raleigh (2009) and Foster et al. (2012).
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1.2.1 Achilles Tendon
The human Achilles tendon permits plantarflexion and dorsiflexion of the foot at 
the ankle joint (Figure 1.4) (Benjamin et al. 2008). The myotendinous junction 
of the Achilles tendon is where it originates from the soleus and gastrocnemius 
muscles, while the osteotendinous junction is where the Achilles tendon inserts 
into the calcaneus (heel) (Cook et al. 2002; Lesic and Bumbasirevic 2004). In 
addition to the epitenon described previously, the Achilles tendon is further 
encased in a single layer of connective tissue cells called the paratenon. 
Collectively the epitenon and paratenon are often termed the peritendon (Schepsis 
et al. 2002; Cook et al. 2002). The paratenon, consisting mainly of type I and 
type III collagen fibrils with some elastic fibres, is a highly vascularised tissue 
responsible for the main blood supply to the tendon (Khan et al. 1999; Lesic and 
Bumbasirevic 2004). During normal physiological movement, the Achilles tendon 
is subjected to high strains and can be considered as an energy storing tendon 
(Birch 2007).
Figure 1.4 Image of Achilles tendon and associated gastrocnemius and soleus 
muscle (http://www.valleo.com/achilles_tendonitis).
Dorsiflexion
* Plantarflexion
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1.2.2 Patellar Tendon
The patellar tendon, in conjunction with the quadriceps tendon, permits extension 
of the knee and connects the patella (knee cap) to the tibia (Figure 1.5) 
(Tandeter and Shvartzman 1999; Khan et al. 1998). By definition it is a ligament 
as it connects bone to bone, however, it is typically referred to as the patellar 
tendon. Supporting knee ligaments including the anterior and posterior cruciate 
ligaments (ACL and PCL respectively) and the medial and lateral collateral 
ligaments (MCL and LCL respectively) help to provide stability at the joint (Figure 
1.5) (Tandeter and Shvartzman 1999).
Quadriceps
muscles
Femur
Articular 
cartilage
Lateral condyle
Posterior cruciate 
ligament 
Anterior cruciate 
ligament 
Lateral collateral 
ligament
Fibula
Tibia
Quadriceps
tendon
Patella (normally 
in center of knee)
Medial collateral 
ligament
Meniscus
Figure 1.5 Image of the right knee showing the patellar tendon and associated 
bones (femur, patella, tibia and fibula) and knee ligaments. Ligaments shown are 
outlined in boxes and include: posterior cruciate ligament (PCL); anterior cruciate 
ligament (ACL); lateral collateral ligament (LCL) and medial collateral ligament
(MCL) (http://orthotape.com/Patella_Knee_support_band_strap.asp).
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1.3 TENDON PATHOLOGY
The understanding of the molecular basis to tendinopathy has changed over time 
(Rees et al. 2013). Before the 1990s, tendinitis was the term used to describe 
painful tendons, implying discomfort of an inflammatory nature (Christian et al. 
2014). This tendinitis model was widely accepted and it seemed that inflammation 
was the process responsible for tendon pain. Further investigation typically 
showed a lack of inflammatory cells in tendon, despite other molecular disruption 
(Cook and Purdam 2009; Rees et al. 2013). However, while inflammation may not 
be the dominant pathology, it is believed that the inflammatory response may 
play a role at different stages (Rees et al. 2013).
The term tendinopathy is now widely accepted and used to describe a process of 
tendon pain classified as degeneration, caused from an abnormal or failed healing 
response following repetitive mechanical loading (Rees et al. 2013; Christian et 
al. 2014; Samiric et al. 2009). Apart from the physical symptoms experienced by 
an individual, at a molecular level the tendon has undergone a number of changes 
that are atypical of normal tendon turnover (Khan et al. 1998; Parkinson et al. 
2010). Microscopically, visible changes can be seen in the appearance of the ECM 
(Parkinson et al. 2010). Whereas normal tendon consists predominantly of an ECM 
abundant in highly organised Type I collagen, tendinopathic tendons often displays 
a disorganisation of the ECM and collagen fibres (Samiric et al. 2009; Parkinson 
et al. 2010). In the long term, tendinopathy that is not addressed can lead to 
permanent tissue damage from a viscous cycle of matrix disorganisation, disrepair 
and subsequent degeneration of tendon tissue (Parkinson et al. 2010).
Furthermore, research now leans towards a multistage model to describe 
tendinopathy. (Cook and Purdam 2009). The three stages (reactive tendinopathy, 
tendon disrepair and degenerative tendinopathy) of tendinopathy described by 
Cook and Purdam (2009) highlight the complexity of tendinopathy and the clinical 
and molecular changes that can differentiate each stage. In brief, reactive 
tendinopathy (stage 1) is typified by a non-inflammatory proliferative response 
that results in thickening of part of the tendon (Cook and Purdam 2009). This is a 
short-term adaptation in response to overload, in an attempt to reduce stress 
and/or to resist compression (Cook and Purdam 2009). Tendon disrepair (stage 
2) is characterised by a further increase in the number of cells and subsequent 
protein synthesis of collagens and proteoglycans, in an effort to attempt tendon 
healing (Cook and Purdam 2009). This disproportionate increase in cellular and 
protein components leads to disorganisation of the ECM (Cook and Purdam 2009). 
Degenerative tendinopathy (stage 3) describes the longer-term effects of 
tendinopathy, resulting in widespread disorganisation of the ECM and areas of cell 
death from apoptosis (Cook and Purdam 2009). Once a tendon has reached this 
stage, some of the pathological changes are likely to be permanent (Cook and 
Purdam 2009).
Throughout this thesis the term tendinopathy will be used to describe the above. 
When discussing tendinopathy and tendon rupture collectively, the term tendon 
pathology will be used.
1.3.1 Epidemiology
The epidemiology of tendinopathy varies amongst active and sedentary 
individuals, as well as in different sports and with regard to different tendons 
(Sobhani et al. 2013; de Jonge et al. 2011; Christian et al. 2014; Young et al. 
2005). In general, tendon related injuries have been said to account for 30-50% 
of all sporting injuries, with 6-18% of these injuries involving the Achilles tendon 
(September et al. 2009; Jarvinen et al. 2005). Despite being the strongest tendon 
in the body, the Achilles is prone to damage and rupture (Lesic and Bumbasirevic 
2004) and is the most commonly ruptured tendon in humans (Young et al. 2005). 
There is a 52% lifetime risk of Achilles tendinopathy in elite long-distance runners 
and an annual incidence rate as high as 9% has been reported in such individuals 
(de Jonge et al. 2011). Furthermore, some of the highest incidence rates (per 
1000 athletes per season) of ankle and foot injuries have been observed in 
runners, ballet dancers and gymnasts (Sobhani et al. 2013). This is not surprising, 
since the increased stress on tendons during physical exercise means that tendon 
injuries are more common in both professional and recreational athletes, typically 
as a result of repetitive mechanical loading (Maffulli et al. 2003; Xu & Murrell, 
2008; Collins & Raleigh, 2009). However, the occurrence of tendon injuries in the 
general population is also evident and the incidence in both athletes and sedentary 
individuals is said to be increasing (Young et al. 2005; de Jonge et al. 2011). 
Indeed, incidence and prevalence rates of Achilles tendinopathy of 1.85 and 2.01 
per 1000 respectively have been described in the general population (de Jonge et 
al. 2011).
Although much of the research in this thesis is concerned with Achilles 
tendinopathy and rupture, Chapter 6 describes the studies into epigenetics, which
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were investigated in the patellar tendon. Patellar tendinopathy is prevalent among 
athletic populations, particularly in athletes competing in sports involving jumping 
(Samiric et al. 2009; Christian et al. 2014). Over 30% of sport related injuries are 
said to be due to patellar tendinopathy (Samiric et al. 2009), with prevalence rates 
0f 44.6% and 31.9% reported in volleyball and basketball players respectively 
(Christian et al. 2014). However, while the term "jumper's knee" can be justified 
by the prevalence in sports such as basketball, where repetitive loading of the 
patellar tendon is apparent, patellar tendinopathy is also common in sedentary 
individuals (Samiric et al. 2009).
1.3.2 Achilles Tendon Pathology
Achilles tendon pathology (ATP) defines a range of Achilles tendon injuries, 
broadly classified as Achilles tendinopathy and Achilles tendon rupture. However, 
further classification identifies complete or partial ruptures, as well as the 
anatomical location and nature of tendinopathy (Schepsis et al. 2002; Raleigh &
Collins, 2012).
1.3.2.1 Non-Insertional Achilles Tendinopathy
Non-insertional Achilles tendinopathy is also termed mid-portion Achilles 
tendinopathy and describes pain and swelling in the tendon 2-7 cm from insertion 
into the calcaneus (van Dijk et al. 2011) (Figure 1.6B). Tendinosis may also be 
evident, describing the presence of tendon degeneration with a lack of clinical or 
histological inflammation, which may be asymptomatic (Lesic and Bumbasirevic 
2004; van Dijk et al. 2011).
Figure 1.6 MRIs of a normal and tendinopathic Achilles tendon.
A. Magnetic resonance image (MRI) of a normal Achilles tendon. B. MRI of a 
pathological degenerate tendon with non-insertional Achilles tendinopathy, where 
a change in signal intensity and swelling/thickening can be seen in the mid-portion 
of the tendon. Images from The Country Clinic, Northampton with permission.
1.3.2.2 Insertional Achilles Tendinopathy
Insertional tendinopathy is described as heel pain and tenderness localised at the 
Achilles tendon insertion, where the presence of bone spurs and calcification is 
common (Schepsis et al. 2002; Lesic and Bumbasirevic 2004). Bone spurs may 
be palpable and these can cause small tears in the tendon at the tendon-bone 
junction (van Dijk et al. 2011). In addition, insertional Achilles tendinopathy is 
often associated with retrocalcanael bursitis and/or Haglund's deformity, although 
the presence of these pathologies alone is not conclusive of a diagnosis of 
tendinopathy. (Schepsis et al. 2002; Lesic and Bumbasirevic 2004).
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1.3.2.3 Achilles Tendon Rupture
The tendon is designed to withstand a certain level of physiological stress exerted 
on it through normal movement, however, stretch exerted that is greater than 5% 
elongation causes damage to the collagen fibres themselves and can lead to 
rupture (Khan et al. 1998). Although Achilles tendon rupture can develop as an 
end result of Achilles tendinopathy, different molecular changes have been 
observed that distinguish it from tendinopathy (Jones et al. 2006; Corps et al. 
2008; Parkinson et al. 2010). Indeed, apparent sporadic rupture may occur 
without any symptoms of pain, yet at a structural and molecular level, altered 
expression levels of certain matrix metalloproteinases has been detected (Jones 
et al. 2006; Parkinson et al. 2010). For example, Jones et al., (2009) showed that 
ADAMTS4 (a disintegrin and metalloproteinase with thrombospondin motifs 4) was 
up-regulated in ruptured Achilles tendons, compared with painful and normal
Achilles tendons.
1.3.3 Patellar Tendinopathy
Patellar tendinopathy is a chronic degenerative condition, characterised by pain 
and tenderness in the knee, that can prevent or impede an individual from 
participating in physical activity and exercise (Parkinson et al. 2010; Samiric et 
al. 2009). Typically the pain is localised to the proximal insertion of the patellar 
tendon to the patella, which intensifies with prolonged activity and flexion of the 
knee (Christian et al. 2014). It is commonly first recognised when an individual is 
asked to undergo a declining squat test (Christian et al. 2014). Ultrasonography 
and MRI can then be used to clinically diagnose patellar tendinopathy, often 
revealing an abnormal tendon appearance and a wider or thicker portion of tendon 
at the site of tenderness in the knee (Christian et al. 2014) (Figure 1.7B). For 
professional athletes, as well as recreational athletes, this chronic pathology can 
mean having to limit training or even end their careers or sporting hobbies 
(Christian et al. 2014).
16
Figure 1.7 MRIs of a normal and abnormal patellar tendon.
A. MRI of a normal patellar tendon. B. MRI of a pathological degenerate proximal 
patellar tendon, showing a change in signal intensity and increased tendon 
thickness characteristic of patellar tendinopathy. Images from The Country Clinic, 
Northampton with permission.
1.3.4 Patellar Tendon Rupture
As with Achilles tendon rupture, it evident that while changes in ECM composition 
and disruption of collagen organisation is concordant in both tendinopathy and 
rupture, these conditions display differences with each other when compared to 
normal tendon (Jones et al. 2006; Cook and Purdam 2009). If the tendon is 
elongated beyond its normal physiological range, then trauma can occur in the 
form of tears in the collagen fibres (Khan et al. 1998). In relation to patellar tendon 
rupture, the risk of rupture is high in sports involving jumping, such as basketball 
(Khan et al. 1998; Christian et al. 2014). This is due to the high levels of stress
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exerted on the patellar tendon that can be 6-8 times an individual's body weight 
(Khan et al. 1998).
1.3.5 Current Management and Treatment
Despite overloading being a key contributing factor of tendinopathy, mechanical 
loading is in fact a vital treatment strategy for managing the condition (Cook and 
Purdam 2014). A complete loss of loading and isolation of the tendon without 
mechanical stimuli can have a detrimental effect on tendon strength and will result 
in a catabolic effect, as tendon homeostasis is maintained through physiological 
loading within a healthy range (Killian et al. 2012; Cook and Purdam 2014; 
Reinking 2012). Mechanical loading maintains tendon homeostasis through ECM 
remodelling, as many of the ECM components are up-regulated in response to 
such stimuli (Killian et al. 2012). However, the treatment of tendinopathy with a 
measured mechanical loading regime can become challenging in athletes 
competing competitively and especially during the peak season of their chosen 
sport (Cook and Purdam 2014). Without any decrease in current activity levels, it 
can be hard for the tendon ECM to be given chance to remodel and repair, 
therefore appropriate loads are important as to not intensify or trigger reactive 
tendinopathy (Cook and Purdam 2014).
The modification of training programmes and physical activity (reduction in 
intensity, frequency and duration) may be necessary initially and the complete 
cessation of activity should be assessed on an individual basis (Schepsis et al. 
2002; Reinking 2012). If required, the correction of any foot alignment problems 
is important in relation to Achilles tendinopathy, as excessive pronation can 
increase the stress exerted on tendons like the Achilles (Schepsis et al. 2002).
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Eccentric strength training (muscle lengthening under load) has been shown to be 
beneficial in the treatment of tendinopathy, where eccentric declining squat 
training is considered an important part of the treatment of patellar tendinopathy 
(Christian et al. 2014). Indeed, eccentric strength training has been shown to 
reduce pain in both Achilles and patellar tendinopathy, through the reduction of 
blood flow to neovessels and the subsequent decline in pain from nerve endings 
(Christian et al. 2014).
Injection therapies, such as high volume ultrasound-guided injections, have been 
effective in treating the pain associated with tendinopathy by impeding 
neovascularisation and may be more effective than eccentric training (Christian et 
al. 2014). Meanwhile, the injection of steroids such as corticosteroids may in fact 
cause tendon ruptures (Schepsis et al. 2002). Finally, although considered a last 
resort to the less invasive treatment measures described above, surgical 
intervention may be necessary in certain chronic cases of tendinopathy, where 
conservative therapies have not been effective (Christian et al. 2014; Kader et al. 
2002) .
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1.4 RISK FACTORS ASSOCIATED WITH TENDON PATHOLOGY
ATP has a complex, multifactorial aetiology, which is yet to be fully defined. A 
range of both intrinsic and extrinsic factors have been identified that increase an 
individual's risk of developing ATP (Meeuwisse, 1994; Raleigh & Collins, 2012) 
(Figure 1.8). It is the presence of numerous factors together that increase the 
risk. Following predisposition and susceptibility, an individual may experience an 
inciting event during training or physical activity, resulting in tendon injury 
(Raleigh & Collins, 2012). The severity and impact of these injuries on athletes 
highlights the importance of research in this area.
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Figure 1.8 Risk Factors for Tendon Injury.
Graphic diagram illustrating the role of intrinsic and extrinsic risk factors in the 
aetiology of tendon pathology (Raleigh and Collins 2012). Several of the intrinsic 
risk factors shown are considered multifactorial phenotypes, determined by 
genetic (G) and environmental (E) factors. The arrow leading from the injured 
athlete back to intrinsic risk factors illustrates that individuals are predisposed to 
additional injuries following recovery (Raleigh & Collins, 2012).
1.4.1 Intrinsic Risk Factors
Intrinsic risk factors such as flexibility, biological age and previous injury can 
predispose individuals to ATP (Raleigh & Collins, 2012) (Figure 1.8). Non- 
modifiable intrinsic factors include increasing age, gender and an individual's 
genetics. Modifiable intrinsic risk factors include muscle inflexibility and obesity
(Reinking 2012). Many intrinsic factors have both an environmental and genetic
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component, showing that these phenotypes are themselves multifactorial (Raleigh 
& Collins, 2012).
1.4.1.1 Age and Gender
Research has shown that older age and male gender appear to be predisposing 
risk factors for tendon injuries including Achilles tendinopathy and Achilles tendon 
rupture (Kraemer et al. 2012). Achilles tendon rupture has been shown to be more 
common in men than women (Vosseller et al. 2013). Research suggests that the 
lower incidence of Achilles tendon injuries in women is due to the decreased 
stiffness and greater elongation noted in the female Achilles during plantarflexion 
and following exercise (Joseph et al. 2014).
1.4.1.2 Anatomical Factors
Anatomic factors affecting the lower limb have also been shown to increase the 
risk of tendon pathology (Jarvinen et al. 2005; Schepsis et al. 2002). These 
include hyper and hypo-pronation, as well as decreased joint flexibility and muscle 
weakness (Jarvinen et al. 2005).
1.4.1.3 Systemic Diseases
There is some evidence to show that certain systemic diseases, such as 
rheumatoid arthritis, can manifest with ATP and may affect the risk of tendon 
injury and/or rupture (Jarvinen et al. 2005; Suzuki and Okamoto 2014; Kraemer 
et al. 2012). Other systemic diseases including gout and ankylosing spondylitis 
(both types of arthritis) have also been suggested to affect the risk of tendon 
rupture (Jarvinen et al. 2005; Gerster et al. 1996). Despite these reports, the 
effect of these concurrent systemic diseases on the risk of Achilles tendon injuries
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and tendon ruptures in general is considered negligible (Jarvinen et al. 2005). 
Only ~2% of Achilles tendon injuries are thought to be attributed to the presence 
of an underlying systemic disease, while the major influencing factor is overuse 
(Jarvinen et al. 2005). These diseases were taken into account when recruiting 
participants and exclusion criteria were implicated where appropriate.
1.4.2 Extrinsic Risk Factors
Further exposure to extrinsic factors (external modifiable factors that impact on 
an athlete) including training volume, exercise intensity, training errors, 
environmental conditions, ground surface and medication, can result in 
predisposed individuals becoming susceptible to ATP (Figure 1.8) (Meeuwisse 
1994; Raleigh and Collins 2012). Ultimately, the occurrence of an inciting event 
leads to tendon injury (Figure 1.8).
1.4.2.1 Activity Levels
As previously described, tendon injuries are prevalent amongst the athletic 
population due to the high levels of physical activity and common overuse due to 
repetitive mechanical loading of the joints (Collins and Raleigh 2009) (Figure 
1.8). Research has shown that 75% of ruptures to the Achilles tendon are related 
to sports (Jarvinen et al. 2005).
1.4.2.2 Environment, Training Errors, Footwear
Other extrinsic risk factors implicated in the risk of ATP include environment 
conditions such as cold weather, a hard training surface and the footwear worn 
(Jarvinen et al. 2005; Raleigh and Collins 2012).
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1.4.2.3 Steroids and Fluoroquinolones
Use of the antibiotics fluoroquinolones has been shown to associate with 
tendinopathy, as research suggests that approximately 2-6% of Achilles tendon 
ruptures in individuals over 60 years old may be credited to quinolone use 
(Sendzik et al. 2005). Fluoroquinolones appear to cause changes in the ECM and 
disrupt tendon homeostasis (Khaliq and Zhanel 2003; Sendzik et al. 2005). 
Changes in collagen fibril size and organisation has been observed in cultured 
human tendon cells, as well as increases in matrix metalloproteinases and the 
apoptosis related caspase 3 (Sendzik et al. 2005). Furthermore, 
neovascularisation, degenerative tendon lesions and necrosis and have also been 
reported in human patients, as a result of certain fluoroquinolones use (Khaliq and 
Zhanel 2003). Likewise, the use of steroids, both injectable corticosteroid 
injections as well oral anabolic steroids taken by competitive athletes, has been 
shown to increase the risk of tendon rupture (Schepsis et al. 2002; Jarvinen et al. 
2005). In relation to anabolic steroid use, tendons have been shown to be stiffer 
and absorb lower loads before rupturing (Schepsis et al. 2002).
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1.4.3 Genetic Risk Factors
In 1989, Jozsa and colleagues were the first to show an association between the 
ABO blood groups and tendon rupture. Specifically, a significant association 
between blood group O and tendon rupture was demonstrated in a Hungarian 
population. Over 50% of tendon rupture patients were blood group O and this 
blood group was overrepresented in comparison with the control population (Jozsa 
et al. 1989). Later in 1992, the increased frequency of tendon injury in people 
with blood group O was confirmed (Kujala et al. 1992). Nevertheless, more recent 
studies have failed to find an association with blood group (Reinking 2012). In 
fact, current research points towards genes proximal to the ABO gene locus on 
chromosome 9 as causal factors for ATP (Mokone et al. 2005; Mokone et al. 2006; 
Reinking 2012). The ABO gene locus is located on chromosome 9q34 and the 
initial research on blood groups and tendon injury was what led to interest in other 
genes located on this chromosome.
Furthermore, family history has been shown to be an important factor in the 
development of ATP (Kraemer et al. 2012). Indeed, a positive family history of 
Achilles tendinopathy was shown to result in a fivefold increased risk of developing 
the condition (Kraemer et al. 2012). Specifically, Achilles tendinopathy patients 
had a significantly increased number of relatives with Achilles tendon disorders 
(Kraemer et al. 2012). This evidence supports the findings from the numerous 
genetic association studies to date investigating genetic variants and the risk of 
ATP. These are summarised in Table 1.1 and described below. In addition, the 
familial link with ATP further reinforces the importance of genetics in the aetiology 
of such conditions and the need for further research in this area.
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1.4.3.1 Repeat Polymorphisms and Single Nucleotide
Polymorphisms
While more than 99% of the DNA sequence in the human genome is identical 
between individuals, a small portion of the genome exhibits genetic variation 
(Shastry 2002). Single nucleotide polymorphisms (SNPs) are a type of small-scale 
genetic variation, where a single nucleotide base is altered in the DNA sequence 
of normal individuals (Shastry 2002). Specifically, they occur at a frequency of 
approximately 1 in 1000 base pairs and the rare allele has a frequency higher than 
1% (Brookes 1999). Repeat polymorphisms are another type of small scale 
genetic variation, also termed microsatellites (September et al. 2007). With this 
type of polymorphism, repeated base pair sequences of DNA are seen in varying 
lengths in individuals (Mokone et al. 2005). For example, a dinucleotide repeat 
polymorphism is a repeated tandem base pair sequence that is present in different 
lengths in genomes (Mokone et al. 2005).
One of the first genes to be investigated for its role in ATP was TNC. Mokone et 
al. (2005) found that a guanine-thymine (GT) repeat polymorphism in the TNC 
gene was associated with ATP. The TNC gene encodes the ECM protein tenascin- 
C (Figure 1.3), which is in close proximity to the ABO gene locus on chromosome 
9q32-q34 and is expressed in a range of tissues, including tendons (Mokone et 
al., 2005). Tenascin-C is believed to play a role in the regulation of cell-matrix 
interactions around tendons, binding to other ECM proteins and cell receptors 
(Mokone et al., 2005). In healthy adult tissues, tenascin-C expression is shown to 
be low, however expression is up-regulated in response to injury (Midwood et al. 
2011). Furthermore, mechanical loading on tendons is shown to regulate TNC 
gene expression in a dose-dependent manner (Jarvinen et al. 1999). Although the
exact mechanisms controlling TNC expression are not fully understood, certain 
cytokines and growth factors including transforming growth factor-(3 (TGF-(3) have 
been shown to induce synthesis of tenascin-C (Jarvinen et al. 1999).
Following this genetic association, in 2006 Mokone et al. showed that the rsl2722 
SNP within the 3' untranslated region (UTR) of COL5A1 gene, also located on 
chromosome 9, was associated with ATP in a South African Caucasian population. 
The alpha 1 type V collagen protein, encoded by the COL5A1 gene, is a minor 
structural protein constituent of tendon (Mokone et al. 2006) and is thought to be 
involved in the regulation of type I collagen fibril diameter (September et al. 
2009). The A2 allele of the rsl2722 variant was significantly overrepresented in 
the CON group, showing a protective benefit of this allele and a decreased risk of 
Achilles tendinopathy in individuals possessing this variant (Mokone et al. 2006). 
In 2009, September et al. (2009) also investigated the rsl2722 variant in 
Australian and South African Caucasian populations. They found that the CC 
genotype was underrepresented in Achilles tendinopathy compared to controls 
and these individuals were at a decreased risk of developing Achilles tendinopathy 
(September et al. 2009). In addition, in the South African Achilles tendinopathy 
group, the TC inferred haplotype (rsl2722-rs3196378) was found to be 
overrepresented (September et al. 2009).
The next gene to be investigated in relation to ATP was matrix metalloproteinase 
3 (MMP3). Research in 2009 highlighted that several SNPs within the candidate 
gene MMP3 were associated with the risk of Achilles tendinopathy (Raleigh et al. 
2009). Specifically it was found that the GG genotype of rs679620, the CC 
genotype of rs591058 and the AA genotype of rs650108 that were found to be
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associated with Achilles tendinopathy. The rs679620 variant is a non-synonymous 
SNP that lies within exon 2 of the MMP3 gene, while the rs650108 SNP lies within 
intron 8 of the gene (Raleigh et al. 2009). In addition, the haplotype analysis of 
the rs679620, rs591058, and rs650108 variants in this study showed that the ATG 
haplotype was underrepresented in Achilles tendinopathy, when compared to 
controls (Raleigh et al. 2009).
In 2010, then next genetic association with ATP was discovered. Although the 
specific role of GDF-5 in tendon is unknown, it has been found to associate with 
the risk of ATP (Posthumus et al. 2010). The rsl43383 variant (T/C) is a functional 
promoter SNP that lies within the 5' UTR of the GDF5 gene and has previously 
been associated with other musculoskeletal conditions including osteoarthritis 
(Posthumus et al. 2010). Individuals from an Australian cohort with the TT 
genotype of the functional GDF5 rsl43383 variant were significantly over-
represented in the ATP group compared to controls (P=0.011) and two times as 
likely to develop ATP. Furthermore, when the Australian and South African cohorts 
were combined, significance was also observed (P=0.004) (Posthumus et al. 
2010).
Two years later in 2012, a new genetic association study investigating genetic 
variants in genes involved in the apoptosis pathway was published, showing the 
association of novel SNPs within the candidate gene CASP8 and the risk of Achilles 
tendinopathy (Nell et al. 2012). The rsl045485 and rs3834129 functional SNPs 
(intronic variants within the CASP8 gene) were independently associated with 
Achilles tendinopathy, as well as associating with risk of tendinopathy when 
combined as a haplotype (Nell et al. 2012). A significant difference in genotype
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(P=0.0294) was detected between the CON and ATP groups for the CASP8 
rsl045485 variant (Nell et al. 2012). While for the CASP8 rs3834129 variant, 
significant differences in genotype and allele frequencies were reported between 
the two Caucasian cohorts investigated (South African and Australian), as well as 
between the CON and ATP groups (Nell et al. 2012).
Saunders et al. (2013) were next to publish data showing that SNPs within the 
COL27A1 and TNC gene were associated with Achilles tendinopathy in Caucasian 
populations (Saunders et al. 2013). They demonstrated the independent allelic 
associations of the rs2104772 (P = 0.017) and rsl330363 (P = 0.020) SNPs within 
the TNC gene and the risk of Achilles tendinopathy (Saunders et al. 2013). 
Furthermore, the GCA haplotype (COL27A1 rs946053 - TNC rsl3321 - TNC 
rs2104772) was also found to associate with an increased risk of Achilles 
tendinopathy (P = 0.019), where an increased frequency of this haplotype was 
observed in Achilles tendinopathy compared to controls (Saunders et al. 2013). 
This was the second study to investigate genetic variants within the TNC gene and 
the risk of ATP, following on from the findings from Mokone et al. (2005).
The most recently published genetic association study in relation to ATP found that 
a variant within the TIMP2 gene was associated with the risk of ATP (El Khoury et 
al. 2013). El Khoury et al. (2013) showed that the genotype frequency of the 
rs4789932 SNP was significantly different in a combined Caucasian population 
(South African and Australian) between the ATP and CON groups. The CC genotype 
was significantly overrepresented in the combined CON group, while the CT 
genotype was significantly overrepresented in the combined ATP group (El Khoury 
et al. 2013).
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To date, no larger scale variants, such as copy number variation (CNV) have been 
associated with ATP. This type of genetic variation is described in section 1.5.


1.5 COPY NUMBER VARIATION
The completion of the Human Genome Project in 2003 revealed many important 
insights into the genome (Ionita-Laza et al. 2009). Variability in the human 
genome is vast and research has shown it can take many forms (Redon et al. 
2006). These range from small scale variants such as SNPs, to large chromosomal 
anomalies (Redon et al. 2006). Data from the Human Genome Project illustrated 
that SNPs constituted a major part of genetic variation amongst individuals 
(Ionita-Laza et al. 2009). As a result, much research was focused on this type of 
genetic variation and by the end of the 20th century, millions of SNPs had been 
identified (Dear 2009). With advances in research came a greater understanding 
of the variation within the genome (Figure 1.9) (Beckmann et al. 2007). An 
important discovery was that missing or additional copies of some DNA regions 
was typical in healthy human genomes (Dear 2009). These structural differences 
were classed as copy number variation (CNV). Copy number variants (CNVs) are 
now considered a common type of genetic variation and account for a substantial 
amount of genetic variability in humans (Ionita-Laza et al. 2009).
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Figure 1.9 Timeline of Studies in Human Genetic Variation (Beckmann et al 
2007).
CNVs are segments of DNA greater than lkb in size, which show altered copy 
number when compared to a reference genome (Redon et al. 2006). These 
structural changes occur in different forms, including insertions, duplications and 
deletions and are attracting increased interest for their potential role in genetic 
diversity and disease (Redon et al. 2006; Henrichsen et al. 2009). Copy number 
variation (CNV) has the potential to influence phenotype via altering gene dosage 
and disrupting coding sequences of DNA (Yang et al. 2008). An increase in copy 
number of a gene or gene region could result in increased expression of that gene, 
while is could similarly silence gene expression if inserted within a coding region 
(Dear 2009).
Since the 1980s the existence of CNV as a form of genetic variation was largely 
accepted, however CNV discovery dates back much further than this (Beckmann 
et al. 2007). In the 1900's the first non-pathological CNV was recognised in
humans, showing that males have a single X sex chromosome and a vestigial Y
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sex chromosome (Dear 2009). In contrast, trisomy 21 or Down's syndrome, was 
the first human autosomal aneuploidy identified causing adverse phenotype 
consequences (Dear 2009). Despite knowledge about the presence of CNV within 
the genome, the mechanism by which CNV arises is still not fully understood. 
Research has shown that CNVs may appear to show a Mendelian pattern of 
inheritance, as opposed to earlier assumptions that CNV arose from independent 
mutations (McCarroll 2008). Nevertheless, while it appears that a considerable 
amount of CNV is inherited, these polymorphisms also occur de novo within the 
genome (Hastings et al. 2009). Furthermore, early knowledge about CNV was 
restricted to changes visible microscopically, whereas advanced technology has 
led to identification of a wide range of CNV (Robberecht et al. 2013). While 
homologous recombination (HR) is an important DNA repair mechanism, it can be 
the cause of structural chromosomal change, namely CNV (Hastings et al. 2009). 
Nonallelic homologous recombination (NAHR) is another important mechanism 
involved in the generation of CNV that can occur in both meiosis and mitosis, 
through rearrangements of the genome such as chromosomal translocations 
(Zhang et al. 2009). Indeed, NAHR can occur following unequal crossing-over 
between two nonallelic DNA sequences (Zhang et al. 2009). Another major 
mechanisms believed to be involved in the formation of CNV is nonhomologous 
end-joining (NHEJ) (Zhang et al. 2009; Hastings et al. 2009). Under normal 
circumstances, NHEJ functions to repair double strand breaks (DSBs) in DNA 
caused by reactive oxygen species, as well as physiological V(D)J recombination 
(Zhang et al. 2009).
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1.5.1 The Effect of CNV on the Genome
In comparison to SNPs, CNVs appear to have a much higher de novo locus-specific 
mutation rate (Zhang et al. 2009). While the mutation rate of SNPs is known to 
be comparatively constant across the genome, CNVs show a diverse and varied 
mutation rate at different loci (Zhang et al. 2009). It is estimated that CNV locus- 
specific mutation rates can vary from 1.7 x 10~6 to 1.0 x 10-4 per locus per 
generation (Zhang et al. 2009). Indeed, more than 10% of the human genome is 
believed to contain CNVs, highlighting the extent of this type of variation (Redon 
et al. 2006). The majority of CNV within the genome is believed to be benign and 
have no phenotypic consequences (Dear 2009). It is expected that CNV causing a 
phenotypic effect would largely be selected out of the population, however there 
is evidence showing associations with CNV and complex diseases (Dear 2009; 
Ionita-Laza et al. 2009).
Research into neurological disorders including autism spectrum disorder, Major 
Depressive Disorder and schizophrenia has revealed potential associations with 
CNV (Holt et al. 2012; Degenhardt et al. 2012; Grozeva et al. 2012). However, 
the association between CNV and schizophrenia described by Grozeva et al. 
(2012) was not supported by Zhao et al. (2012), who reported a lack of 
association. CNV is also believed to associate with the autoimmune diseases 
rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), where low 
copy number of the Fc gamma receptor 3B (FCGR3B) gene was observed in both 
RA and SLE (Graf et al. 2012; Yu et al. 2010; Molokhia et al. 2011). Molokhia et 
al. (2011) reported that low copy number of the FCGR3B gene was associated 
with an increased risk of SLE in an Afro-Caribbean population. In addition, 
increased copy number of the histamine H4 receptor (HRH4) has also been shown
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to increase the risk of SLE, suggesting that CNV may be responsible in part for 
the increased expression of HRH4 observed in SLE patients (Yu et al. 2010). These 
seems plausible since altered copy number is known to affect gene expression, 
alter gene dosage and cause phenotypic variation (Redon et al. 2006).
Graf et al. (2012) investigated CNV within intron 5 of the FCGR3B gene and 
reported that low copy number at this loci was associated with an increased risk 
of RA in patients recruited from hospitals in Australia (Graf et al. 2012). As the Fc 
gamma receptor 3B is known to be involved in interactions between immune 
complexes and immune cells including neutrophils, it is clear to see how altered 
copy number of the FCGR3B gene can have a physiological effect on the genome 
and alter the risk of such autoimmune diseases discussed above (Graf et al. 2012). 
RA is a musculoskeletal soft tissue pathology, as is ATP, highlighting an interest 
in investigating CNV in other musculoskeletal conditions. As predisposition to 
certain multifactorial diseases appears to be associated with CNV within the 
human genome (Estivill & Armengol, 2007), it is plausible therefore to hypothesise 
that CNV may also have a role in ATP. This hypothesis has never been tested.
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1.6 EPIGENETICS
Epigenetics is a term used to describe the heritable changes in gene expression 
that arise without changes in the coding DNA sequence (Reynard and Loughlin 
2012; Raleigh 2012; Roach et al. 2005). The epigenetic regulation of the genome 
occurs by three principal mechanisms, namely histone modification, non-coding 
RNAs (for example micro RNAs (m'RNAs)) and DNA methylation (Rakyan et al. 
2011; Reynard and Loughlin 2012). While histone modification and DNA 
methylation can influence gene transcription, miRNAs can act post- 
transcriptionally, with all mechanisms having the shared role of regulating gene 
expression and affecting downstream protein production (Reynard and Loughlin 
2012; Auclair and Weber 2012).
In order or all the DNA to fit inside the nucleus of a eukaryotic cell, it needs to be 
tightly packaged and organised (Das and Tyler 2013). Consequently, DNA is 
combined with chromatin and wrapped around histone proteins to form a histone 
octamer (Reynard and Loughlin 2012). This unit forms the structure of a 
nucleosome, a stable structure within the nucleus supported by hundreds of DNA- 
protein interactions, that in addition to packaging the DNA, functions to regulate 
DNA replication, transcription and repair (Das and Tyler 2013). Histone acetylation 
is an example of histone modification, which regulates gene expression without 
altering the DNA sequence (Rakyan et al. 2011; Raleigh 2012). Epigenetic 
regulation of the genome can also occur through the action of miRNAs on mRNA 
(Bartel 2004; Reynard and Loughlin 2012). At around 20 bp in length, these 
miRNA molecules are present in the cytoplasm of the cell and can bind to target 
mRNAs, regulating gene expression post-transcriptionally (Bartel 2004; Reynard 
and Loughlin 2012). Specifically the interaction of miRNA and mRNA occurs within
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the 3-UTR of the target mRNA molecule through complementary base pairing 
(Reynard and Loughlin 2012). Depending on the level of complementarity, the 
mRNA may be cleaved and degraded, or translation may be suppressed and result 
in gene silencing (Reynard and Loughlin 2012; Bartel 2004). The epigenetic 
mechanism focused on in this thesis is DNA methylation, namely CpG island 
methylation. This is described in section 1.6.1 below.
1.6.1 DNA Methylation
Of the epigenetic mechanisms detailed above, DNA methylation is the most 
common epigenetic modification present in eukaryotic DNA (Auclair and Weber 
2012). Indeed, DNA methylation of cytosine residues within CpG islands of a gene 
promoter is predominantly responsible for silencing non-expressed genes within a 
cell (Roach et al. 2005). This results in distinct cell types with specific functions 
and is a vital process during embryonic development and cellular differentiation 
(Roach et al. 2005; Auclair and Weber 2012). The process of DNA methylation 
typically occurs within CG dinucleotides (CpG sites) and involves the addition of a 
methyl group to carbon 5 of the cytosine residue to make 5-methylcytosine 
(Auclair and Weber 2012; Reynard and Loughlin 2012). These sites are collectively 
termed CpG islands are sparse throughout the genome but are known to be 
concentrated within the promoter regions of around 30% of genes, where their 
methylation status can regulate gene transcription by preventing the binding of 
transcription factors (Reynard and Loughlin 2012). Hypermethylation of a gene 
promoter is generally associated with the silencing of that gene or suppressed 
expression (Raleigh 2012). Meanwhile, hypomethylation typically results in 
increased gene expression (Raleigh 2012; Reynard and Loughlin 2012). As such, 
the regulation and maintenance of DNA methylation is vital, as abnormal changes
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in this epigenetic process can have pathologic consequences (Roach et al. 2005; 
Auclair and Weber 2012; Rakyan et al. 2011).
1.6.2 DNA Methylation and Disease
While epigenetic profiles of individuals change during development and the 
differentiation of different tissue types, altered epigenetic states have been 
associated with disease (Reynard and Loughlin 2012). Although epigenetic 
variation has largely been investigated in relation to cancer, research in to the 
epigenetic component of other complex diseases is now emerging (Rakyan et al. 
2011). Research into the musculoskeletal disease osteoarthritis is highlighting that 
altered DNA methylation status is involved in this polygenic disease (Reynard and 
Loughlin 2012). For example, loss of DNA methylation and altered expression of 
metalloproteinase genes including ADAMTS4 has been observed in chondrocytes 
in osteoarthritis, showing an association between the ADAMTS4 gene and this 
musculoskeletal disease (Roach et al. 2005). ADAMTS4 is an enzyme involved in 
the homeostasis of the ECM and as well as its association with osteoarthritis, 
higher levels of ADAMTS4 mRNA have been detected in ruptured Achilles tendon 
compared with normal and tendinopathic tendon (Corps et al. 2008). Furthermore, 
loss of DNA methylation and altered expression was identified in the promoters of 
the MMP3, MMP9 and MMP13 genes in these chondrocytes (Roach et al. 2005). 
Promoter DNA methylation has also been demonstrated to contribute to the 
regulation of the GDF5 gene in osteoarthritis (Reynard et al. 2011).
Many of the proteins involved in tendon biology show altered expression levels in 
ATP (Ireland et al. 2001). For example, expression of tenascin-C has been shown 
to increase, while MMP3 expression was shown to decrease in ATP (Ireland et al.
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2001; Jelinsky et al. 2011). This highlights the interest in investigating DNA 
methylation status in tendon-associated genes, to see whether methylation status 
may be influencing expression levels or modifying the risk of ATP. There is no 
published research to date on the role of epigenetics as a risk factor for ATP. 
Therefore, CpG methylation status was an important focus of this thesis.
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1.7 AIMS AND OBJECTIVES
This research focuses on the novel genetic and epigenetic basis of sport related 
tendinopathies. Published research on the genetic predisposition to tendon injury 
is increasing, further highlighting the importance of this risk factor in relation to 
tendinopathy. Although there is evidence for a genetic predisposition to ATP, 
research to date has focused on the involvement of small-scale variants including 
SNPs. The role of genomic copy number variation in relation to ATP has never 
been investigated. Based on this, the primary aims of this thesis were:
• To determine whether CNV in a number of candidate genes previously 
associated with ATP (CASP8, COL5A1, MMP3 and 77VC) was associated with 
ATP in South African and Australian Caucasian populations.
• To determine whether CNV in a number of novel candidate genes (ADAM8, 
COL4A1 and MMP23B) was associated with ATP South African and 
Australian Caucasian populations.
• To investigate whether CNV in both previously associated and novel 
candidate genes was associated with ATP in a newly recruited British UK 
case-control population.
The additional aims of this thesis were focused around novel SNPs within candidate 
genes and the risk of ATP and the investigation of DNA methylation status in 
relation to patellar tendinopathy. Accordingly the further aims of this thesis were:
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To determine whether SNPs in novel candidate genes involved in apoptosis 
(TNFRSF1A and CASP3) were associated with ATP in a UK and South African 
population.
To determine whether there were differences in promoter DNA methylation 
profiles within the ADAMTS4, TIMP1 and MMP11 genes in patellar 
tendinopathy and healthy patellar tendon tissue.
CHAPTER 2: METHODS
2.1 INVESTIGATING GENETIC ASSOCIATIONS IN COMPLEX DISEASES
The research undertaken in this thesis was based on the candidate gene case- 
control study approach, where genes and/or pathways were investigated based 
on their biological role in the tendon, or where genes had been previously 
associated with tendon pathology. The candidate gene approach is a form of 
genetic association study, where genetic variation and disease status are 
investigated to look for potential correlations (Lewis and Knight 2012). For 
example, a higher observed frequency of a particular genetic variant in a disease 
population may mean that the variant increases the risk of that disease (Lewis 
and Knight 2012). Likewise, an increased frequency of a genetic variant in a 
control population could indicate a protective effect and a reduced risk of disease. 
Genetic association studies are vital in identifying risk factors for complex 
diseases, where many polymorphisms in candidate genes have been shown to 
associate with complex diseases such as autoimmune and psychiatric diseases 
(Lewis and Knight 2012). While single nucleotide polymorphisms SNPs are the 
most commonly explored markers in genetic association studies, other types of 
genetic variants including insertion/deletions, variable-number tandem repeats 
(VNTRs) and copy number variants CNVs are also investigated (Lewis and Knight 
2012) .
The investigation of the genetic component of complex diseases is centred on two 
predominant methods, genome-wide association studies (GWAS) and the 
candidate gene approach (Amos et al. 2011; Wilkening et al. 2009). While 
candidate gene association studies were historically the approach of choice when
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investigating the genetic susceptibility to a disease or trait, advancing technology 
has now also highlighted the relevance of the GWAS method (Amos et al. 2011; 
Wilkening et al. 2009). However, each approach has its strengths and weaknesses 
and are both relevant methods for association studies (Amos et al. 2011; Patnala 
et al. 2013). Furthermore, important things to consider when conducting either 
type of genetic association study include the clear definition of the disease 
phenotype, as well as the use of a matched control population, which will help to 
reduce the chance of false-positive results from population stratification (Lewis 
and Knight 2012).
Candidate gene association studies employ a hypothesis driven approach, where 
a prior knowledge of a genes function or biological pathway is required (Wilkening 
et al. 2009). Indeed, the selection of genes is based on previous associations with 
the disease or trait in question (Patnala et al. 2013). GWAS do not require a prior 
knowledge of gene function, as the whole genome can be screened and 
associations may be found in genes with no obvious relevance to the disease being 
studied (Amos et al. 2011). While it may seem advantageous to be able to discover 
many associations within genes without a knowledge of their functional relevance, 
these studies require a very large samples size and an alpha level many times 
lower than p < 0.05, due to the low power of these studies as a result of multiple 
testing (Amos et al. 2011). This is important to reduce the risk of detecting false 
positives in this GWAS approach (Amos et al. 2011). In contrast, the candidate 
gene approach can provide higher statistical power and can also prove beneficial 
in combination with GWAS (Amos et al. 2011; Patnala et al. 2013). Candidate 
gene association studies can be a useful method for post-GWAS research, where 
the identification of the causal variants for a trait can be unearthed from all the
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associated genes identified (Wilkening et al. 2009). The candidate gene approach 
may often be a more cost and time effective method for investigating genetic 
associations, particularly when a prior knowledge of gene function is employed 
when selecting candidates (Wilkening et al. 2009). As such, despite the 
advancement of high throughput genotyping and the screening of many variants 
at a time, there is a vital place for the candidate gene approach in genetic 
association studies (Lewis and Knight 2012; Peters 2009). These types of genetic 
association studies can advance our understanding of complex diseases and 
identify candidates for further functional/mechanistic studies (Peters 2009). 
Furthermore, the value of genetic association studies alone is also significant, as 
certain variants that are associated with a disease are in non-coding regions or 
are synonymous, resulting in no change to the amino acid sequence of the protein 
(Peters 2009). In relation to Achilles tendon pathology, the case-control candidate 
gene approach has been widely used in many studies in multiple cohorts to identify 
genetic risk factors for this pathology (Raleigh and Collins 2012).
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2.2 PARTICIPANTS
2.2.1 Ethical Approval
The research conducted and reported in this thesis forms part of a multicentred, 
on-going, collaborative study between the University of Northampton (headed by 
Dr Stuart M Raleigh) and colleagues based at the University of Cape Town 
(Professor Malcolm Collins), Monash University (Professor Jill Cook) and Seth 
O'Neill based at the University of Leicester. Ethical approval for these studies was 
granted from the Research Ethics Committees of the Faculty of Health Sciences at 
the University of Cape Town (South Africa), La Trobe University (Australia), 
Monash University (Australia), the University of Northampton (UK) and the 
University of Leicester (UK). Further information regarding the ethics approval can 
be found in the Appendix I.
2.2.2 British Achilles Tendon Cohort
A total of one hundred and thirty seven British Caucasian participants diagnosed 
with ATP were recruited for this case-control genetic association study through 
the County Clinic in Northampton, UK. One hundred and thirty one asymptomatic 
Caucasian control (CON) participants (apparently healthy, physically active and 
without history of tendon/ligament pathology) were recruited from the East 
Midlands region of the UK. Recruitment was initially undertaken by Dr Louis El 
Khoury, and later continued by the author. The ATP participants were all non-NHS 
patients clinically diagnosed by Professor William J Ribbans. Patients with either 
chronic Achilles tendinopathy (noninsertional or insertional tendinopathy) (TEN) 
or partial/complete Achilles tendon ruptures (RUP), based on established 
published criteria (Schepsis et al. 2002; Kader et al. 2002; Mokone et al. 2006),
47
were included in the study. For all cases, the clinical d iagnosis  of Achil les 
tendinopathy was verif ied by subsequent imaging with MRI and/or u ltrasound.
The clinical criteria used for the d iagnosis of chronic Achil les tend inopathy  were 
gradual progress ive pain over the Achil les tendon area for g reater than 6 months, 
together with at least one of six criteria (Mokone et al. 2006; Sep tem ber  et al. 
2009). These were: 1) ear ly -morn ing  pain of Ach il les tendon area; 2) ear ly- 
morning st iffness of Achil les tendon area; 3) h istory of swell ing of Ach i l les tendon 
area; 4) tenderness to palpation of Ach i l les tendon; 5) palpable nodular th icken ing 
of affected Achil les; 6) m ovem en t  of the painful area in the Ach i l les tendon with 
p lantar-dors i-f lex ion (posit ive " sh i f t "  test) (Mokone et al. 2006).
Written informed consent was given by all part ic ipants accord ing to the 
Declaration of Helsinki. The part ic ipant information sheet and consent form can 
be seen in Append ix  II. Part ic ipants who returned signed consent fo rms were then 
asked to completed a physical act iv ity/med ica l h is tory/ in jury quest ionna ire  
(Appendix III) and provide a sal iva sample.
An additional 28 British Caucas ian non -NHS ATP part ic ipants were recruited 
through phys io therap ist Seth O'Neil l at the Univers ity  of Leicester, via adverts  at 
running clubs and through the www.ach i l les tendonresearch .com  website. All 
participants were runners with se lf-reported tendon pain for more than 3 months. 
Achil les tend inopathy was d iagnosed during clinical exam inat ion with the presence 
of localised tendon pain, with pain on palpation and increased pain with tendon 
loading (bilateral heel raise, unilateral heel raise, hopping, jum p ing  and running). 
Ultrasonography was completed on all indiv iduals. These samples were included
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in the studies in Chapte r  5, but none of the o ther studies. An overv iew of the
British (both g roups com b ined) partic ipan t cha racte ris tics  can be seen in Table
2 .1 .
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2.2.3 South African and A ustra lian  A ch illes Tendon Cohorts
One hundred and seventy-f ive  (115 South African (SA) and 60 Austra l ian (AUS)) 
self-reported Caucas ian part ic ipants d iagnosed with ATP and 247 (98 SA  and 149 
AUS) asymptomat ic  CON were recruited, as prev iously described (Mokone et al. 
2006; Sep tem ber et al. 2009). To avoid possib le effects of population 
stratif ication, the ATP and CON groups were matched for country of birth 
(September et al. 2009).
SA ATP part ic ipants with a current/past clinical h istory of ATP were recruited from 
the Medical Practice at the Sports  Sc ience Institute of South Africa and other 
clinical practices within the Cape Town area of South Africa. Initial d iagnoses of 
ATP were made by an exper ienced clin ician using clinical criteria and the d iagnoses 
of all SA ATP part ic ipants was rev iewed and conf irmed by Martin P Schwel lnus 
(Mokone et al. 2005; Mokone et al. 2006). SA CON part ic ipants (apparent ly  
healthy, physica l ly  active and w ithout h istory of ATP) were recru ited from 
recreational sport ing c lubs (Mokone et al. 2006). AUS ATP part ic ipants were 
recruited by the Muscu loske leta l Research Centre  at La Trobe Univers ity  in 
Melbourne, Austra l ia  and were d iagnosed by Jill Cook using clinical criteria 
(Mokone et al. 2005; Mokone et al. 2006). AUS  CON part ic ipants (apparent ly  
healthy and w ithout h istory of tendon/ l igam ent pathology) were recruited from 
Melbourne, Austra l ia (Sep tem ber  et al. 2009). As with the British cohort, 
participants gave written in formed consent and completed a physical 
activ ity/medical h is tory/ in jury quest ionna ire  s im ilar to those shown in Append ix  
II and III. Ethical approval for use of the samples is detailed in Append ix  I.
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The SA and AUS  ATP groups consisted of part ic ipants c l in ical ly d iagnosed with 
either chronic Achil les tend inopathy or part ia l/complete  Achil les tendon ruptures 
(defined for the SA  cohort only). Cases of Achil les tend inopathy typ ica l ly  presented 
with gradual progress ive pain with ear ly -morn ing  pain/st if fness in the Achil les 
tendon area. The clinical criteria used for the d iagnosis of chronic Achil les 
tendinopathy are described in detail e lsewhere (Mokone et al. 2005; Mokone et 
al. 2006). In addit ion, soft-t issue u ltrasound exam inat ion  was performed (all AUS  
ATP part ic ipants and a sub-group of SA  ATP part ic ipants) to confirm diagnosis. 
Achil les tendon rupture for the SA  cohort was d iagnosed with cl in ical ly va lidated 
criteria, conf irmed by exam inat ion  at t ime of su rgery  and/or by u ltrasound 
imaging, magnet ic  resonance imaging (MRI) or computer ised tom ography  (CT) 
scan, as prev ious ly  descr ibed (Mokone et al. 2006). Details of the SA  and AUS 
participant character is t ics  can be seen in Table  2.2 and 2.3.
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2.2.4 Australian  Patellar Tendon T issue  Sam ples
In addition to the Achil les tendon cohorts  recruited and described above, DNA 
samples from 20 pate l lar tendon samp les  (all male) were used for DNA 
methylation analysis. These were obta ined from La Trobe Univers ity, Melbourne, 
Australia. As prev iously  descr ibed by Park inson et al. (2009), the pate l lar tendon 
samples included 10 abnormal samp les  obta ined from indiv iduals during surgical 
debridement for reca lc itrant overuse  pate l lar tend inopathy  and 10 healthy 
samples obta ined during anter io r cruc iate l igament (ACL) reconstruct ion surgery 
using a pate l lar tendon graft (Park inson et al. 2010). DNA from the pate l lar tendon 
tissue samples was isolated by m em bers  of staff at La Trobe Univers ity  using the 
PureLink Genom ic  DNA Kit (Invitrogen, Carlsbad, CA, USA) as per the 
manufacturer 's recommendat ions.
2.2.5 DNA Extraction and Q uantification
For the British cohort, DNA was extracted from 2 mL of sa l iva col lected using 
ORAGENE-DNA collection kits (OG-500) and DNA purification was carr ied out using 
the prepIT-L2P DNA extract ion kit (DNA Genotek  Inc., Ontario, Canada).  PrepIT- 
L2P purifier reagent was added and mixed by vortex ing to precip itate impurit ies 
and inhibitors. A fter incubation on ice, sam p les  were centr ifuged at 13,000 rpm, 
resulting in a formed pellet of impurit ies at the bottom of the m icro-centr ifuge 
tubes and samples with reduced turb id ity. The supernatant was transferred into 
clean m icro-centr ifuge tubes and 90% ethanol added. This precip itated the DNA, 
forming a vis ible clot of DNA fibres. Sam p les  were centr ifuged again at 13,000 
rpm, with the DNA forming as a small pellet. Supernatant was removed and 
discarded and 70% ethanol was then added. Once removed, any remain ing 
ethanol was allowed to evaporate. DNA pellets were hydrated in TE buffer and left
55
at room tempera ture  overnight. Sam p les were vortexed to ensure full rehydrat ion 
before m easu rem ent of concentrat ion and sample  storage. The protocol for DNA 
extraction can be seen in Append ix  IV.
DNA concentrat ion (ng/pL) and purity (260/280  ratio) were measured using the 
Nano Drop 2000 (Thermo Fisher Scientif ic, USA). The 260/280 ratio is the ratio of 
absorbance at 260 nm and 280 nm and is used as a measure  of nucle ic acid purity. 
A ratio of ~1.8 is typ ica l ly  accepted as pure for DNA, a lthough it is dependent 
upon the nucleotide composit ion of the nucle ic acid. A ratio of lower than th is may 
indicate the presence of contam inants , such as protein, that absorb strongly at 
~280 nm. W ork ing -s tock  plates of DNA samples were prepared by diluting DNA 
samples to 10 ng/pL with TE buffer. These work ing-s tock  p lates were stored at 2- 
5 °C. Long-stock DNA samp les  were stored in a l iquots at -20 °C. Dr Louis El 
Khoury assisted with part ic ipant recru itment and DNA extract ion for the British
cohort.
For the South African cohort, DNA was provided as al iquots. Sam p les  had been 
prepared from 4.5 mL of venous blood, obta ined by ven ipuncture  of a forearm 
vein and collected into an e thy lened iam inete traacet ic  acid (EDTA) vacu ta iner  tube. 
Blood samples were stored at 4°C  until total DNA extract ion, using a procedure 
described by Lahiri and Nurnberger (1991), with modif icat ions by Mokone et al. 
(2006). DNA was extracted for the Austra l ian cohort by m em bers  of staff  from the 
Musculoskeletal Research Centre at La Trobe Univers ity, from approx imate ly  4.5 
mL of venous blood, using a sequence extract ion techn ique (F lex iGene DNA Kit, 
Qiagen P/L, Va lencia, California, USA) as per the manufacturer 's  
recommendations.
2.3 QUANTITATIVE PCR METHODS  
2.3.1 TaqMan Technology
TaqMan technology was the p redom inant method used in th is thesis for the 
sections on both CNV and SNP genotyp ing, using a quantita t ive PCR (qPCR) 
platform. TaqMan Copy Num ber  A ssays  were used for all the stud ies on copy 
number and are a we l l-estab l ished and robust method for copy number 
determination (D 'haene et al. 2010). Advan tages  of this method include the fact 
that reactions can be performed as rea l- t ime duplex PCR reactions. This means 
that the target CNV  region co-amplif ies with the reference assay RNaseP within 
the same well. Indeed, it was found in the present study, that th is m in im ised the 
time and cost of each PCR analys is. A detailed d iscussion of the advantages  of 
using qPCR methods compared  to a lternat ive genotyp ing strateg ies can be found 
elsewhere (Bodin et al. 2005; D 'haene et al. 2010). In addit ion to rapid genotype 
calling and cost effect iveness, the CNV  assays used were found to be reproducible. 
In the present research, copy num ber was determ ined four t im es for each DNA 
sample and for each probe used. Copy number call was identical between each of
the four replicates for all probes.
Validation of our qPCR methods for CNV determ inat ion was also confirmed by 
establishing the PCR eff ic iency for each TaqMan Copy Num ber probe used. 
Standard curves of known DNA concentrat ion vs. probe specif ic f luorescent signal 
can be seen in Append ix  V. For each TaqMan probe used, PCR eff ic iency averaged 
>90% and there was never more than a 10% difference between the eff ic iency of 
the CNV target probe compared to the effic iency of the reference RNaseP probe 
used to normalise copy number values. In addition to determ in ing the quality of 
reproducibil ity, each qPCR run contained no template contro ls (NTCs) to check for
spurious calls and possib le contam inat ion. Furthermore, all samp les  used for the 
qPCR efficiency stud ies were also crosschecked aga inst the original qPCR runs to 
determine if any d iscrepanc ies  in concordance existed in copy number.
2.3.2 SNP Selection and Genotyping
The predicted genotype and allele frequencies of the SNPs within the candidate 
genes investigated in th is thes is  were checked on databases including Ensembl 
(h t tp ://www.ensem b l.o rg / index .h tm l), NCBI dbSNP
(h ttp ://www.ncb i.n lm .n ih .gov/SNP/) and SNPper
(h t tp ://snpper.ch ip .o rg/b io /snpper-en te r/). It was cons idered importan t that the 
minor allele for each SNP invest igated was detected in our sample  size, to enable 
an accurate representat ion of genotypes as seen in the predicted frequencies. 
Therefore, SNPs were se lected with a reported m inor allele frequency (MAF) of > 
0.15 in Caucas ian populat ions. A lower MAF may have resulted in 
underrepresentat ion of the m inor allele, affecting the ana lys is  and interpretat ion 
of results. A rational for the se lect ion of each gene and assay  is detailed within
Chapter 5.
TaqMan SNP Genotyp ing Assay, TaqMan Universa l PCR Master Mix, No AmpErase  
UNG and genom ic DNA (gDNA) were combined per well o f a 96-well plate (Table 
2.4). The total reaction vo lum e per well was 12 pL, giving a final DNA reaction 
concentration of 1 ng/pL.
Table 2.4 Reaction Com ponen ts  for a Typical SNP Genotyp ing Real-T ime PCR.
Volum e per well
Reaction Com ponent
(ML)
TaqMan Universal PCR Master Mix, No Am pErase  UNG 6.0
TaqMan SNP Genotyp ing Assay, 40x 0.3
Nuclease-free water 4.5
gDNA 1.2
Total Reaction Vo lum e 12.0
The alleles were determ ined from genom ic  DNA using TaqMan SNP Genotyp ing 
Assays, according to the manufacturer 's  instructions. Each TaqMan SNP 
Genotyping Assay  conta ined sequence-spec if ic  forward and reverse pr imers to 
amplify the target sequence and two TaqMan probes, which conta ined a m inor 
groove b inder (MGB) and a non-f luorescent quencher (NFQ) at the 3' end (Figure  
2.1 Part 1). One probe was provided labelled with VIC  dye at the 5' end of the 
probe and the other with FAM dye at the 5' end of the probe, to detect the m inor 
and major alleles. TaqMan MGB probes provided a f luorescence signal for the 
amplification of each allele. Table 2.5 gives an overv iew  of the f luorescence 
detected and the allele associated with that probe. Assays  were diluted from a 40x 
concentration to a l x  concentrat ion in each reaction.
Real-time qPCR react ions were run in 96-well p lates on a S tepOneP lus Rea l-T ime 
PCR System, running StepOne Software vers ion 2.1 (Applied B iosystems, Foster 
City, California, USA). During qPCR, the samp les  were heated at 92°C  to denature 
the gDNA template  (Figure 2.1 Part 2). Following cooling to 60 °C, the TaqMan 
SNP Genotyping MGB probes annealed to their com p lementary  sequence between
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the forward and reverse pr imer binding sites (Figure 2.1 Part 2). While the 
oligonucleotide probe is intact, reporter dye f luorescence is quenched due to the 
proximity of the quencher dye. The TaqMan Universal PCR Master Mix, No 
AmpErase UNG contained AmpliTaq Gold DNA Po lymerase (Life Technolog ies), 
which amplif ied the target gDNA by extend ing the sequence-spec if ic  pr imers 
bound to the DNA template . (Figure 2.1 Part 3). The AmpliTaq Gold DNA 
Polymerase c leaved the probes hybrid ised to the ir  target com p l im en ta ry  
sequences, separat ing the reporter dye from the quencher, causing f luorescence 
of the reporter (Figure 2.1 Part 3). The PCR products were amplif ied after each 
PCR cycle and this was detected by the increase in f luorescence of the reporter 
dyes. The f luorescence signal generated indicated which al le les were present in 
the samples. F luorescence from a single dye only (FAM or VIC) indicated a 
homozygote genotype at the loci. The detect ion of f luorescence from both FAM 
and VIC dyes indicated a heterozygote  genotype at the loci (Table 2.5). This 
process continued with each cycle of the PCR.
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Figure 2.1 Sum m ary  of the s tages in a rea l- t ime qPCR reaction conta in ing 
TaqMan SNP Genotyp ing Assay. Image from page 43 of the TaqMan SNP 
Genotyping Assay  Protocol with kind perm iss ion of Thermo Fisher Scientif ic.
Table 2.5 Fluorescence detected and the corresponding genotype identified
Fluorescence Genotype
VIC dye f luorescence only 
FAM dye f luorescence only
Hom ozygote  for Alle le 1 
Hom ozygote  for Allele 2
Both VIC  and FAM dye f luorescence Heterozygote Allele 1/AIIele2
In summary, the cycl ing condit ions were holding at 95 °C for 10 min, fo l lowed by 
50 cycles of denatur ing at 92 °C for 15 sec and annea l ing/extens ion at 60 °C for 
1 min. Each plate included within and through plate posit ive contro ls and no
template controls (NTCs) to check reproducib i l ity and to ensure no contam inat ion
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within and across plates. Genotype c lusters were automatica l ly  generated by the 
software, which d ist ingu ished between the homozygote  and heterozygote 
samples. Som e samples did not automat ica l ly  genotype and amplif icat ion was 
checked and samples were manual ly  called where applicable.
2.3.3 CNV Selection and Genotyping
Catalogued CNVs were identif ied with reference to the Database of Genom ic  
Variants (DGV) (h ttp ://p ro jec ts . tcag .ca/var ia t ion/) hosted by The Centre for 
Applied Genom ics, Toronto. TaqMan Copy Num ber Assays  (Applied B iosystems, 
Foster City, Cal iforn ia, USA) were se lected using the TaqMan Assay  Search  Tool
(h ttps://www.l i fe techno log ies .com/uk/en/home/ l i fe -sc ience/pcr/rea l- t ime- 
pc r/ rea l- t im e-pcr-assays/cnv-ana lys is -us ing -taqm an .h tm l). The criteria used in
selecting re levant TaqMan Copy Num ber  Assays  for ana lys is  was based on the 
region being within, or close to, a cand idate  gene prev iously assoc iated with ATP 
and/or in a gene with a known role in tendon biology. Se lect ion was also based 
on the copy number var iat ion being within a cata logued region reported in the 
DGV; the probe being in an exon ic  region of the gene and being in a region where 
CNV was reported at a frequency >10% in the populat ion studied. Where  possible 
one or more of these selection criteria were met for each assay chosen, a lthough 
there were t imes when assays were selected in novel genes w ithout previously 
reported CNV. Regard less of the selection criteria, a rational for the selection of 
each gene and target CNV region is detailed within the specif ic chapters  (Chapter 
3, 4 & 5). Details of all the TaqMan Copy Number Assays  selected and investigated
can be seen in Table 2.6.

The TaqMan Copy Num ber Assays  detected the target genom ic sequences of 
interest, while the Reference Assay  (RNase P) detected a sequence known to exist 
in two copies in a diploid genom e (Mayo et al. 2010). Specif ical ly, the reference 
probe detected the human r ibonuclease P RNA com ponent HI (H1RNA) gene 
(RPPH i)  on ch rom osom e 14 (Mayo et al. 2010). The TaqMan Copy Number 
Reference Assay  RNase P is the standard reference assay for human gDNA CN 
quantification (Mayo et al. 2010).
TaqMan Copy Number Assay, TaqMan Copy Num ber Reference Assay, TaqMan 
Universal PCR Master Mix No Am pErase  UNG and gDNA were combined per well 
of a 96-well plate (Table 2.7). Total reaction vo lume per well was 10 pL, g iv ing a 
final DNA reaction concentrat ion of 1 ng/pL.
Table 2.7 Reaction Com ponen ts  for Copy Num ber Rea l-T ime PCR.
Reaction Com ponent
Volum e per 
well (pL)
TaqMan Universal PCR Master Mix, No 
AmpErase UNG
5.0
TaqMan Copy Number Assay, 20x 0.5
TaqMan Copy Number Reference Assay, 20x 0.5
Nuclease-free water 3.0
gDNA 1.0
Total Reaction Vo lume 10.0
Real-time qPCR reactions were run on a StepOneP lus Rea l-T ime PCR System  
running StepOne Software version 2.1 (Applied B iosystems, Foster City, California,
USA) in 96-well plates. CN was determ ined from genom ic DNA using TaqMan Copy 
Number Assay with Reference Assay RNase P, performed as a duplex reaction and 
according to the manufacturer 's  instructions. The TaqMan Copy Number Assay 
contained two pr imers (forward and reverse) and a FAM dye-labelled 
nonfluorescent-m inor groove b inder (NFQ-MGB) probe (Figure 2.2 Part a). The 
TaqMan Copy Num ber Reference Assay  RNase P conta ined two pr imers and a VIC 
dye-labelled TAMRA probe (Figure 2.2 Part a). Both assays are 5' nuclease assays 
and were diluted from a 20x concentrat ion to a l x  concentrat ion in each reaction.
Initially, the gDNA  tem p la te  was denatured at 95 °C and assay pr imers (Copy 
Number and Reference Assay) annealed to the ir  specif ic target sequences upon 
cooling to 60 °C (Figure 2.2 Part b). Sequenc ing probes also annealed to the ir  
complementary sequences between forward and reverse p r im er binding sites. 
While intact, the reporter dye signal of the probes (FAM for Copy Num ber  Assay  
and VIC for Reference Assay  respect ive ly) was quenched, due to the prox im ity  of 
the quencher (NFQ-MGB /TAMRA for Copy Num ber Assay  and Reference Assay 
respectively). During each PCR cycle, the target and reference sequences were 
s imultaneously amplif ied by AmpliTaq Gold DNA Po lymerase (Life Technologies). 
AmpliTaq Gold DNA Po lymerase, with 5' nuc lease activ ity, c leaved the 
oligonucleotide probes hybrid ised to each amplicon sequence. Each t ime a probe 
was cleaved, the quencher separated from the reporter dye, causing f luorescence 
to be detected in the rea l-t ime PCR reaction (Figure 2.2 Part c). The increase of 
amplified PCR products was detected by the increase in f luorescence of the 
reporter dyes following each PCR cycle.
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Figure 2.2 Sum m ary  of the stages in a duplex rea l- t ime qPCR reaction contain ing 
TaqMan Copy Num ber and Reference Assay. Image from page 36 of the TaqMan 
Copy Number A ssay  Protocol with kind permiss ion of Therm o F isher Scientific.
In summary, the cycl ing condit ions were holding at 95 °C for 10 min, fo l lowed by 
40 cycles of denatur ing at 95 °C for 15 sec and annea l ing/extens ion  at 60 °C for 
1 min. Each samp le  was tested in quadrup licate and all PCR runs included NTCs. 
Data were exported to CopyCa l le r  Software vers ion 2.0 (Applied B iosystems, 
Foster City, California, USA) for calculation of CN.
The CN of target sequence was determ ined by relative quantif icat ion (RQ) using 
the comparative Ct (AACt) method, where cycle threshold (Ct) is the num ber of 
PCR cycles at which PCR product f luorescence is detected (Mayo et al. 2010). CN 
call was based on the Ct difference (ACt) between target and reference (Figure
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2.3) and the CopyCa l le r  Software used a m ax im um-l ike l ihood  a lgor ithm to 
determine an integer va lue for predicted CN (d iscrete CN va lue) (Park et al. 2012; 
Liu et al. 2011) and presented this along with the initial ca lculated CN, as non -
integer va lues (continuous CN value). This method was used to calculate the 
relative CN of the ta rget gene normalised to RNase P, w ithout the use of a 
calibrator sample. CopyCa l le r  Software was used to calcu late Conf idence and Z- 
Score quality metr ics. All CN calls were rev iewed and accepted with a Confidence 
Value > 80% (a lthough confidence was typ ica l ly  > 99% ) and a Z -Sco re  of Z  < 
2.65.
Figure 2.3 Amplif icat ion plot showing the quant ita t ive  determ inat ion  of copy
number using the AAC t  method. CN calls were based on the AC t  between the
target (FAM-labelled) and reference (VIC-label led) probes, a) shows an example
of CN = 2 for the target, while c) shows an exam p le  of CN = 3 for the target, when
compared with the ir  corresponding reference assay amplif icat ions (b and d 
respectively).
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2.3.4 QPCR Efficiency
For quality control of CN results, qPCR was carried out using twofold serial d i lut ions 
of genomic DNA for each TaqMan Copy Num ber and Reference Assay. Standard 
curves were generated, with a l inear trend line fit to the data to determ ine the 
PCR eff ic iency for each assay, plott ing cycle threshold (Ct) aga inst DNA 
concentration (log concentrat ion) (D 'haene et al. 2010). Eff ic iency (E) was 
calculated using the equation E = 10(' 1/m)- l ,  where m is the s lope of the l inear 
trend line of the standard curve (Liu et al. 2011). Optimal effic iency (100%) would 
be il lustrated when m = -3.32 and would dem onstra te  the doubling of PCR product 
with each comple te  cycle (D 'haene et al. 2010). Amplif icat ion eff ic iencies between 
the range of 90 -110%  are typ ica l ly  cons idered acceptab le and l inearity 
(represented by the corre lat ion coeff ic ient r2) should be c lose to 1 to show linearity 
across dilution ser ies (D 'haene et al. 2010). Details of QPRC eff ic iencies for each 
assay can be seen in Append ix  V.
68
2.4 DNA METHYLATION AND PYROSEQUENCING
Candidate genes of interest were v iewed in NCBI Gene 
(www.ncb i.n lm .n ih .gov/gene). Predesigned PyroMark CpG Assays  were identified 
using the Qiagen PyroMark CpG Assay  search tool
(h ttp ://www.q iagen.com/products/ca ta log/assay-
techno log ies/pyrosequenc ing/pyromark-cpg-assays) .  For the PyroMark Custom
Designed CpG Assays, probes and pr imers were indiv idually des igned using 
PyroMark Assay  Design 2.0 software (Q iagen Valencia, CA, USA). A section of the 
promoter region before the start site of the ta rget gene was se lected and the 
FASTA sequence downloaded. This was then opened in SnapGene  V iewer vers ion
2.2.2 (w ww .snapgene .com /produc ts /snapgene_v iewer/), to be able to v iew the
sequence. The nucleotide sequence was then copied into CpG Island Sea rche r  
(www.cpg is lands.usc .edu), which detailed CpG is lands present in the target 
region. The selected CpG island identified in CpG Island Sea rche r  was then located 
in the FASTA sequence. This was copied into PyroMark Assay  Design 2.0 software 
(Qiagen), to design the PCR and sequencing pr imers for the Pyrosequencing 
assays. The pr imer sets  were generated by the software based on the sequence 
entered. Quality scores were ass igned to each pr imer set to indicate the suitabil ity 
for Pyrosequencing analys is and to ass ist the selection of an assay. Table 2.8 
details the pre-des igned and custom PyroMark CpG Assays  investigated.

2.4.1 Bisulphite Treatm ent
Prior to Pyrosequencing analysis, bisulf ite convers ion was carried out on DNA 
samples from the pate l lar tend inopathy cases and controls. Bisulfite t rea tm en t of 
target DNA converted unmethy la ted  cytos ine residues into uracil. The methy lated 
cytosines remained unchanged and th is resulted in d ifferent DNA sequences for 
methylated and unmethy la ted  DNA (Table 2.9).
Table 2.9 The Effect of Bisulfite Treatment.
Original sequence A fter bisulfite treatm ent A fter PCR amplification
Unmethylated DNA A -C -G -T -C -G -T -C -A  A -U -G -T -U -G -T -U -A  A-T-G-T-T-G-T-T-A
Methylated DNA A -C -G -T -C -G -T -C -A  A -C -G -T -C -G -T -U -A  A -C -G -T-C -G -T -T -A
Example sequences showing the effect of bisulfite t rea tm en t on unmethy la ted  and
methylated DNA and the result ing sequences after PCR amplif ication.
Unmethylated cytos ines (C) are converted to uracil (U) during bisulf ite conversion.
Subsequent PCR results in on ly methy lated cytos ines (C) being present in the
sequence, as uracil became thym ine  (T) (Madi et al. 2012).
The conversion of unmethy la ted  cytos ines to uracil was crit ical for the accurate 
determination of methy lat ion status (Anderson and Brown 2005; Madi et al. 
2012). The temp la te  DNA was incubated in high bisulfite salt concentra t ions at a 
high temperature and low pH. The EpiTect Fast Bisulfite Convers ion  Kit (Q iagen) 
was used for convers ion and purif ication of sample  DNA. In brief, temp la te  
genomic DNA was combined with Bisulfite Solut ion, DNA Protect Buffer and RNase- 
free water in PCR tubes and mixed thorough ly  (Table 2.10). Once added to the 
reaction mix, the DNA Protect Buffer turned from green to blue, ind icating the 
correct pH for the bisulfite conversion.
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Table 2.10 React ion Com ponen ts  for Bisulf ite T reatment.
Reaction C om ponent
V o lum e per 
well (pL)
DNA 2
RNase-free  wate r 18
Bisulf ite So lut ion 85
DNA Protect Buffer 35
Total React ion Vo lum e 140
Bisulfite convers ion  was pe r fo rm ed  on a Techne TC -512  therma l cyc le r  (B ibby 
Scient if ic  Ltd, S ta f fo rdsh ire ,  UK) on a 30 m inute  p rog ram m e. The therma l cyc ler 
cond it ions can be seen in Table  2.11.
Table 2.11 Therm a l Cyc l ing  Cond it ions  for Bisulf ite T rea tment.
Step Tim e Tem perature
Denaturat ion 5 min 95 °C
Incubation 10 min cn o o n
Denaturat ion 5 min 95 °C
Incubation 10 min <r» o o n
Hold Indefin ite 20 °C
Following the bisulf ite t rea tm en t  in the the rm a l cycler, a ser ies of s teps were 
undertaken to purify the DNA. These steps were necessary  to rem ove salts and 
chem ica ls  used in the bisulf ite convers ion process that could inhibit 
Pyrosequencing. These  s teps included the addit ion of d ifferent buffers and ethanol
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and centrifugation through MinElute DNA spin columns into collections tubes. 
These steps started with the addition of 310 pL of Buffer BL and 250 pL ethanol 
(95-100%), vortexing between each addition. The contents were transferred into 
MinElute DNA spin columns with collection tubes and centrifuged (1 min at 13,000 
rpm) to separate the DNA from the leftovers from the bisulfite conversion 
reactions. Next, 500 pL of Buffer BW (wash buffer) was passed through the spin 
columns (centrifuge 1 min at 13,000 rpm) and 500 pL of Buffer BD (desulfonation 
buffer) was added and incubated at room temperature for 15 min. Again the spin 
columns were centrifuged for 1 min at 13,000 rpm. After two more wash steps (2 
x 500 pL Buffer BW centrifuged for 1 min at 13,000 rpm), 250 pL ethanol (95- 
100%) was added to each spin column and centrifuged. The spin columns were 
then transferred to new 2 mL collection tubes and spun again to remove any 
residual liquid. Finally, the spin columns were transferred to 1.5 mL micro-
centrifuge tubes and the DNA samples were eluted in 15 pL of Buffer EB (elution 
buffer), quantified using the Nano Drop 2000 (Thermo Fisher Scientific, USA) and 
stored at -20 °C.
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2.4.2 PCR Amplification of Target CpG Region
The target region of interest was amplified using the PyroMark PCR Kit (Qiagen). 
Target DNA was combined with the PCR kit components, along with the specific 
PCR primers supplied with the PyroMark CpG Assay (Qiagen) for the specific gene 
promoter region of interest (Table 2.12). One primer of the set was biotinylated 
at its 5' end, which was necessary for the preparation of single-stranded PCR 
product for subsequent Pyrosequencing. PCR was performed on a Techne TC-512 
thermal cycler (Bibby Scientific Ltd, Staffordshire, UK). The thermal cycling 
conditions for the PyroMark PCR can be seen in Table 2.13.
Table 2.12 Reaction Components for PyroMark PCR.
Reaction Component
Volume per 
well (pL)
PyroMark PCR Master Mix 12.5
CoralLoad Concentrate 2.5
PyroMark PCR Primers 2.5
RNase-free water 5.5
Template DNA 2.0
Total Reaction Volume 25.0
Table 2.13 Thermal Cycling Conditions for PyroMark PCR.
Step Time Temp
Initial PCR activation step (activation of HotStar 
Taq DNA Polymerase)
3-step cycling (45 cycles):
15 min 95 °C
Denaturation 30 sec 94 °C
Annealing 30 sec 56 °C
Extension 30 sec 72 °C
Final extension 10 min 72 °C
2.4.3 Gel Electrophoresis
Product amplification was checked prior to Pyrosequencing analysis by running 
samples (along with a 1 kb ladder) on a 1% agarose gel stained with SYBR Safe 
DNA gel stain (Invitrogen, Carlsbad CA, USA). Typical gel images showing 
amplicon purity are shown in Chapter 6.
2.4.4 Pyrosequencing
A Qiagen Q24 PyroMark (Qiagen) was used to sequence the target gene promoter 
regions. The Pyrosequencing method enabled quantification of DNA methylation 
status at CpG sites in the promoter regions of the selected genes, providing 
accurate and detailed profiles of DNA methylation patterns. The proportion of 
methylated DNA at each site was illustrated by the peak heights in the Pyrograms 
generated by the PyroMark Q24 software.
The first step of Pyrosequencing involved immobilising the biotinylated PCR 
product onto streptavidin-coated Sepharose beads (Streptavidin Sepharose High- 
Performance, GE Healthcare, UK). PCR product was combined with streptavidin- 
coated Sepharose beads, PyroMark Binding Buffer and high-purity water in a 24- 
well PCR plate sealed with cap strips. Reagent volumes required for this 
immobilisation step can be seen in Table 2.14.
Table 2.14 Reagents for PCR Product Immobilisation.
Reagent
Volume per 
well (pL)
PyroMark Binding Buffer 40
Streptavidin-coated Sepharose beads 2
High-purity water 28
PCR product 10
Total Volume 80
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The PCR plate was then agitated constantly for 10 min at 1400 rpm. Immediately 
following this, the Sepharose beads were captured using the PyroMark Q24 
Vacuum Workstation (Qiagen). After being processed through a series of wash 
steps using the PyroMark Vacuum Workstation (Table 2.15), the immobilised PCR 
product was released into a 24-well PyroMark Q24 plate containing 2.5 pL 
PyroMark Sequencing Primer (3 pM) and 22.5 pL PyroMark Annealing Buffer 
(Qiagen) and incubated at 80 °C for 2 min on a pre-heated hot plate. The PyroMark 
Annealing Buffer enhanced the hybridisation of the PyroMark Sequencing Primer 
to the single-stranded DNA template.
Table 2.15 Steps for Capturing Sepharose Beads using PyroMark Vacuum 
Workstation.
Volume Time
Step
(mL) (sec)
70% ethanol (wash) 50 5
PyroMark Denaturation Solution8 40 5
PyroMark Wash Bufferb 50 10
aThe PyroMark Denaturation Solution separated the complimentary DNA strand 
from the biotin-tagged strand, which would be the template used for 
Pyrosequencing. bThe PyroMark Wash Buffer ensured that only the single-stranded 
biotin-tagged DNA was immobilised to the PyroMark Vacuum Tool.
After cooling for 10 min, the PyroMark Q24 plate was loaded into the PyroMark 
Q24. PyroMark Q24 software was used to generate the nucleotide dispensation 
order and the volumes of nucleotides (dATPaS, dGTP, dCTP and dTTP), enzyme 
mix and substrate mix to add to the PyroMark Q24 Cartridge for Pyrosequencing.
The enzyme mix contained: DNA polymerase (incorporated dispensed 
nucleotides), ATP sulfurylase (converted pyrophosphate to ATP), luciferase 
(generated light signal) and apyrase (degraded ATP and unincorporated 
nucleotides). The substrate mix contained: adenosine 5' phosphosulfate (APS) (for 
generation of ATP) and luciferin (substrate for luciferase). After each nucleotide 
incorporation event, pyrophosphate (PPi) is released and converted to ATP by ATP 
sulfurylase (Figure 2.4). The ATP then drives the conversion of luciferin to 
oxyluciferin by luciferase. The light generated by this reaction is detected as a 
peak in the Pyrogram (Figure 2.4) (Madi et al. 2012).
3"
5'
Polymerase
/
-CGTCCGGAGGCCAAGTTCCA
m i n i  rrrr m f t  rr -r— r
i 1.1 i . i  i i,-i.
GCAGGCCT 3'
5#
T h/1
light
tim e
Figure 2.4 Overview of the Pyrosequencing cascade. Figure from PyroMark Gold
Q24 Reagents Handbook. ©QIAGEN, all rights reserved.
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2.5 STATISTICS
2.5.1 Power Calculations
The statistical power of our SNP analyses was calculated using Quanto version
1.2.4 (http://hydra.usc.edu/gxe) (Gauderman 2002). Assuming a 10% 
prevalence of ATP, an odds ratio (OR) of 2.2, an allele frequency of 0.45 and a 
recessive mode of inheritance, our analyses had 80% power to detect associations 
at the p < 0.05 significance level (based on 137 cases and 137 controls). However, 
when the individual cohorts were combined, our analyses had >90% power to 
detect associations at the p < 0.05 significance level (based on 330 cases and 330 
controls).
For our discrete CNV data analyses, we used Sampsize version 0.6 
(http://sampsize.sourceforge.net/) for a power calculation (Glaziou 2005). With 
an assumed CN exposure frequency of 20%, an OR of 2.2 and without a specified 
mode of inheritance, our cohort size (based on 130 cases and 130 controls) was 
sufficient for 80% power. When the cohorts were combined, the number of cases 
exceeded 300, resulting in >99% power to detect associations with the same 
parameters. Furthermore, lowering the CN exposure frequency to 10% in the 
model based on a combined cohort, power reached >90%.
For our continuous CNV data analyses, we used G*Power Software version 3.1.9.2 
(http://www.gpower.hhu.de/en.html) (Faul et al. 2007). With an effect size of d 
= 0.5 (medium effect), a sample size of 90 cases and 90 controls resulted in > 
90% power to detect associations at the p < 0.05 significance level. Based on the 
same parameters, our continuous CNV data analyses on a combined cohort (based 
on 300 cases and 300 controls) had > 99% power to detect associations.
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2.5.2 Data Analysis
All data were analysed using IBM SPSS Statistics, version 20 (IBM Corp. Armonk, 
NY). Details about specific analyses and findings are discussed in the relevant 
chapters.
For the SNP genotype and CNV discrete CN data (<2 CN, =2 CN and >2 CN), a 
Pearson's chi-squared (x2) Test or Fisher's Exact Test was used to analyse for any 
differences between groups. When the cell count in categories did not exceed 5, 
the p value considered was based on Fisher's exact test, due to not meeting the 
assumptions for the x2 test. For the SNP data, Hardy-Weinberg equilibrium (HWE) 
was established using a HWE calculator (Michael H. Court, 2005-2008) accessed 
from www.tufts.edu/~mcourt01/Documents/Court lab - HW calculator.xls. with p 
< 0.05 considered to be a deviation from HWE. A x2 test was also used to 
determine any significant differences between the gender distributions of the 
groups.
Continuous CN data (non-integer values) were tested for normality using a 
Shapiro-Wilk/Kolmogorov-Smirnov Test. When considering normally distributed 
CN data sets, an independent samples t-Test was used to analyse for differences 
in the continuous CN data, based on the means. Levene's Test for Equality of 
Variance determined the appropriate p value to be considered. A Levene's Test 
value of > 0.05 meant equal variance was assumed, while a value < 0.05 meant 
equal variance was not assumed. If not normally distributed, the non-parametric 
Mann-Whitney U Test was used to test for differences in the continuous CN data. 
The CN data was principally analysed as discrete calls, although the continuous
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data was also analysed for clarity, as it has been suggested that a degree of 
rounding error can occur during the process of discriminating CN into discrete 
integer groups (Park et al. 2012). However, on the whole, we found concordance 
in our analyses and therefore have confidence that the degree of error in CN calling 
was minor. Differences in DNA methylation (%) between the patellar tendinopathy 
and control groups were also analysed using an independent samples t-Test or 
Mann-Whitney U Test, with signif icance at p < 0.05.
A one-way analysis of var iance (ANOVA) was used to determ ine any significant 
differences between the characterist ics (age, height, weight, BMI) of the cases 
and controls, co-var ied where appropriate. ANOVA was also used to determine 
any relationship between genotypes (SNP/CNV) and participant characteristics.
Comparisons included controls (CON) vs. the collective ATP cases (UK, SA and 
AUS cohorts combined), CON vs. tendinopathy (TEN) and CON vs. rupture (RUP). 
Cohorts (UK, SA  and AUS) were also analysed separately and split for gender. 
Details of the specif ic analyses can be seen in the re levant chapters. For all 
analyses signif icance was accepted when p < 0.05. Analyses were also undertaken 
when a subset of the UK cohort were excluded for certain potentially relevant 
comorbidity, as described in the literature in Chapter 1 (1.4.1.3 System ic 
Diseases) and indicated by the participant in the questionnaire upon recruitment 
(Appendix III). No changes in signif icance or non-signif icance from the original 
analyses were noted. Therefore, P values shown are based on the whole cohort.
SNPator is a web-based data analysis tool used for SNP data, freely available at
http://www.snpator.org/public/new_login/index.php (Morcil lo-Suarez et al.
2008). The SNP genotype data analyses were validated using this software 
resource. GraphPad Prism version 5.0 (GraphPad Software, San Diego, California, 
USA) was also used for certain data analysis and the production of graphs, which 
can be seen in the re levant chapters.
CHAPTER 3: COPY NUMBER VARIANTION WITHIN SELECTED COLLAGEN  
AND TNC GENES AS RISK FACTORS FOR ACHILLES TENDON PATHOLOGY
3.1 INTRODUCTION
While over 90% of the cellular content of tendon consists of tenocytes, the gross 
structure of tendon consists of an extracellu lar matrix (ECM) rich in collagens 
(Kader et al. 2002). The collagen fibrils are bundled together in an organised 
framework to form fascicles, providing high tensile strength (Kader et al. 2002). 
Tenasc in-C is an ECM glycoprotein expressed particularly in musculoskeletal 
t issue, which is known to interact with other ECM components and cell surface 
receptors (Midwood et al. 2011). Variants within a number of collagen genes and 
within the TNC gene have been associated with Achil les tendon pathology (ATP) 
(Mokone et al. 2005; Mokone et al. 2006; September et al. 2008; September et 
al. 2009; Abraham s et al. 2013; Saunders et al. 2013). However, the effect of 
copy number variation (CNV) on the risk of ATP has never been investigated.
3.1.1 COL5A1
The COL5A1 gene encodes the alpha 1 type V collagen protein, a minor structural 
protein constituent of tendons (Mokone et al. 2006). Although the function of the 
type V collagen is not fully defined, it is thought to be involved in the regulation 
of type I collagen fibril d iameter and despite being a minor structural component, 
may have a more predominant role in developing connective t issues (September 
et al. 2009).
In 2006, Mokone et al. showed that the BstUI restriction fragment length 
polymorphism (RFLP) ( r s l2 722 )  within the 3'-untranslated region (UTR) of the
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C0L5A1 gene was associated with ATP in a South African Caucasian cohort. The 
allele frequencies of the COL5A1 BstUl RFLP between the ATP and control (CON) 
groups were signif icantly different (p = 0.006) (Mokone et al. 2006). The COL5A1 
BstUl RFLP was also later found to associate with Achil les tendinopathy in an 
Australian Caucasian cohort, where the CC genotype was associated with a 
significantly decreased risk of developing Achil les tendinopathy (September et al. 
2009). More recently in 2013, three single nucleotide po lymorphisms (SNPs) 
within the functional COL5A1 3 '-UTR region were independently associated with 
Achil les tend inopathy (Abrahams et al. 2013).
While certain mutat ions in collagen genes including the COL5A1 gene are known 
to cause the inherited connective t issue disorder Ehlers-Danlos syndrome (EDS), 
other po lymorph isms mentioned in the previous chapter have been shown to 
associate with the risk of ATP (Figure 3.1) (Collins and Posthumus 2011). As can 
be seen in the figure below, mutations in the COL5A1 gene can result in abnormal 
collagen fibre formation compared to the typical wild-type collagen structure. 
While the CC genotype of the COL5A1 r s l2 7 2 2  was associated with a decreased 
risk of Achil les tendinopathy, the TT genotype was found to be associated with 
Achil les tend inopathy and increased COL5A1 mRNA stabil ity (Mokone et al. 2006; 
Collins and Posthumus 2011; Laguette et al. 2011). It is proposed that the TT 
genotype results in an increase in type V collagen production where more is 
incorporated into the collagen fibril, resulting in collagen fibres containing smaller 
fibrils and a tendon with increased stiffness and reduced tensile strength (Collins
and Posthumus 2011).
C0L5A1 gene 
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Figure 3.1 The relationship between COL5A1 genotypes, disease risk and the 
associated effect on connective t issue and collagen fibre assembly (Collins and 
Posthumus 2011).
The COL5A1 gene was selected for CNV investigation as a number of variants 
within this gene have previously been associated with ATP (Mokone et al. 2006; 
September et al. 2009; Abrahams et al. 2013). In addition, CNV was reported in
the Database of Genomic Variants for this gene
(http ://dgv.tcag .ca/dgv/app/home). Two TaqMan Copy Number Assays 
(Hs00180523_cn and Hs02980647_cn) (Life Technologies) were selected within 
this region, spanning intron 4 - exon 5 and exon 14 - intron 14 respectively
(Figure 3.2).
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Chromosome 9 -  COL5A1
Hs00180523_cn Hs02980647_cn
Intron 4-Exon 5 Exon 14-lntron 14
Figure 3.2 Location of the Hs00180523_cn and Hs02980647_cn Copy 
Number Assays within the COL5A1 gene
(a) Chromosomal location of the COL5A1 gene (Chr. 9:137,533,620- 
137,736,686). (b) Size and exonic structure of the COL5A1 gene with location of 
the TaqMan Copy Number Assays (Hs00180523_cn Chr.9 :137,619,157 and 
Hs02980647_cn Chr .9 :137 ,644 ,529). All locations referenced from NCBI build 37. 
Compiled from www.ensembl.org and www.l ifetechnolog ies.com.
3.1.2 COL4A1
Another structural component of the tendon ECM is the alpha 1 type IV collagen, 
encoded by the COL4A1 gene (Seals and Courtneidge 2003; Jelinsky et al. 2011). 
While COL4A1 protein is known to be cleaved by several MMPs including MMP2, 3, 
9, 10 and 13, both ADAM10 and ADAM15 are also involved in the degradation and 
remodell ing of COL4A1 (Somerv i l le  et al. 2003; Seals and Courtneidge 2003).
Mutations in the COL4A1 gene have been associated with congenital muscular 
dystrophies (CMDs) in humans and mice (Labelle-Dumais et al. 2011). 
Specifically, certain mutat ions within the COL4A1 gene are known to interfere with 
the folding and assembly  of the COL4A1 protein via the disruption of splicing and 
the subsequent deletion of am ino acids from its sequence (Labelle-Dumais et al. 
2011). In human tendinopathy, altered expression levels of the COL4A1 gene have 
also been identified, with a 2.7 fold increase in expression compared to normal 
tendon (Jelinsky et al. 2011).
The COL4A1 gene was selected for CNV investigation as altered expression of this 
gene was reported between tendinopathy and normal tendon (Jelinsky et al. 
2011), which it was hypothesised could be the result of CNV. Furthermore, CNV 
was reported in the Database of Genom ic Variants for this gene. Two TaqMan Copy 
Number Assays (Hs00739915_cn and Hs02119212_cn) (Life Technologies) were 
selected within this region, spanning intron 22 - exon 22 and exon 21 respectively 
(Figure 3.3).
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Figure 3.3 Location of the Hs00739915_cn and Hs02119212_cn Copy
Number Assays within the COL4A1 gene
(a) Chromosomal location of the COL4A1 gene (Chr. 13:110,801,318- 
110,959,496). (b) Size and exonic structure of the COL4A1 gene with location of 
the TaqMan Copy Number Assays (Hs00739915_cn C h r .13:110,847,375 and 
Hs02119212_cn C h r .13:110,850,912). All locations referenced from NCBI build
37. Compiled from www.ensembl.org and www.l ifetechnolog ies.com.
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3.1.3 TNC
The TNC gene encodes the ECM glycoprotein tenascin-C, which is expressed in a 
range of tissues, including tendons (Mokone et al., 2005). In relation to tendon, 
tenascin-C plays a role in the regulation of cell-matrix interactions around the 
tendon, by binding to other ECM proteins and cell receptors (Mokone et al., 2005). 
Tenascin-C expression is low in healthy adult tissue, however, expression is shown 
to be up-regulated in response to injury (Midwood et al. 2011). In addition, 
mechanical loading on tendons is shown to regulate TNC gene expression in a 
dose-dependent manner (Jarvinen et al. 1999; Saunders et al. 2013).
The TNC gene was one of the first genes to be investigated for its role in ATP and 
research has highlighted some interesting findings (Mokone et al. 2005; 
September et al. 2012; Saunders et al. 2013). Mokone et al. (2005) found that a 
guanine-thymine (GT) repeat polymorphism within intron 17 of the TNC gene was 
associated with ATP in a South African population, although the functional effect 
of this variant is unknown. Furthermore, Saunders et al. (2013) showed that 
certain SNPs were associated with Achilles tendinopathy in South African and 
Australian cohorts (Saunders et al. 2013). There was a significant allelic 
association between the rs2104772 and rsl330363 variants and Achilles 
tendinopathy (Saunders et al. 2013). Accordingly, two TaqMan Copy Number 
Assays (Hs06903309__cn and Hs00634176_cn) (Life Technologies) were selected 
within this region (Figure 3.4).
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Chromosome 9 - TNC
Hs00634176_cn Hs06903309_cn
Intron 23-Exon 23 Intron 15
Figure 3.4 Location of the Hs00634176_cn and Hs06903309_cn Copy 
Number Assays within the TNC gene
(a) Chromosomal location of the TNC gene (Chr.9:117,782,806-117,880,536).
(b) Size and exonic structure of the TNC gene with location of the TaqMan Copy 
Number Assays (Hs00634176_cn Chr.9:117,793,858 and Hs06903309_cn 
Chr.9:117,812,454). All locations referenced from NCBI build 37. Compiled from 
www.ensembl.org and www.lifetechnologies.com.
3.1.4 Chapter Aims
The specific aim of this chapter was to determine whether CNV within the 
candidate genes COL5A1 (measured using the Hs00180523_cn and 
Hs02980647_cn Copy Number Assays), COL4A1 (using the Hs00739915_cn and 
Hs02119212_cn Copy Number Assays) and TNC (using the Hs00634176_cn and 
Hs06903309_cn Copy Number Assays) was associated with ATP in a UK, South 
African and Australian Caucasian population.
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3.2 METHODS
The methods below are specific to this chapter and are described in brief. An 
overview of the detailed methodology is detailed in Chapter 2.
3.2.1 Participants
A total of 290 (122 UK, 111 SA, 57 AUS) Caucasian participants diagnosed with 
ATP were recruited for this study. A total of 357 (131 UK, 95 SA, 131 AUS) 
physically active Caucasian control participants (asymptomatic and without 
history of ATP) were recruited as controls.
3.2.2 DNA Collection and Extraction
For the UK cohort, DNA was extracted from 2 mL of saliva collected using 
ORAGENE-DNA kits (OG-500) and DNA purification was carried out using the 
prepIT-L2P DNA extraction kit (DNA Genotek Inc., Ontario, Canada). For the South 
African cohort, DNA was extracted from 4.5 mL of venous blood, obtained by 
venipuncture of a forearm vein and collected into an ethylenediaminetetraacetic 
acid (EDTA) vacutainer tube. For the AUS cohort, DNA was extracted from 
approximately 4.5 mL of venous blood, using a sequence extraction technique 
(FlexiGene DNA Kit, Qiagen P/L, Valencia, California, USA). Full details of DNA 
collection and extraction are described in Chapter 2.
3.2.3 Copy Number Genotyping
Copy number genotyping was carried out using a StepOnePlus Real-Time PCR 
System (Applied Biosystems, Foster City, California, USA). TaqMan Copy Number 
Assay and TaqMan Copy Number Reference Assay RNase P were run 
simultaneously in a duplex real-time PCR reaction. Reactions were performed in
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96-well plates using universal PCR cycling conditions. Each reaction comprised of 
10 ng of purified genomic DNA, combined with a mastermix containing AmpliTaq 
Gold DNA Polymerase and probes and primers for both the target copy number 
and reference assay. Reactions were run in quadruplicate for each DNA sample. 
NTCs were included within each plate to check for quality control and to check for 
contamination. The data were exported to CopyCaller Software version 2.0 
(Applied Biosystems, Foster City, California, USA) for calculation of copy number.
3.2.4 Data Analysis
Data were analysed using IBM SPSS Statistics version 20 (IBM Corp. Armonk, NY). 
A one-way analysis of variance (ANOVA) was used to test for any significant 
differences between the characteristics (age, height, weight, BMI) of the CON and 
ATP groups, as well as to test for differences between the characteristics and copy 
number. A Pearson's chi-squared (x2) test was used to determine any significant 
differences between the gender of the CON and ATP groups. A x2 or Fisher's Exact 
Test was used to determine any significant differences in discrete copy number 
(<2, =2, >2 copies) between the CON and ATP groups, while differences in 
continuous copy number were analysed with a non-parametric Mann-Whitney U 
Test. The ATP group was also split to analyse the TEN and RUP groups separately. 
Data were analysed by gender and reported if significant. Significance was 
accepted at p < 0.05 for all analyses.
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3.3 RESULTS
When the characteristics of the CON and ATP cohorts were compared, some 
significant differences were identified. Weight and BMI were significantly different 
between the CON and ATP group in the SA cohort and the AUS cohort (both p < 
0.05). For the SA cohort, the mean weight (kg) of the CON and ATP participants 
was 72.1 ± 12.2 and 81.1 ± 15.3 respectively. For the AUS cohort, the mean 
weight of the CON and ATP participants was 73.4 ± 14.0 and 80.4 ± 14.9 
respectively. There was a significant difference in age between the CON and ATP 
group in both the UK (CON, 41.3 ± 11.3; ATP, 46.3 ± 13.6; p = 0.001), and the 
SA (CON, 36.8 ± 9.9; ATP, 40.5 ± 12.9; p = 0.025) cohorts. Furthermore, gender 
distribution (% males) was significantly different between the CON and ATP groups 
in the AUS cohort (p < 0.05). Full details of participant characteristics can be seen 
in Chapter 2.
Copy number was calculated using CopyCaller Software version 2.0 (Applied 
Biosystems, Foster City, California, USA) based on the calling algorithm detailed 
in the methods in Chapter 2. A typical CopyCaller output graph can be seen in 
Figure 3.5.
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Data were analysed as both continuous and discrete CN to check calling accuracy. 
Figure 3.6 shows the relationship between the continuous CN values and the 
discrete CN calls. Clusters can be seen, showing how the CopyCaller Software calls 
each continuous CN value to the nearest discrete CN.
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Figure 3.6 Scatter plot showing the raw continuous CN values on the y-axis, 
plotted against the discrete integer CN values on the x-axis. Graph shown was for 
the Hs06903309_cn assay within the TNC gene with a combined cohort (UK, SA
and AUS).
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3.3.1 COL5A1 Copy Number Frequencies
There were no significant differences in discrete copy number for the 
Hs00180523_cn assay within the COL5A1 gene for the combined CON vs. ATP (p 
= 0.131), CON vs. TEN (p = 0.195) or CON vs. RUP (p = 0.460) groups (Table 
3.1a). When the SA and AUS cohorts where analysed separately, there were no 
differences for the SA cohort between the CON vs. ATP (p = 1.000), CON vs. TEN 
(p = 0.702) or CON vs. RUP (p = 0.513) groups. For the AUS cohort, there was a 
significant difference in copy number between the CON and ATP groups (p = 
0.012). Although the total number of AUS ATP participants is relatively small (n = 
44), the distribution of copy number was significantly different between the CON 
(CN<2, n=4; CN = 2, n = 65; CN>2, n = 0) and ATP (CN<2, n = 0; CN = 2, n=40; 
CN>2, n=4) groups. This is also shown for the CON vs. TEN analysis, however, 
this is due to the AUS cohort comprising of only tendinopathy cases and no 
ruptures. Nevertheless, when the continuous copy number data were also 
analysed with a Mann-Whitney U Test, there was no significant difference between 
the AUS CON and ATP groups (p value not shown). This was also the case for all 
other analyses for the continuous CN data (p values not shown).
For the F1s02980647_cn assay within the COL5A1 gene, there were no differences 
in discrete CN for the UK cohort between the CON vs. ATP (p = 1.000), CON vs. 
TEN (p = 1.000) or CON vs. RUP (p = 1.000) groups (Table 3.1b).
The QPCR efficiencies of the COL5A1 assays both exceed 97%. Efficiency graphs 
for the Hs00180523_cn and Hs02980647_cn assays can be seen in Appendix V 
(Figure V.5 and Figure V.6 respectively).
Table 3.1a Copy number distribution within the COL5A1 gene in the cases 
(ATP/TEN/RUP) and CON groups using the Hs00180523_cn assay.
C o h o rt M ean  CN < 2 CN = 2 CN > 2 CN n p -va lu e
C O M B IN E D
C O L 5 A 1
H s0 0 1 8 0 5 2 3 _ cn
CO N 1 .94  ± 0 .27 4 150 1 155
A TP 2 .0 0  ± 0 .25 1 146 5 152 0 .131
TEN 1 .99  ± 0 .25 1 110 4 115 0 .195
R U P 2 .02  ± 0 .25 0 36 1 37 0 .460
SA C O N 1 .97  ± 0 .18 0 85 1 86 -
A TP 1 .99  ± 0 .21 1 106 1 108 1.000
TEN 1 .97  ± 0 .18 1 70 0 71 0 .7 0 2
R U P 2 .0 2  ± 0 .25 0 36 1 37 0 .513
A U S C O N 1.91  ± 0 .35 4 65 0 69 ̶
A TP 2 .03  ± 0 .34 0 40 4 44 0.012
TEN 2 .03  ± 0 .34 0 40 4 44 0.012
R U P ̶ 0 0 0 0 ̶
Differences in discrete copy number between the CON vs. ATP, CON vs. TEN and 
CON vs. RUP groups were analysed with a x2 or Fisher's Exact Test. Mean CN (± 
SD) represents the continuous CN data, which were analysed with a Mann-Whitney 
U Test.
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Table 3.1b Copy number distribution within the COL5A1 gene in the cases 
(ATP/TEN/RUP) and CON groups using the Hs02980647_cn assay.
C o h o rt M ean  CN < 2 CN = 2 CN > 2 CN n p -va lu e
UK
C O L 5 A 1
H s0 2 9 8 0 6 4 7 _ cn
CO N 2 .0 0  ± 0 .12 0 129 1 130
A T P 1 .99  ± 0 .08 0 118 0 118 1.000
T E N 1 .98  ± 0 .08 0 84 0 84 1.000
R U P 2 .0 0  ± 0 .08 0 34 0 34 1.000
Differences in discrete copy number between the CON vs. ATP, CON vs. TEN and 
CON vs. RUP groups were analysed with a Fisher's Exact Test. Mean CN (± SD) 
represents the continuous CN data, which were analysed with a Mann-Whitney U
Test.
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3.3.2 COL4A1 Copy Number Frequencies
When the combined cohort (UK and SA) was analysed for differences in discrete 
CN for the Hs00739915_cn assay, there was a significant differences between 
both the CON vs. ATP (p = 0.014) and the CON vs. TEN (p = 0.033) groups (Table 
3.2a). Specifically, the distribution of copy number was significantly different 
between the combined CON (CN<2, n = 5; CN = 2, n = 208; CN>2, n = 2) and ATP 
(CN<2, n = 0; CN = 2, n=211; CN>2, n = 7) groups. The distribution of copy number 
was also significantly different between the combined CON and the TEN (CN<2, 
n = 0; CN = 2, n = 146; CN>2, n = 6) groups. In both analyses, the CON participants 
had a higher frequency of participants with CN<2, while the ATP and TEN cases 
had a higher frequency of participants with CN>2. However when the continuous 
CN data was analysed with a Mann-Whitney U Test, there were no significant 
differences observed. In addition, there was no significant difference in CN for the 
combined CON vs. RUP groups (p = 0.425).
When the UK and SA cohorts were analysed separately, there were no significant 
differences for the discrete CN data between the CON vs. ATP (UK, p = 0.061; SA, 
p = 0.180), the CON vs. TEN (UK, p = 0.083; SA, p = 0.075), nor the CON vs. 
RUP (UK, p = 0.584; SA, p = 1.000) groups. There were also no significant 
differences between the continuous CN data (p values not shown).
For the Hs02119212_cn assay within the COL4A1 gene, there were no differences 
in discrete CN for the combined cohort between the CON vs. ATP (p = 0.615), 
CON vs. TEN (p = 0.512) or CON vs. RUP (p = 0.575) groups (Table 3.2b). When 
the UK and SA cohorts were analysed separately, there were no significant 
differences between the CON vs. ATP (UK, p = 1.000; SA, p = 1.000), CON vs.
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TEN (UK, p = 1.000; SA, p = 1.000) nor the CON vs. RUP (UK, p = 1.000; SA, p 
= 0.506) groups. When the continuous CN data were analysed, there were no 
significant differences for any comparisons (combined or separate cohorts).
The QPCR efficiencies of the COL4A1 assays both exceed 94%. Efficiency graphs 
for the Hs00739915_cn and Hs02119212_cn assays can be seen in Appendix V 
(Figure V.3 and Figure V.4 respectively).
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Table 3.2a Copy number distribution within the COL4A1 gene in the cases 
(ATP/TEN/RUP) and CON groups using the Hs00739915_cn assay.
C o h o rt M ean  CN < 2 CN = 2 CN > 2 CN n p -va lu e
C O M B IN E D
C O L 4 A 1
H s0 0 7 3 9 9 1 5 _ cn
C O N 1 .96  ± 0 .29 5 208 2 215
A TP 2 .01  ± 0 .31 0 211 7 218 0.014
T E N 2 .0 0  ± 0 .27 0 146 6 152 0.033
R U P 2 .03  ± 0 .38 0 65 1 66 0 .4 2 5
UK C O N 1.93  ± 0 .31 5 121 0 126 -
A T P 1 .96  ± 0 .13 0 115 1 115 0 .061
T E N 1 .95  ± 0 .14 0 85 0 85 0 .083
R U P 2 .0 0  ± 0 .12 0 30 0 30 0 .5 8 4
SA C O N 2 .01  ± 0 .24 0 87 2 89 -
A TP 2 .0 6  ± 0 .42 0 96 7 103 0 .1 8 0
TEN 2 .0 6  ± 0 .36 0 61 6 67 0 .0 7 5
R U P 2 .06  ± 0 .24 0 35 1 36 1.000
Differences in discrete copy number between the CON vs. ATP, CON vs. TEN and 
CON vs. RUP groups were analysed with a Fisher's Exact Test. Mean CN (± SD) 
represents the continuous CN data, which were analysed with a Mann-Whitney U 
Test.
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Table 3.2b Copy number distribution within the COL4A1 gene in the cases 
(ATP/TEN/RUP) and CON groups using the Hs02119212_cn assay.
C o h o rt M e a n  CN < 2 CN = 2 CN > 2 CN n p -va lu e
C O M B IN E D
C O L 4 A 1
H s0 2 1 1 9 2 1 2 _ cn
C O N 1 .99  ± 0 .1 3 0 214 2 216
A T P 1 .99  ± 0 .14 0 226 1 227 0 .6 1 5
T E N 1 .99  ± 0 .12 0 156 0 156 0 .5 1 2
R U P 1 .98  ± 0 .1 7 0 70 1 71 0 .5 7 5
UK C O N 1 .98  ± 0 .12 0 127 1 128 —
A T P 1 .99  ± 0 .0 6 0 120 0 120 1.000
T E N 1 .99  ± 0 .0 6 0 86 0 86 1.000
R U P 1 .98  ± 0 .07 0 34 0 34 1.000
SA C O N 2 .0 0  ± 0 .15 0 87 1 88 —
A T P 1 .99  ± 0 .19 0 106 1 107 1.000
T E N 1 .99  ± 0 .17 0 70 0 70 1.000
R U P 1 .98  ± 0 .23 0 36 1 37 0 .5 0 6
Differences in discrete copy number between the CON vs. ATP, CON vs. TEN and 
CON vs. RUP groups were analysed with a Fisher's Exact Test. Mean CN (± SD) 
represents the continuous CN data, which were analysed with a Mann-Whitney U 
Test.
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3.3.3 TNC Copy Number Frequencies
There were no significant differences in copy number for either loci investigated 
within the TNC gene (Hs00634176_cn and Hs06903309_cn) between the 
combined CON and ATP groups (Hs00634176_cn assay, p = 0.829;
Hs06903309_cn assay, p = 0.676), nor between the combined CON and TEN 
(Hs00634176_cn assay, p = 0.641; Hs06903309_cn assay, p = 0.275) or CON 
and RUP (Hs00634176_cn assay, p = 1.000; Hs06903309_cn assay, p = 0.706) 
groups (Table 3.3a and 3.3b). There were also no differences for the UK, SA and 
AUS cohorts when analysed separately. Furthermore, when the continuous CN 
data were analysed, there were no significant differences between the combined 
or separate cohorts.
The QPCR efficiency of the TNC assays averaged >90%. The efficiency graphs for 
the Hs00634176_cn and Hs06903309_cn assays can be seen in Appendix V 
(Figure V.9 and Figure V.10 respectively).
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Table 3.3a Copy number distribution within the TNC gene in the cases 
(ATP/TEN/RUP) and CON groups using the Hs00634176_cn assay.
Cohort Mean CN < 2 CN = 2 CN > 2 CN n p-value
COMBINED
TNC
H s 0 0 6 3 4 1 7 6 _ c n
CON 1.98 ± 0.12 2 302 1 305
ATP 1.96 ± 0.15 3 274 0 277 0.829
TEN 1.96 ± 0.17 3 203 0 206 0.641
RUP 1.98 ± 0.08 0 71 0 71 1.000
UK CON 2.00 ± 0.12 0 127 1 128 -
ATP 1.97 ± 0.08 0 121 0 121 1.000
TEN 1.97 ± 0.09 0 87 0 87 1.000
RUP 1.98 ± 0.08 0 34 0 34 1.000
SA CON 1.97 ± 0.09 0 88 0 88 -
ATP 1.97 ± 0.10 0 107 0 107 —
TEN 1.97 ± 0.11 0 70 0 70 —
RUP 1.98 ± 0.08 0 37 0 37 —
AUS CON 1.95 ± 0.15 2 87 0 89 —
ATP 1.91 ± 0.30 3 46 0 49 0.347
TEN 1.91 ± 0.30 3 46 0 49 0.347
RUP — 0 0 0 0 —
Differences in discrete copy number between the CON vs. ATP, CON vs. TEN and
CON vs. RUP groups were analysed with a Fisher's Exact Test. Mean CN (± SD) 
represents the continuous CN data, which were analysed with a Mann-Whitney U
Test.
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Table 3.3b Copy number distribution within the TNC gene in the cases
(ATP/TEN/RUP) and CON groups using the Hs06903309^cn assay.
Cohort Mean CN < 2 CN = 2 CN > 2 CN n p-value
TNC
H s 0 6 9 0 3 3 0 9 _ c n
COMBINED CON 2.03 ± 0.25 0 325 12 337 -
ATP 2.04 ± 0.25 0 254 12 266 0.676
TEN 2.05 ± 0.27 0 185 11 196 0.275
RUP 2.01 ± 0.18 0 69 1 70 0.706
UK CON 2.00 ± 0.11 0 128 1 129 —
ATP 2.01 ± 0.14 0 120 2 122 0.613
TEN 2.02 ± 0.16 0 86 2 88 0.567
RUP 1.98 ± 0.10 0 34 0 34 1.000
SA CON 2.02 ± 0.19 0 86 2 88 —
ATP 2.04 ± 0.23 0 98 5 103 0.455
TEN 2.04 ± 0.23 0 63 4 67 0.404
RUP 2.03 ± 0.23 0 35 1 36 1.000
AUS CON 2.08 ± 0.37 0 111 9 120 -
ATP 2.14 ± 0.46 0 36 5 41 0.350
TEN 2.14 ± 0.46 0 36 5 41 0.350
RUP - 0 0 0 0 -
Differences in discrete copy number between the CON vs. ATP, CON vs. TEN and 
CON vs. RUP groups were analysed with a Fisher's Exact Test. Mean CN (± SD) 
represents the continuous CN data, which were analysed with a Mann-Whitney U 
Test.
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3.4 CHAPTER SPECIFIC CONCLUSIONS
For the Hs00180523_cn assay, that measures CNV within the COL5A1 gene, there 
was a significant difference in discrete CN between the AUS CON and ATP groups 
(p = 0.012) (Table 3.1a). The distribution of CN was significantly different 
between the AUS CON (CN<2, n=4; CN = 2, n = 65; CN>2, n = 0) and AUS ATP 
(CN<2, n = 0; CN = 2, n=40; CN>2, n=4) groups. Specifically, the CON group had 
a higher frequency of participants with CN<2 and the ATP group had a higher 
frequency of participants with CN>2.
We also found significant differences in discrete CN between both the combined 
CON vs. ATP (p = 0.014) and the combined CON vs. TEN (p = 0.033) groups for 
the COL4A1 Hs00739915_cn assay (Table 3.2a). In both cases, the CON group 
had a higher frequency of participants with CN<2, while the ATP and TEN cases 
had a higher frequency of participants with CN>2.
When the continuous CN data for the COL5A1 Hs00180523_cn and COL4A1 
Hs00739915_cn assay were analysed, there were no significant differences 
reported (data not shown). This highlights the importance of analysing data as 
both discrete and continuous copy number, as potential associations may be 
missed if only one type of analysis is used. Indeed, the findings from the 
continuous and discrete CN analyses were not always concordant and it has been 
suggested that rounding errors can occur during the process of discriminating CN 
into discrete integer groups (Park et al. 2012).
The discrete CN data for the COL5A1 Hs00180523_cn and COL4A1 
Hs00739915_cn assays showed that the CON groups had a higher frequency of
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participants with CN<2, when compared to the ATP groups. Although the data 
were not concordant with the continuous CN data, the tentative differences in 
discrete CN reported in the COL5A1 and COL4A1 genes could suggest that lower 
copy number at these loci may be protective against ATP.
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CHAPTER 4: COPY NUMBER VARIATION WITHIN MMP AND ADAM GENES 
AS RISK FACTORS FOR ACHILLES TENDON PATHOLOGY
4.1 INTRODUCTION
The matrix metalloproteinases (MMPs) are a large family of metal-dependent 
proteases involved in the remodelling of the extracellular matrix (ECM) through 
the degradation of ECM proteins (Birkedal-Hansen et al. 1993; Somerville et al. 
2003). Over 20 specific enzymes have been identified in humans and despite 
differences in structure and function, many share substrate specificities and can 
cleave a range of collagenous and non-collagenous ECM proteins (Somerville et 
al. 2003). Although remodelling is vital for ECM homeostasis, the activity of the 
MMPs must also be controlled (Visse and Nagase 2003). This role is carried out by 
specific enzymes called tissue inhibitors of metalloproteinases (TIMPs) (Visse and 
Nagase 2003). The balance of MMPs and TIMPs is important as an imbalance could 
lead to pathology (Schulze-Tanzil et al. 2011). In addition to the MMPs, the a 
disintegrin and metalloproteinases (ADAMs) are important enzymes with roles in 
tendon remodelling that are also regulated by the action of TIMPs (El Khoury et 
al. 2013). The ADAMs belong to the zinc protease superfamily, as do the MMPs, 
and both are in the same subgroup (metzincin) based on the primary structure of 
their catalytic sites (Seals and Courtneidge 2003).
4.1.1 MMP3
MMP3 (stromelysin 1) is one member of the MMP family, encoded by the MMP3 
gene and located on chromosome 11 (Visse and Nagase 2003). MMP3 substrates 
include several collagens (types II, IV, V, IX, X), the proteoglycans aggrecan and 
decorin, fibronectin and laminin (Somerville et al. 2003; Raleigh et al. 2009). This
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is not an exclusive list, as MMP3 also degrades a number of other collagenous and 
non-collagenous ECM proteins, as well as activating proMMPs into their functional 
forms (Somerville et al. 2003; Visse and Nagase 2003). For example, MMP3 is 
required for the activation of proMMPl to MMP1 (Visse and Nagase 2003). MMP1 
(collagenase 1) can cleave collagens I, II and III, and as type I collagen is the 
predominant collagen in tendon (Collins and Raleigh 2009), it is clear to see how 
variation within the MMP3 gene can have a downstream effect on collagen 
turnover and the structure of the tendon itself. For example, if levels of the gene 
were over expressed and more MMP3 protein produced, there could be an increase 
in collagen turnover. This would disrupt the homeostatic balance, impairing tendon 
structure and potentially leading to pathology.
In 2009, Raleigh et al. published research showing that three SNPs within the 
MMP3 gene were associated with the risk of Achilles tendinopathy in a Caucasian 
population. Independent associations were found with the GG genotype of 
rs679620, the CC genotype of rs591058 and the AA genotype of rs650108, which 
were all overrepresented in the Achilles tendinopathy group compared to controls 
(Raleigh et al. 2009). This study genotyped controls and individuals with either 
Achilles tendinopathy or Achilles tendon rupture (partial or complete). When the 
tendinopathy and rupture groups were grouped and compared collectively against 
controls, there were no significant differences in genotype or allele distributions. 
However, when considering the pathologies separately, the authors found that 
there were significant differences in both genotype (p = 0.031) and allele (p = 
0.037) distributions between the control and Achilles tendinopathy group for the 
MMP3 rs679620 SNP (Raleigh et al. 2009).
110
The rational for selection of the MMP3 gene for investigation of genomic CNV was 
based on the fact that SNPs within this gene have previously been associated with 
Achilles tendinopathy (Raleigh et al. 2009). In addition, altered expression levels 
of the MMP3 gene have been observed, with lower levels of MMP3 RNA seen in 
degenerate Achilles tendon tissue compared to control (Jones et al. 2006; Ireland 
et al. 2001). There was only one recorded CNV reported within this gene 
(esv2663139) in the Database of Genomic Variants 
(http://dgv.tcag.ca/dgv/app/home). Two TaqMan Copy Number Assays were used 
to genotype two loci within the MMP3 gene and details of the location of these 
assays are shown in Figure 4.1.
I l l
Chromosome 11 - MMP3
Chr 11
Hs02908568_cn Hs02276714_cn
Exon 7 Intron 4-Exon 4
Figure 4.1 Location of the Hs02908568_cn and Hs02276714_cn Copy 
Number Assays within the MMP3 gene
(a) Chromosomal location of the MMP3 gene (Chr. 11:102,706,532- 
102,714,534). (b) Size and exonic structure of the MMP3 gene with location of 
the TaqMan Copy Number Assays (Hs02908568_cn Chr.11:102,709,884 and 
Hs02276714__cn Chr. 11:102,712,920). All locations referenced from NCBI build 
37. Compiled from www.ensembl.org and www.lifetechnologies.com.
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4.1.2 MMP23B
Initially identified in 1998 by Gururajan et al. and originally named MMP22, the 
MMP23B gene is located on chromosome 1 (Gururajan et al. 1998). The MMP23B 
gene is located in a duplicated region of the chromosome, along with the MMP23A 
gene, which is almost identical in nucleotide sequence and was previously named 
MMP21 (Somerville et al. 2003; Gururajan et al. 1998). Also known as cysteine 
array MMPs (CA-MMPs), the two closely related MMP23 enzymes differ in structure 
to the other MMP family members, with the presence of a cysteine-rich domain 
followed by an immunoglobulin like domain (Visse and Nagase 2003).
MMP23A/B are known to degrade the collagenous substrate gelatin (Somerville et 
al. 2003) and are of interest in human tendinopathy as changes in gene expression 
have been observed in painful compared with normal Achilles tendon (p = 0.001), 
as well as painful compared with ruptured Achilles tendon (p = 0.002) (Jones et 
al. 2006). Specifically, higher levels of MMP23 were detected in painful tendon, 
compared with normal tendon (Jones et al. 2006; Schulze-Tanzil et al. 2011). 
Based on the observed changes seen in ATP, CNV within the MMP23B gene was 
investigated to see if this form of genetic variation may have a role in the 
pathology. Furthermore, there has been CNV reported within the location of the 
MMP23B gene in the Database of Genomic Variants. One TaqMan Copy Number 
Assays was used to genotype a region within exon 1 of the MMP23B gene. Details 
of the location of this assay are shown in Figure 4.2.
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Figure 4.2 Location of the Hs07485808_cn Copy Number Assay within the 
MMP23B gene
(a) Chromosomal location of the MMP23B gene (Chr.1:1,567,474-1,570,639). (b) 
Size and exonic structure of the MMP23B gene with location of the TaqMan Copy 
Number Assay (Chr.1:1,567,625). All locations referenced from NCBI build 37.
Compiled from www.ensembl.org and www.lifetechnologies.com.
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4.1.3 ADAM8
The ADAMs are a family of multi-domain transmembrane proteins, that share 
similarities to the MMPs with the presence of a metalloproteinase domain 
(Primakoff and Myles 2000; Xu and Murrell 2008). There are 19 identified ADAM 
genes and although the specific functions of many of the ADAM gene products is 
unknown, the function of each of the protein domains has been broadly 
distinguished (Seals and Courtneidge 2003; Primakoff and Myles 2000). The 
catalytic activity of the metalloproteinase site of the ADAMs is regulated by the 
prodomain, which while intact, renders the metalloproteinase domain of the 
protein inactive (Seals and Courtneidge 2003). Cleavage of the prodomain from 
the protein enables the ADAM protein to be active in its mature form (Seals and 
Courtneidge 2003).
The ADAMs are known to have numerous functions throughout the body, with 
roles in cell migration, muscle development and fertilisation being just a few 
examples (Seals and Courtneidge 2003). Generally, the metalloproteinase domain 
has protease activity while the disintegrin and cysteine-rich domains have 
adhesion activity, enabling the enzyme to bind substrates (Primakoff and Myles 
2000). The EGF-like domain of the enzyme is understood to be involved in 
membrane fusion and the phosphorylated cytoplasmic tail is thought to regulate 
the activity of other ADAMs (Primakoff and Myles 2000).
In relation to Achilles tendinopathy, elevated expression of the ADAM8 gene has 
been identified in ruptured Achilles tendon compared to controls (Jones et al. 
2006). A 19-fold difference in expression was shown (p = 0.002). In addition, 
Jones et al. (2006) also reported a 20-fold difference (p = <0.0001) in gene
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expression in ruptured compared with painful tendon, highlighting the changes 
occurring within the tendon at a molecular level in different forms of ATP 
(tendinopathy and rupture). Due to this association between expression levels of 
the ADAM8 gene and ATP, this gene was selected as a candidate for analysis of 
CNV. The Database of Genomic Variants also indicated CNV within the ADAM8 
gene. One TaqMan Copy Number Assays was used to genotype a region within 
exon 23 of the ADAM8 gene. Details of the location of this assay is shown in Figure 
4.3.
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Figure 4.3 Location of the Hs02429708_cn Copy Number Assay within the 
ADAM8 gene
(a) Chromosomal location of the ADAM8 gene (Chr. 10:135,075,907- 
135,090,372). (b) Size and exonic structure of the ADAM8 gene with location of 
the TaqMan Copy Number Assay (Chr.10:135,076,357). All locations referenced 
from NCBI build 37. Compiled from www.ensembl.org and
www.lifetechnologies.com.
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4.1.4 Chapter Aims
The specific aim of this chapter was to determine whether CNV in the candidate 
genes MMP3 (measured using the Hs02908568_cn and Hs02276714_cn Copy 
Number Assays), MMP23B (using the Hs07485808_cn Copy Number Assay) and 
ADAM8 (using the Hs02429708_cn Copy Number Assay) was associated with ATP 
in UK, South African and Australian Caucasian populations.
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4.2 METHODS
For an overview of the detailed methodology used please see Chapter 2. The 
methods below are specific to this chapter and are described in brief.
4.2.1 Participants
A total of 286 (123 UK, 110 SA, 53 AUS) Caucasian participants diagnosed with 
ATP were recruited for this study. For controls, 345 (131 UK, 94 SA, 120 AUS) 
physically active Caucasian participants (asymptomatic and without history of 
ATP) were recruited.
4.2.2 DNA Collection and Extraction
For the UK cohort, DNA was extracted from 2 ml_ of saliva. For the South African 
and Australian cohorts, DNA was extracted from approximately 4.5 mL of venous 
blood. Full details of DNA collection and extraction are described in Chapter 2.
4.2.3 Copy Number Genotyping
TaqMan Copy Number Assay and TaqMan Copy Number Reference Assay RNase P 
were run simultaneously in a duplex real-time PCR reaction using a StepOnePlus 
Real-Time PCR System (Applied Biosystems, Foster City, California, USA). 
Reactions were performed in 96-well plates using universal PCR cycling conditions. 
Each reaction contained 10 ng purified genomic DNA combined with a mastermix 
containing AmpliTaq Gold DNA Polymerase and the probes and primers for both 
the target copy number and reference assay. Quadruplicate reactions were run 
for each DNA sample and NTCs were included within each plate. Data were 
exported to CopyCaller Software version 2.0 (Applied Biosystems, Foster City, 
California, USA) for calculation of copy number.
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4.2.4 Data Analysis
A one-way analysis of variance (ANOVA) was used to test for any significant 
differences between the characteristics (age, height, weight, BMI) of the CON and 
ATP groups, as well as to test for differences between the characteristics and copy 
number. A Pearson's chi-squared (x2) test was used to determine any significant 
differences between the gender of the CON and ATP groups. A Fisher's Exact Test 
was used to determine any significant differences in discrete copy number (<2, 
= 2, >2 copies) between the CON and ATP groups. A t-Test or Mann-Whitney U 
Test was used to test for differences in the continuous CN data and were reported 
if significant. CON and ATP were compared within cohorts and with a combined 
Caucasian cohort (UK, SA and AUS). The ATP group was also split to analyse the 
TEN and RUP groups separately and data were analysed by gender and reported 
if significant. Significance was accepted at p < 0.05 for all analyses.
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4.3 RESULTS
When the characteristics of the CON and ATP cohort were compared, there was a 
significant difference in age between the CON and ATP group in the UK (p = 
0.001), and the SA (p = 0.025) cohorts. Weight and BMI were also significantly 
different between the CON and ATP group in the SA cohort and the AUS cohort 
(both p < 0.05). Gender distribution (% males) was significantly different between 
the AUS CON and ATP groups (p < 0.05). See Chapter 2 for full details of 
participant characteristics.
The relationship between the continuous CN values and the discrete CN calls for 
the Hs02276714_cn assay can be seen in Figure 4.4. Good clustering is obtained 
around each whole copy number, with the continuous CN values grouping into 
distinct clusters for CN = 1, CN = 2 and CN = 3. The CopyCaller software made 
calls of discrete copy number based on the continuous copy number data.
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Figure 4.4 Scatter plot showing the raw continuous CN values on the y-axis, 
plotted against the discrete integer CN values on the x-axis. Graph shown was for 
the Hs02276714_cn assay within the MMP3 gene with a combined cohort (UK, SA 
and AUS).
122
4.3.1 MMP3 Copy Number Frequencies
There were no significant differences in copy number for either loci investigated 
within the MMP3 gene (Hs02276714_cn and Hs02908568_cn) between the 
combined CON and ATP groups, nor between the combined CON and TEN or CON 
and RUP groups. There were also no differences for the UK and SA cohorts when 
analysed separately (Table 4.1a and 4.1b). There was a significant difference in 
copy number within the MMP3 gene (Hs02908568_cn) between the AUS CON and 
ATP group (p = 0.035) and between the AUS CON and TEN group (p = 0.035). 
However, the low sample size (CON, 87; ATP, 33; TEN,33) had reduced power 
(Table 4.1b) and analysis of the continuous CN data with a Mann-Whitney U Test 
showed a lack of significance (p = 0.057) (data not shown).
The QPCR efficiency of the MMP3 assay was >95%. The efficiency graph for the 
Hs02276714_cn assay can be seen in Appendix V (Figure V.7). Data was not 
obtained for the Hs02908568_cn assay.
Table 4.1a Copy number distribution within the MMP3 gene in the cases
(ATP/TEN/RUP) and CON groups using the Hs02276712_cn assay.
C o h o rt M ean  CN < 2 CN 2 CN > 2 CN n p -va lu e
M M P 3
H s O 2276714_cn
C O M B IN E D C O N 1 .97  ± 0 .21 4 305 2 311 -
A T P 1 .98  ± 0 .15 0 257 1 258 0 .244
T E N 1 .99  ± 0 .1 6 0 186 1 187 0 .3 3 9
R U P 1.98  ± 0 .12 0 71 0 71 1.000
UK C O N 1 .98  ± 0 .23 2 125 2 129 —
A T P 1 .99  ± 0 .14 0 118 1 119 0 .623
TEN 1.99  ± 0 .16 0 85 1 86 0 .7 9 0
R U P 2 .0 0  ± 0 .10 0 33 0 33 1.000
SA CO N 1.97  ± 0 .19 0 93 0 93 -
A T P 1.98  ± 0 .15 0 106 0 106 -
TEN 1.99  ± 0 .15 0 68 0 68 —
R U P 1.96  ± 0 .14 0 38 0 38
—
A U S CO N 1.95  ± 0 .19 2 87 0 89 —
A TP 1.97  ± 0 .21 0 33 0 33 1.000
T E N 1.97  ± 0 .21 0 33 0 33 1.000
RU P - 0 0 0 0 —
Differences in discrete copy number between the CON vs. ATP, CON vs. TEN and 
CON vs. RUP groups were analysed with a Fisher's Exact Test. Mean CN (± SD) 
(± SD) represents the continuous CN data, which were analysed with a Mann-
Whitney U Test.
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Table 4.1b Copy number distribution within the M M P 3 gene in the cases
(ATP/TEN/RUP) and CON groups using the Hs02908568^cn assay.
C o h o rt M ean  CN < 2 CN 2 CN > 2 CN n p -va lu e
M M P 3
H s02908568_.cn
C O M B IN E D C O N 2.01  ± 0 .24 0 272 5 277 -
A TP 2 .00  ± 0 .21 0 216 5 221 0 .7 5 7
T E N 2 .0 2  ± 0 .2 4 0 151 5 156 0 .5 0 6
R U P 1 .97  ± 0 .10 0 65 0 65 0 .5 8 8
UK C O N 1 .99  ± 0 .10 0 101 1 102 -
A T P 1 .98  ± 0 .07 0 88 0 88 1.000
T E N 1 .98  ± 0 .06 0 60 0 60 1 .000
R U P 1.98  ± 0 .08 0 28 0 28 1.000
SA CO N 2 .0 0  ± 0 .17 0 87 1 88 -
A T P 1.97  ± 0 .12 0 100 0 100 0 .4 6 8
T E N 1 .97  ± 0 .13 0 63 0 63 1.000
R U P 1.97  ± 0 .11 0 37 0 37 1.000
AU S C O N 2 .04  ± 0 .38 0 84 3 87
—
A TP 2 .16  ± 0 .45 0 28 5 33 0.035
TEN 2 .1 6  ± 0 .45 0 28 5 33 0.035
RU P - 0 0 0 0
—
Differences in discrete copy number between the CON vs. ATP, CON vs. TEN and 
CON vs. RUP groups were analysed with a Fisher's Exact Test. Mean CN (± SD) 
(± SD) represents the continuous CN data, which were analysed with a Mann-
Whitney U Test.
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4.3.2 MMP23B Copy Number Frequencies
For the MMP23B gene within exon 1, we found no significant differences in copy 
number between the combined CON and ATP (p = 0.090), the CON and TEN (p = 
0.387) or the CON and RUP (p = 0.436) groups. There were also no significant 
differences when the UK and SA cohorts were analysed separately (Table 4.2).
The QPCR efficiency of the MMP23B assay was >86%. The efficiency graph for the 
Hs07485808_cn assay can be seen in Appendix V (Figure V.8).
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Table 4.2 Copy number distribution within the MMP23B gene in the cases 
(ATP/TEN/RUP) and CON groups using the Hs07485808_cn assay.
C o h o rt M ean  CN < 2 CN = 2 CN > 2 CN n p -va lu e
C O M B IN F D
M M P 2 3 B
H s0 7 4 8 5 8 0 8 _ cn
CO N 1 .96  ± 0 .3 2 6 206 3 215
A T P 1 .96  ± 0 .19 3 218 0 221 0 .0 9 0
TEN 1 .95  ± 0 .20 3 150 0 153 0 .3 8 7
R U P 2 .00  ± 0 .15 0 68 0 68 0 .4 3 6
UK CO N 1 .97  ± 0 .25 2 124 2 128 -
A T P 1 .97  ± 0 .12 0 117 0 117 0 .249
T E N 1 .96  ± 0 .13 0 86 0 86 0 .421
R U P 2 .0 0  ± 0 .10 0 31 0 31 1.000
SA C O N 1 .94  ± 0 .40 4 82 1 87 -
A T P 1.95  ± 0 .24 3 101 0 104 0 .456
T E N 1 .93  ± 0 .26 3 64 0 67 1.000
R U P 2 .0 0  ± 0 .17 0 37 0 37 0 .5 1 9
Differences in discrete copy number between the CON vs. ATP, CON vs. TEN and 
CON vs. RUP groups were analysed with a Fisher's Exact Test. Mean CN (± SD) 
represents the continuous CN data, which were analysed with a Mann-Whitney U
Test.
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4.3.3 ADAM8 Copy Number Frequencies
We found no significant differences in copy number between the combined CON 
and ATP (p = 0.727), the CON and TEN (p = 0.707) or the CON and RUP (p = 
1.000) groups within the A DAM 8 gene. When the UK, SA and AUS cohorts were 
analysed separately, there were no significant difference between groups (Table 
4.3).
The QPCR efficiency of the ADAM8 assay was >92%. The efficiency graph for the 
Hs02429708_cn assay can be seen in Appendix V (Figure V.l).
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Table 4.3 Copy number distribution within the ADAM8 gene in the cases 
(ATP/TEN/RUP) and CON groups using the Hs02429708_cn assay.
C o h o rt M ean  CN  < 2 CN  = 2 CN  > 2 CN  n p -va lu e
C O M B IN E D
A D  A M  8
H s02429708_cn
C O N  2 .01  ± 0 .2 6  0 299  5 304  
A T P  2 .0 0  ± 0 .1 5  0 272  3 275  0 .7 2 7  
T E N  1 .99  ± 0 .15  0 202  2 204  0 .707  
R U P  2 .0 2  ± 0 .1 6  0 70 1 71 1 .000
UK C O N  2 .0 0  ± 0 .1 2  0 128 1 129 
A T P  1 .99  ± 0 .09  0 122 0 122 1 .000  
T E N  1 .99  ± 0 .0 9  0 88  0 88  1 .000  
R U P  2 .0 0  ± 0 .1 0  0 34  0 34 1 .000
SA C O N  2 .02  ± 0 .3 7  0 88  1 89  - 
A T P  1 .99  ± 0 .17  0 106  1 107 1 .000  
T E N  1 .96  ± 0 .1 5  0 70  0 70  1 .000  
R U P  2 .0 4  ± 0 .20  0 36 1 37  0 .503
AU S C O N  2 .0 3  ± 0 .2 7  0 83  3 8 6  - 
A T P  2 .0 3  ± 0 .2 1  0 44  2 4 6  1 .000  
T E N  2 .03  ± 0 .21  0 4 4  2 46  1 .000  
R U P  - 0 0 0 0 -
Differences in discrete copy number between the CON vs. ATP, CON vs. TEN and 
CON vs. RUP groups were analysed with a Fisher's Exact Test. Mean CN (± SD) 
represents the continuous CN data, which were analysed with a Mann-Whitney U
Test.
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4.4 CHAPTER SPECIFIC CONCLUSIONS
Despite a range of frequencies reported in the Database of Genomic Variants for 
the MMP23B and ADAM8 genes (Chapter 2), when genotyped, the majority of 
samples from all three cohorts gave a copy number of 2, with only a small number 
of individuals showing either a loss or gain in copy number.
There was no prior data available to predict the frequency of CNV within the MMP3 
gene at the two exonic loci we investigated, as no CNV has been reported in the 
Database of Genomic Variants at these loci. However, we reported variation in 
copy number at both these loci. It is recognised that the predicted frequency of a 
given CNV derived from databases alone might incorporate a degree of error, due 
to uncertainty into the actual extent of CNV in human populations of different 
backgrounds (Pinto et al. 2007; Grozeva et al. 2012).
There were significant differences between the participant characteristics between 
groups (Chapter 2). However, these were not found to influence the relationship 
between CNV in the loci tested and ATP, as none of the anthropometric data were 
associated with or interacted with copy number.
The discrete CN data for the MMP3 Hs02908568_cn assay showed that the AUS 
ATP group had a higher frequency of participants with CN>2, compared with the 
AUS CON group. While this analysis was underpowered, it could imply that 
increased copy number at this locus may increase the risk of ATP.
Although we found no statistically powered associations between CNV in the 
metalloproteinase genes investigated and ATP, research has shown their
130
2005).
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CHAPTER 5: INVESTIGATING THE ROLE OF APOPTOSIS ASSOCIATED 
GENES AND THE RISK OF ACHILLES TENDON PATHOLOGY
5.1 INTRODUCTION
The removal of damaged tenocytes by apoptosis is a normal mechanism in tendon 
healing (September et al. 2012), however, relatively little is known about genetic 
variation within genes involved in apoptosis and the risk of ATP. Previous research 
has been limited to variants within the caspase-8 (CASP8 rs384129 and 
rsl045485), nitric oxide synthase 2 (NOS2 rs2779249) and nitric oxide synthase 
3 (N053 rsl799983) genes in two cohorts from the Southern Hemisphere (South 
Africa and Australia) (Nell et al. 2012).
5.1.1 TNFRSF1A
Tumour necrosis factor receptor 1 (TNFR1), encoded by the TNFRSF1A gene, is a 
cell receptor that can signal apoptosis in response to the pro-inflammatory 
cytokine tumour necrosis factor-alpha (TNF-a) (Hosaka et al. 2005; Gaida et al. 
2012). TNF-a is involved in an intracellular apoptotic signalling pathway that can 
result in apoptosis through binding to TNF receptors and the subsequent initiation 
of a cascade of reactions (Figure 5.1) (Hosaka et al. 2005).
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Figure 5.1 TNFR1 Pathway showing the cascade of reactions following the binding
of TNF-a to the TNFR1 receptor. © 2009 QIAGEN, all rights reserved.
TNFR1 can signal cell death in response to TNF-a by recruiting TNF receptor-
associated death domain (TRADD), which then interacts with Fas-associated death
domain (FADD) (Hosaka et al., 2005). The FADD protein can then activate
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procaspase-8 to caspase-8 (Hosaka et al. 2005). TNF-a and its receptors TNFR1 
& TNFR2 have been identified in cultured tenocytes (Backman et al. 2013) and 
TNFR1 mRNA and protein have been identified in human Achilles tendon (Gaida et 
al. 2012). Furthermore, TNFR1 is known to be highly expressed in tenocytes 
isolated from Achilles tendinosis (Gaida et al. 2012), but the pathological 
significance of this is not fully understood. While variants within the TNFR5F1A 
gene, including the rs4149577 variant, have previously been associated with 
musculoskeletal diseases (ankylosing spondylitis) (Karaderi et al. 2012) and 
inflammatory demyelinating diseases (neuromyelitis optica) (Park et al. 2013), 
this variant has not been investigated as a risk factor for ATP. One TaqMan 
Genotyping Assay was used to genotype the rs4149577 C/T intronic SNP within 
the TNFRSF1A gene. Details of the location of this assay are shown in Figure 5.2.
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Chromosome 12 - TNFRSF1A
Figure 5.2 Location of the rs4149577 SNP within the TNFRSF1A gene
(a) Chromosomal location of the TNFRSF1A gene (Chr.12:6,437,923-6,451,283).
(b) Size and exonic structure of the TNFRSF1A gene with location of the rs4149577 
C/T variant (Chr.12:6,447,522). All locations referenced from NCBI build 37. 
Compiled from www.ensembl.org and www.lifetechnologies.com.
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5.1.2 CASP8
Caspases form a family of proteases that are important in the regulation of 
apoptosis (Hengartner 2000). They can mediate inflammation and apoptosis and 
are known to have a direct role in tendon apoptosis (Lamkanfi et al. 2007; Nell et 
al. 2012). Caspase-8 is an enzyme component of the caspase pathway, encoded 
by the CASP8 gene, which regulates apoptosis of tendon fibroblasts (September 
et al. 2012) and can activate downstream effector caspases (Figure 5.1) (Hosaka 
et al. 2005). Regulating the balance between synthesis and degradation is vital 
for maintaining ECM homeostasis and the removal of damaged tendon fibroblasts 
during normal tendon turnover is important (September et al. 2012). However, 
atypical tenocyte apoptosis has been shown in tendinopathy, where elevated 
expression levels of CA5P8 have been observed (Nell et al. 2012). Previously, two 
SNPs (rsl045485 and rs3834129) within the CA5P8 gene have been 
independently associated with ATP (Nell et al. 2012). For the CA5P8 rsl045485 
variant, a significant difference in genotype (P=0.0294) was detected between 
CON and ATP groups (Nell et al. 2012). For the CASP8 rs3834129 variant, 
significant differences in genotype and allele frequencies were identified between 
the two countries (South African and Australian cohorts), as well as between the 
CON and ATP groups (Nell et al. 2012). However the role of copy number variation 
within this gene has not been considered in relation to ATP. The CASP8 gene has 
many CNV regions recorded on the Database of Genomic Variants 
(http://dgv.tcag.ca/dgv/app/home). One TaqMan Copy Number Assays was used 
to genotype a region within intron 11 - intron 12 of the CA5P8 gene. Details of 
the location of this assay are shown in Figure 5.3.
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Figure 5.3 Location of the Hs02601709_cn Copy Number Assay within the 
CASP8 gene
(a) Ch rom osom a l locat ion of the C A SP8  gene (Ch r .2 :202 ,098 ,166 -202 ,152 ,434 ) .
(b) S ize and exon ic  s truc tu re  of the CA5P8  gene with location of the TaqMan Copy 
Num ber A ssay  (C h r .2 :202 ,146 ,600 ) .  All locat ions referenced from NCBI build 37. 
Compiled  from w ww .ensem b l.o rg  and www .l i fe techno log ies .com .
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Caspase-3  is one of th ree  known effector caspases, which can se lect ive ly  c leave 
target prote ins, such as Bcl-2, a fter asparta te  res idues in the ir  pr imary sequence 
(Hengartner 2000; K irsch et al. 1999). Apoptos is  can be act ivated th rough a 
number of com p lex  pathways ,  however, caspase-3  appears  to have a critical role 
in chromat in  condensa t ion  and DNA fragmenta t ion  (Porter and Jan icke 1999). The 
CASP3 r s l0 4 9 2 5 3  va r ian t  lies w ith in the 3' untrans la ted region (UTR) of the gene 
and is known site for m ic roRNA  (m iRNA) binding (Guan et al. 2013). M iRNAs can 
bind m RNAs and have  an im portan t role in regulat ing apoptos is  assoc iated with 
carc inogenes is  (Guan et al. 2013). Spec if ica l ly , the r s l0 4 9 2 5 3  var iant is known to 
inf luence the b inding of m iR -885 -5p  to CA5P3  m RNA (Guan et al. 2013). It has 
been assoc ia ted with the  r isk of certa in cancers  and the CC  genotype of this 
var iant has been shown to in f luence leve ls of C A SP3  m RNA  express ion  (Guan et 
al. 2013). The potentia l role of the CA5P3  r s l0 4 9 2 5 3  var ian t as a risk factor for 
ATP is unknown. One  TaqMan Genotyp ing  A ssay  was used to genotype the 
r s l0 4 9 2 5 3  C/T  3’-UTR SNP with in the C A SP3  gene. Deta i ls  of the location of this
assay are shown in Figure 5.4.
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Figure 5.4 Location of the rs l0 4 9 2 5 3  SNP within the CASP3 gene
(a) Ch rom osom a l locat ion of the C A SP3  gene (Ch r .4 :185 ,548 ,850 -185 ,570 ,663 ) .
(b) S ize and exon ic  s t ruc tu re  of the C A SP3  gene with location of the r s l0 4 9 2 5 3  
C/T var iant (Ch r .4 :185 ,548 ,951 ) .  All locat ions referenced from  NCBI build 37. 
Compiled from w ww .ensem b l.o rg  and w ww . l i fe techno log ie s .com .
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5.2 METHODS
For an ove rv iew  of the  deta i led m ethodo logy  used p lease see Chapte r  2. The 
methods below are specif ic  to th is  chap te r  and are descr ibed in brief.
5.2.1 Participants
For th is s tudy, 294  (165 UK, 114 SA, 15 AUS)  Caucas ian  part ic ipants d iagnosed 
with ATP were  recru ited. A tota l of 316 (131 UK, 97 SA, 88 AUS) phys ica l ly  act ive 
Caucas ian contro l part ic ipan ts  (a sym ptom at ic  and w ithout h istory of ATP) were 
recruited as contro ls.
5.2.2 DNA Collection and Extraction
For the UK cohort, DNA was extracted from 2 mL of sal iva. For the South  African 
and Austra l ian  cohorts ,  DNA was extracted  from approx im ate ly  4.5 mL of venous 
blood. Full deta i ls  of DNA collect ion and extract ion are descr ibed in Chap te r  2.
5.2.3 TaqMan SNP Genotyping
Rea l-t ime PCR react ions  were run with TaqMan SNP Genotyp ing  Assays  using a 
S tepOneP lus  Rea l-T im e PCR Sys tem  (Applied B iosys tem s, Foster City, California, 
USA). TaqMan SNP Genotyp ing  Assay, TaqMan Universa l PCR Master Mix, No 
Am pErase  UNG and genom ic  DNA (gDNA) were combined per well of a 96-well 
plate. TaqMan SNP Genotyp ing  Assays  conta ined sequence-spec if ic  forward and 
reverse p r imers  to ampl i fy  the ta rget sequence  and two TaqMan f luorescent 
probes, to detect the m inor and m ajo r  alleles. Hom ozygote  and heterozygote 
samples were au tom at ica l ly  determ ined by the software as the samp les  grouped 
into genotype c lusters. Som e  sam p les  were  manual called after ana lys is  of the
amplif icat ion and f luorescence detected.
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5.2.4 Copy Number Genotyping
TaqMan Copy  N um be r  A ssay  and TaqMan Copy  Num ber  Reference A ssay  RNase P 
were run s im u ltaneous ly  in a dup lex rea l- t im e  PCR reaction using a S tepOneP lus 
Rea l-T ime PCR Sys tem  (Applied B iosys tem s, Foster City, Cal ifornia, USA). Each 
reaction conta ined 10 ng purif ied genom ic  DNA combined with a maste rm ix  
conta in ing Am p l iTaq  Gold DNA Po lym erase  and the probes and pr imers  for both 
the ta rge t  copy num be r  and re ference assay. Data were exported to CopyCa l le r  
So ftware  vers ion  2.0 (Appl ied B iosys tem s, Foster  City, Ca l iforn ia, USA) for 
calculation of copy number.
5.2.5 Data Analysis
A x2 or F isher 's Exact Tes t  was used to de te rm ine  any s ign if icant d if ferences in 
d iscrete copy num be r  (<2, =2, >2 cop ies) and SNP genotypes  between the CON 
and ATP groups. D if ferences in con t inuous copy num ber  were ana lysed with a non- 
parametr ic  M ann-W h itney  U Test. The ATP group was also split to ana lyse the TEN 
and RUP g roups separa te ly  and data were  ana lysed by gender  and reported if 
signif icant. S ign if icance  was accepted at p < 0.05 for all ana lyses. For the SNP 
genotyp ing data, Ha rdy-W e inberg  equ i l ib r ium  (HWE) was estab l ished using a HWE 
ca lcu lator (M ichael H. Court, 2005 -2008 )  accessed from
w w w .tu f ts .edu /~ m cou r t01 /Docum en ts /Cou r t  lab - HW calcu lator.x ls. P < 0.05 
was cons idered to be a dev iat ion from HWE.
5.3 RESULTS
As prev ious ly  reported in preced ing chapters , there were s ign if icant d ifferences 
between certa in part ic ipan t characte r is t ics  of the CON and ATP cohort. Full details 
can be seen in Chap te r  2 and will be cons idered in the d iscuss ion in Chap te r  7.
A typical c lu s te r  p lot genera ted  by the  S tepOne  Software  for TaqMan SNP 
Genotyp ing  can be seen in Figure 5.5. This is the output generated after the 
comple ted  qPCR cycle. The c lu s te r  plot shown is for the C A 5P3  r s l0 4 9 2 5 3  SNP.
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5.3.1 TNFRSF1A Genotype Frequencies
There were no significant differences in genotype for the TNFRSF1A rs4149577 
variant between the combined CON and ATP groups (p = 0.556), nor between the 
combined CON and TEN (p = 0.648) or CON and RUP groups (p = 0.559) (Table 
5.1). There were no significant differences in allele frequency between the 
combined CON and ATP (p = 0.282), CON and TEN (p = 0.405) or CON and RUP 
groups (p = 0.298). There were also no significant differences in genotype or allele 
frequency for the UK and SA cohorts when analysed separately (Table 5.1). 
Hardy-Weinberg equilibrium was observed for all frequencies in the combined and 
individual cohorts for the CON, ATP, TEN and RUP groups.
Table 5.1 Genotype frequency distribution for the rs4149577 variant within the
TNFRSF1A gene in the cases (ATP/TEN/RUP) and CON groups.
C o h o rt T T C T CC n p -va lu e M AF p -va lu e H W E
T N F R S F 1 A
r s 4 1 4 9 5 7 7
C O M B IN E D
CO N
26 .9
(61)
4 8 .5
(110)
24 .7
(56)
227 -
48 .9
(222)
- 0 .6 4 7
A T P
30 .9
(86)
47 .1
(131 )
21 .9
(61)
278 0 .5 5 6
45 .5
(253)
0 .2 8 2 0 .4 0 6
T E N
31 .0
(63)
4 5 .8
(93)
23 .2
(47)
203 0 .6 4 8
46 .1
(187)
0 .4 0 5 0 .2 6 6
R U P
30 .7
(23)
50 .7
(38)
18.7
(14)
75 0 .5 5 9
44 .0
(66)
0 .2 9 8 0 .807
UK
C O N
27 .5
(36)
48 .9
(64)
23 .7
(31)
131 —
48 .1
(126)
- 0 .8 0 6
A T P
32.1
(53)
46 .1
(76)
21 .8
(36)
165 0 .6 9 6
44 .8
(148)
0 .432 0 .3 7 6
TEN
29 .7
(38)
46 .9
(60)
23 .4
(30)
128 0 .9 3 4
46 .9
(120)
0 .7 8 2 0 .5 0 6
R U P
40 .5
(15)
43 .2
(16)
16.2
(6)
37 0 .2 8 5
37 .8
(28)
0 .1 1 8 0 .623
SA
CO N
26 .0
(25 )
47 .9
(46)
26 .0
(25)
96 -
50.0
(96)
- 0 .683
A T P
29 .2
(33)
48 .7
(55)
22.1
(25)
113 0 .7 8 9
46 .5
(105)
0 .470 0 .8 1 8
T E N
33 .3
(25)
44 .0
(33)
22 .7
(17)
75 0 .5 7 5
44 .7
(67)
0 .3 2 7 0 .341
RU P
21.1
(8)
57 .9
(22)
21 .1
(8)
*  a  «  v  •  •  l
38 0 .632
50.0
(38)
1  »  •
1.000 0 .3 3 0
•
Values expressed as a frequency (%) with number of participants (n) in
parenthesis. HWE: Hardy-Weinberg equilibrium. MAF: minor allele frequency. 
Differences in genotype and allele frequency between the CON vs. ATP, CON vs. 
TEN and CON vs. RUP groups were analysed with a x2 or Fisher's Exact Test.
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5.3.2 CASP8 Copy Number Frequencies
There were no significant differences in copy number for the locus investigated 
within the CA5P8 gene (Hs02601709_cn) between the combined CON and ATP 
groups (p = 0.402), nor between the combined CON and TEN (p = 0.653) or CON 
and RUP groups (p = 0.363) (Table 5.2). When the UK, SA and AUS cohorts 
where analysed separately, there were also no differences between the CON and 
ATP groups (UK, p =0.155; SA, p = 0.327; AUS, p = 1.000). This was also the 
case for the CON vs. TEN (UK, p = 0.124; SA, p = 0.861; AUS, p = 1.000) and 
CON vs. RUP groups (UK, p = 0.695; SA, p = 0.064) (Table 5.2). Although the p 
= 0.065 is approaching significance, the total number of SA RUP in this group is 
n = 28. There were no rupture cases in the AUS cohort, hence why there is no 
comparison for the CON vs. RUP groups in this instance.
In addition to the main analyses of copy number using a x2 or Fisher's Exact Test 
for the discrete data, the continuous copy number data were also analysed with a 
Mann-Whitney U Test, to check concordance. The mean CN ± SD are shown for 
each group. The p values are not shown, however, there were no significant 
differences in any of the comparisons of the combined or separate cohorts shown 
in Table 5.2. This supports the findings reported from the discrete copy number
analyses.
The QPCR efficiency of the CA5P8 assay exceed 100%. The efficiency graph for 
the Hs02601709_cn assay can be seen in Appendix V (Figure V.2).
Table 5.2 Copy number distribution within the CASP8 gene in the cases 
(ATP/TEN/RUP) and CON groups using the Hs02601709_cn assay.
C o h o rt M ean  CN < 2 CN = 2 CN > 2 CN n p -va lu e
C O M B IN E D
C A S P 8
H s 0 2 6 0 1 7 0 9 _ c n
C O N 2 .1 5  ± 0 .56 6 138 56 200
A T P 2 .13  ± 0 .54 4 142 43 189 0 .402
TEN 2 .14  ± 0 .55 3 104 34 141 0 .6 5 3
R U P 2 .11  ± 0 .54 1 38 9 48 0 .363
UK C O N 2 .09  ± 0 .59 2 46 14 62 -
A T P 1 .95  ± 0 .44 4 73 9 86 0 .155
TEN 1.94  ± 0 .44 3 57 6 66 0 .124
R U P 1.99  ± 0 .46 1 16 3 20 0 .6 9 5
SA C O N 2 .35  ± 0 .51 0 40 31 71
—
A T P 2 .32  ± 0 .58 0 57 31 88 0 .327
T E N 2 .3 8  ± 0 .57 0 35 25 60 0 .861
R U P 2 .20  ± 0 .58 0 22 6 28 0 .0 6 4
AU S CO N 1 .98  ± 0 .52 4 52 11 67
-
A T P 2 .03  ± 0 .48 0 12 3 15 1.000
TEN 2 .03  ± 0 .48 0 12 3 15 1.000
R U P - 0 0 0 0 -
Differences in discrete copy number between the CON vs. ATP, CON vs. TEN and
CON vs. RUP groups were analysed with a x2 or Fisher's Exact Test. Mean CN (±
5D) represents the continuous CN data, which were analysed with a Mann-Whitney 
U Test.
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5.3.3 CASP3 Genotype Frequencies
There were no significant differences in genotype for the CASP3 rsl049253 variant 
between the combined CON and ATP groups (p = 0.804), nor between the 
combined CON and TEN (p = 0.680) or CON and RUP (p = 0.745) groups. There 
were no significant differences in allele frequency between the combined CON and 
ATP (p = 0.966), CON and TEN (p = 0.627) or CON and RUP groups (p = 0.380). 
There were also no significant differences in genotype or allele frequency for the 
UK and SA cohorts when analysed separately (Table 5.3).
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Table 5.3 Genotype frequency distribution for the rsl049253 variant within the 
CASP3 gene in the cases (ATP/TEN/RUP) and CON groups.
C o h o rt T T C T CC n p -va lu e M AF p -va lu e H W E
C A S P 3
r s l 0 4 9 2 5 3
C O M B IN E D
C O N
63 .7
(142 )
32 .3
(72)
4 .0
(9)
223 -
20 .2
(90)
— 0 .973
A TP
64 .5
(178 )
30 .4
(84)
5.1
(14)
276 0 .804
20.3
(112)
0 .9 6 6 0 .3 2 6
T E N
62 .9
(127 )
31 .2
(63 )
5.9
(12)
202 0 .680
21 .5
(87)
0 .627 0 .309
RU P
68 .9
(51 )
28 .4
(21)
2 .7
(2)
74 0 .7 4 5
16.9
(25)
0 .3 8 0 0 .9 2 6
UK 62 .6 34 .4 3.1 20 .2
CO N 131 - — 0 .461
(82) (45) (4) (53)
61 .6 32 .3 6.1 22.3
A TP 164 0 .468 0 .5 5 0 0 .3 9 7
(101 ) (53 ) (10) (73)
62 .2 30 .7 7.1 22 .4
T E N 127 0 .3 0 9 0 .540 0 .184
(79) (39) (9) (57)
59 .5 37 .8 2.7 21 .6
R U P 37 0 .8 7 6 0 .793 0 .4 7 9
(22) (14) (1) (16)
SA
CO N
65 .2 29 .3 5.4
92 m m
20.1
(37)
- 0 .4 0 6
(60) (27) (5)
68 .8 27 .7 3.6 17.4
0 .691A T P 112 0 .743
(39)
0 .486
(77) (31) (4)
64 .0 32 .0 4 .0 20 .0
1 .000T E N 75 0 .893
(30)
0 .9 8 0
(48) (24) (3)
RU P
78 .4 18.9 2.7
(1)
M  m m  «  ^  •  •  1
37 0 .412
12.2
(9)
 •  •
0 .132 0 .4 8 6
(29) (7)
•
Values expressed as a frequency (%) with number of participants (n) in
parenthesis. HWE: Hardy-Weinberg equilibrium. MAF: minor allele frequency. 
Differences in genotype and allele frequency between the CON vs. ATP, CON vs. 
TEN and CON vs. RUP groups were analysed with a x2 or Fisher's Exact Test.
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5.4 CHAPTER SPECIFIC CONCLUSIONS
The TNFRSF1A rs4149577, CASP3 rsl049253 and CASP8 variants did not 
associate with ATP in our combined cohort or separate UK/SA/AUS cohorts. This 
study seems to exclude these three variants from a role in ATP.
Despite TNFR1 having a role in apoptosis and being expressed at significantly 
higher levels in tenocytes from Achilles tendinosis compared to controls (Gaida et 
al. 2012), we only investigated a single SNP within this gene (TNFRSF1A 
rs4149577) and it is possible that other variants within the DNA sequence may 
influence the risk of ATP. For example, the TNFRSF1A rs4149577 variant is an 
intronic SNP that is in linkage disequilibrium (LD) with a number of other variants, 
including TNFRSF1A rsl800693 and rs4149578 (www.ensembl.org) (Karaderi et 
al. 2012; Park et al. 2013; Swaminathan et al. 2010). These variants have been 
associated with musculoskeletal and inflammatory diseases and may be worthy of 
future investigation in ATP (Karaderi et al. 2012; Park et al. 2013; Swaminathan
et al. 2010).
Nell et al. (2012) previously reported that variants within the CASP8 gene were 
associated with Achilles tendinopathy in a South African and Australian cohort. 
The copy number variant spanning intron 11 - intron 12 of the CASP8 gene that 
we investigated here overlaps the rsl045485 SNP investigated by Nell et al. 
(2012), but it is approximately 50 000 base pairs from the rs3834129 SNP. We 
found no association between CNV at this locus and ATP, in contrast to Nell et al. 
(2012). This may be related to a number of factors. SNPs like the CASP8 
rsl045485 variant may have a more profound impact on the development of ATP, 
compared to larger-scale variants such as CNV. This claim is supported by the fact
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that the CASP8 rsl045485 SNP is a non-synonymous G>C polymorphism that 
results in an amino acid change (Asp302His), which may affect interaction with 
other proteins (September et al. 2012). In contrast, the functional effect of altered 
copy number at the CASP8 locus we investigated is presently unknown.
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CHAPTER 6: DNA METHYLATION WITHIN THE ADAMTS4, TIMP1 AND 
MMP11 GENE PROMOTERS IN PATELLAR TENDINOPATHY
6.1 INTRODUCTION
Patellar tendinopathy (jumper's knee) is a common injury in sporting populations, 
with prevalence rates of higher than 30% in both basketball and volleyball players 
(Christian et al. 2014). While commonly affecting athletic populations, it is evident 
that patellar tendinopathy also occurs in the general population that lead a 
sedentary lifestyle (Samiric et al. 2009). DNA methylation is one way in which the 
genome is regulated, so that different cell types can be produced with specific 
functions (Auclair and Weber 2012). Altered DNA methylation of genes can result 
in a change in gene expression (Auclair and Weber 2012) and in relation to tendon 
injury, this could potentially disrupt the tendon environment and increase the risk 
of injury. The way in which DNA methylation influences gene expression is 
discussed in the introduction section on epigenetics (1.6.1).
6.1.1 ADAMTS4
ADAMTS4 (a disintegrin and metalloproteinase with thrombospondin motifs 4) is 
an enzyme involved in the homeostasis of the extracellular matrix (ECM) (Corps 
et al. 2008) and is able to cleave the proteoglycans aggrecan, versican and 
brevican (Corps et al. 2008; Jones and Riley 2005). ADAMST4 has also been 
shown to cleave COMP (cartilage oligomeric matrix protein), indicating that its 
proteolytic activity is not limited to proteoglycans (Jones and Riley 2005). COMP 
in a non-collagenous glycoprotein which can bind to type I, II and IX collagens, 
facilitating collagen-collagen interactions and influencing fibril formation (Verma 
and Dalai 2013). Therefore it is clear to see how hypomethylation of the AD AMT54
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gene and the subsequent increased expression of the gene could contribute to the 
degradation of cartilage in musculoskeletal pathologies like osteoarthritis, through 
an increase in the cleavage of COMP. In addition, cartilage is a connective tissue 
consisting of extracellular matrix and collagen fibrils, as are tendons (Verma and 
Dalai 2013).
Indeed, a loss of DNA methylation and altered expression of the ADAMT54 gene 
has been observed in chondrocytes in osteoarthritis (Roach et al. 2005), 
identifying it as an interesting candidate to research in other musculoskeletal 
conditions like ATP. In relation to tendinopathy, higher levels of ADAMTS4 mRNA 
have been detected in ruptured Achilles tendon compared with normal and 
tendinopathic tendon (Corps et al. 2008). However, in one study on patellar 
tendinopathy, there was no significant difference in ADAMTS4 expression between 
cases and controls (Parkinson et al. 2010).
6.1.2 TIM PI
Tissue inhibitors of metalloproteinases (TIMPs) are a small family of proteins, 
encoded by the TIMP genes, that can inhibit MMP activity (Jones et al. 2006). 
TIMPs also inhibit the action of ADAMs and ADAMTSs, however this role appears 
more limited (El Khoury et al. 2013; Jones et al. 2006). Nevertheless, TIMP3 is 
believed to be the prominent TIMP inhibitor of ADAMs and ADAMTSs (Jones et al. 
2006) and ECM homeostasis is maintained in part from a balance of 
metalloproteinases and TIMPs (Karousou et al. 2008).
An 8-fold difference in expression of the TIMP1 gene has been reported in ruptured 
compared with normal Achilles tendon, as well as a 5-fold increase between
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ruptured and painful Achilles tendon (Jones et al. 2006). In addition, research by 
El Khoury et al. (2013) found that a SNP in the TIMP2 gene was associated with 
ATP in a combined Caucasian cohort. The TIMP2 rs4789932 variant was shown to 
be genotypically associated, highlighting this variant as a risk factor for ATP (El 
Khoury et al. 2013).
6.1.3 MMP11
Matrix metalloproteinase 11 (MMP11), also known as stromelysin 3, is an ECM 
enzyme of the MMP family known to cleave the proteoglycan laminin (Somerville 
et al. 2003). Differences in expression levels of the MMP11 gene have also been 
reported in normal and pathologic Achilles tendon (Jones et al. 2006). In painful 
compared with normal tendon, a 5-fold increase in expression was observed, while 
a 6-fold increase was noted in ruptured compared with normal tendon (Jones et 
al. 2006).
6.1.4 Chapter Aims
The specific aim of this chapter was to determine whether there were differences 
in promoter DNA methylation profiles within the ADAMTS4, TIMP1 and MMP11 
genes in patellar tendinopathy and healthy patellar tendon tissue.
6.2 METHODS
An overview of the detailed methodology related to this chapter is detailed in 
Chapter 2. The methods below are specific to this chapter and are described in 
short.
6.2.1 Participants
DNA from 20 tissue samples from the patellar tendon of male participants were 
collected for this study. These samples consisted of 10 normal healthy samples 
(CON) from individuals undergoing ACL reconstruction surgery and 10 abnormal 
samples from individuals undergoing surgery for patellar tendinopathy (Parkinson 
et al. 2010). Ethical approval was gained from the relevant research ethics 
committees, details of which can be seen in Appendix I.
6.2.2 DNA Collection and Bisulphite Treatment
DNA from patellar tendon samples was isolated by members of staff at La Trobe 
University, using the PureLink Genomic DNA Kit (Invitrogen, Carlsbad, CA, USA). 
Bisulfite treatment of target DNA converted the unmethylated cytosine residues 
into uracil. This process was critical for the accurate determination of methylation 
status. The methylated cytosines remained unchanged and this resulted in 
different DNA sequences for methylated and unmethylated DNA.
6.2.3 Loci Selection
The purpose of this study was to identify whether DNA methylation within the 
ADAMTS4, TIMP1 and MMP11 genes were altered in tissue from patellar 
tendinopathy (PT) compared to healthy control tissue (CON). To do this, part of 
the gene promoter of each gene was sequenced using Pyrosequencing.
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6.2.3.1 ADAMTS4 Hs_NDUFS2_01_PM Assay
The Hs_NDUFS2_01_PM PyroMark CpG Assay (Qiagen) was selected in the 
promoter of the ADAMTS4 gene (Figure 6.1). The location of the ADAMTS4 gene 
is at Chr. 1:161,154,098-161,168,846 (14.75 kb in length) in Assembly 
GRCh37.pl3 (www.ensembl.org). The location of Hs_NDUFS2_01_PM is at 
Chr.l:161,171,810-161,171,848 (39 bp in length) in Assembly GRCh37.pl3. This 
is the precise location in the human genome of the sequence analyzed by the 
assay, (www.ensembl.org). The last bp of the assay is approximately 3 kb (2964 
bp) from the start site of the ADAMTS4 gene. Data obtained from Gene Cards 
Human Gene Database (www.genecards.org) and NCBI Gene 
(www.ncbi.nlm.nih.gov/gene).
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Figure 6.1 Location of the Hs_NDUFS2_01_PM CpG Assay within the
ADAMTS4 gene
Chromosomal location of ADAMT54 gene (Chr. 1:161,154,098-
161,168,846). (b) Size and exonic structure of the ADAMTS-4 gene with location
the Hs_NDUFS2_01_PM PyroMark Assay (Chr.1:161,171,810-
161,171,848) in the promoter region, 2964 bp from the start site of the gene, (c)
Nucleotide sequence of the Hs_NDUFS_01_PM PyroMark CpG Assay with CpG sites
in bold. Compiled from w w w .ensem bl.org ,www.qiagen.com and
www.lifetechnologies.com.
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6.2.3.2 TIMP1 Custom Designed Assays
Two PyroMark CpG Assays (Qiagen) were custom designed in the promoter of the 
TIMP1 gene (Figure 6.2). The location of the TIMP1 gene is at Chr.X:47,441,712- 
47,446,188 (4.48 kb in length) in Assembly GRCh37.pl3 (www.ensembl.org). 
CpG Island Searcher (www.cpgislands.usc.edu) was used to screen a 10 kb region 
of the promoter of the TIMP1 gene (47,431,427-47,441,644) to identify CpG 
islands present. A CpG island of 200 bp in length was identified in CpG Island 
Searcher, located at Chr.X:47,432,856-47,433,055. This region was used to 
design the Pyrosequencing assays in PyroMark Assay Design 2.0 software 
(Qiagen). Below is the nucleotide sequence of the CpG island selected.
ATCTAAGGGTGAGGTGTCTAGGAGGGCATAGAAAGGGCTTGGACCAAGGACAGGCTG
TTGGGCAAGTCAGCCTAAGGCAGAGCAGCTGGGTGGGGCAGGGAGGACGTCTGAGC
TGGGATGGGAGTTGGAATGGACCAGAAAAGGCAGATGGGTGATGATTCGCGGG
GAGACTGAGATGGGCCAGAAGGATGTGAAGGAGG/AGGAAAAGTATGAGGAT
GGAGTGGGAAGAGCCAGATGATAGGAGGACTAGGACTCGGGCCAGGAGTTTTA
GGGATGGGTTGGTGGCGGGGGGGCGAGTTTGGCAGGGAAGGCTCTGGGCTGGGC
AGGAAGTTGCAGAGGGTGGGTCAGCCAGGTGCCTGGGAGGCCCTGGAGGAGGAAACT
TTCCCAGGGCCTTTGAGGA
The CpG island identified is indicated in bold, with 100 bp of sequence included 
either side for designing primers in the PyroMark Assay Design 2.0 software 
(Qiagen). The / indicates the distinction between the two 100 bp regions that 
assays were designed for (Region A and Region B respectively). The CpG island is 
approximately 8.8 kb from the start site of the TIMP1 gene. Data obtained from 
Gene Cards Human Gene Database (www.genecards.org) and NCBI Gene 
(www.ncbi.nlm.nih.gov/gene).
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Figure 6.2 Location of the Custom Designed CpG Assays within the TIMP1 
gene
(a) Chromosomal location of the TIMP1 gene (Chr.X:47,441,712-47,446,188). (b) 
Size and exonic structure of the TIMP1 gene with location of the Custom PyroMark 
CpG Assays. Custom Designed PyroMark CpG Assays were designed in a CpG 
island (Chr.X:47,432,856-47,433,055) in the promoter region, 8.8 kb from the 
start site of the TIMP1 gene. Compiled from www.ensembl.org,www.qiagen.com 
and www.lifetechnologies.com.
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6.2.3.3 MMP11 Hs_CHCHD10_01_PM Assay
The Hs_CHCHD10_01_PM PyroMark CpG Assay (Qiagen) was selected in the 
promoter of the MMP11 gene (Figure 6.3). The location of the MMP11 gene is at 
Chr.22:24,110,413-24,126,503 (16.09 kb in length) in Assembly GRCh37.pl3 
(www.ensembl.org). The location of Hs_CHCHD10_01_PM is at 
Chr.22:24,110,347-24,110,382 (36 bp in length) in Assembly GRCh37.pl3. This 
is the precise location in the human genome of the sequence analyzed by the 
assay, (www.ensembl.org). The last bp of Hs_CHCHD10_01_PM is approximately 
30 bp from the start site of the MMP11 gene. Data obtained from Gene Cards 
Human Gene Database (www.genecards.org) and NCBI Gene 
(www.ncbi.nlm.nih.gov/gene).
161
aa a
S 8 R
b
MMP11 (16.09 kb)
5’ 3’
□ n — d o -d o — n — t
CpG Assay
Hs CHCHD10 01 PM
c 5' TACTGTCGCCCTCCTTAAGCCCTCGGCGCTTTGCGA 3'
Figure 6.3 Location of the Hs_CHCHD10_01_PM CpG Assay within the 
MMP11 gene
(a) Chromosomal location of the MMP11 gene (Chr.22: 24,110,413-24,126,503).
(b) Size and exonic structure of the MMP11 gene with location of the 
Hs_CHCHD10_01_PM PyroMark CpG Assay (Chr.22: 24,110,347-24,110,382) in 
the promoter region 30 bp from the start site, (c) Nucleotide sequence of the 
Hs_CHCHD10_01_PM PyroMark CpG Assay with CpG sites in bold. Compiled from 
www.ensembl.org,www.qiagen.com and www.lifetechnologies.com.
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6.2.4 PCR Amplification and Gel Electrophoresis
The target regions of interest were amplified using the PyroMark PCR Kit (Qiagen) 
and PCR was performed on a Techne TC-512 thermal cycler (Bibby Scientific Ltd, 
Staffordshire, UK). Product amplification was checked prior to Pyrosequencing 
analysis by running samples (along with a 1 kb ladder) on a 1% agarose gel 
stained with SYBR Safe DNA gel stain (Invitrogen, Carlsbad CA, USA).
6.2.5 Pyrosequencing
A Qiagen Q24 PyroMark (Qiagen) was used to sequence the target gene regions. 
The Pyrosequencing method enabled quantification of DNA methylation status at 
CpG sites in the promoter regions of the selected genes. This provided accurate 
and detailed profiles of DNA methylation patterns. The peak heights in the 
Pyrograms generated by the PyroMark Q24 software illustrated the proportion of 
methylated DNA at each site. See Figure 6.7, 6.8 and 6.9.
6.2.6 Data Analysis
Differences in DNA methylation (%) between the patellar tendinopathy and control 
groups were analysed using an independent samples t-Test, with significance at p
< 0.05.
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6.3 RESULTS
The CON and PT groups in this study were matched for gender as all participants 
were male. The groups were similarly matched for age, with no significant 
difference between the CON (25.1 ± 6.4) and PT (23.2 ± 4.4) groups (p = 0.449). 
Height and weight data were not available.
The PCR reactions conducted prior to Pyrosequencing were successful, as can be 
seen in the gel images in Figure 6.4, 6.5 and 6.6.
CON PT Qiagen
samples samples control DNA
1000 bp
500 bp 
200 bp
1 2 3 4 5 6 7 8 9  10 11
Figure 6.4 Image of ADAMTS4 PCR product from a 1% agarose gel 
electrophoresis confirming the amplification of PCR product. Well 1, 1 kb ladder; 
wells 2-4, CON samples; wells 5-7, PT samples; well 8, hypermethylated control; 
well 9, hypomethylated control; well 10, bisulfite converted hypomethylated 
control; well 11, no template control (negative control).
1000 bp
500 bp 
200 bp
oresisFigure 6.5 Image of TIMP1 PCR product from a 1% agarose gel electroph
confirming the amplification of PCR product. Well 1, 1 kb ladder; wells 2-4, CON
samples, wells 5-7, PT samples; well 8, hypermethylated control; well 9,
hypomethylated control; well 10, bisulfite converted hypomethylated control; well 
11, no template control (negative control).
1000 bp
500 bp
200 bp
10 11 12 13 14 15 16
Figure 6.6 Image of MMP11 PCR product from a 1% agarose gel electrophoresis 
confirming the amplification of PCR product. Well 1, 1 kb ladder; well 2, no 
template control (negative control); wells 3-8, CON samples; well 9, 1 kb ladder; 
wells 10-13, PT samples; well 14, hypermethylated control; well 15,
hypomethylated control; well 16, bisulfite converted hypomethylated control.
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6.3.1 ADAMTS4 CpG Methylation Status
M ed ia tion  status was measured within 6 CpG sites of the ADAMTS4 gene 
promoter (Figure 6.7). While hve of the sites showed no significant difference in 
mean CpG site methylation, one site was significantly different between the 
and PT groups (Table 6.1). Mean methylation in the PT samples (5.1 ± 0.6, n = 10)
was significantly higher (p = 0.016) than mean methylation of the CON samples 
(2.8 ± 0.6, n = 9) (Table 6.1 and Figure 6.10).
CON
geneTable 6.1 Mean methylation percentages within CpG sites of the AD AMTS 4 
promoter in Patellar tendinopathy (PT) cases and asymptomatic controls (CON).
AD AM TS4 CON PT p-value
CpG 1 2.6 ± 0.6 (10) 5.2 ± 1.3 (10) 0.086
CpG 2 5.4 ± 0.9 (10) 6.3 ± 1.0 (10) 0.524
CpG 3 2.8 ± 0.6 (9) 5.1 ± 0.6 (10) 0.016
CpG 4 4.0 ± 0.5 (9) 3.4 ± 0.9 (10) 0.594
CpG 5 3.2 ± 0.8 (9) 2.6 ± 0.7 (10) 0.555
CpG 6 2.1 ± 0.4 (9) 2.7 ± 0.5 (10) 0.409
Average 3.4 ± 0.4 (10) 4.2 ± 0.7 (10) 0.294
Differences in mean DNA methylation between the CON and PT groups were 
analysed with an independent samples t-Test. Values represent percentages (%) 
± standard error of the mean (SEM).
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Figure 6.10 Comparison of the mean DNA methylation between CON and PT at 6
CpG sites within the promoter of the ADAMTS4 gene. Bars represent mean (%) ±
standard error of the mean (SEM). CON, white bars and PT, shaded bars.*, p = 
0.016.
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6.3.2. TIMP1 CpG Methylation Status
For the TIMP1 gene promoter, methylation status was measured within 3 CpG 
sites (Figure 6.8) using a Custom Designed PyroMark CpG Assay (Region A). The 
Custom Designed PyroMark Assay for Region B did not sequence and is therefore 
not mentioned in these results. There was a significant difference (p = 0.012) in 
methylation at one CpG site between the CON and PT groups (Table 6.2). Mean 
methylation in the PT samples (20.2 ± 2.0, n=9) was significantly higher than the 
mean methylation of the CON samples (12.6 ± 1.7, n = 8) (Table 6.2 and Figure 
6.11). No data was obtained for the third CpG site pyrosequenced.
Table 6.2 Mean methylation percentages within CpG sites of the TIMP1 gene 
promoter (custom assay region A) in Patellar tendinopathy (PT) cases and 
asymptomatic controls (CON).
R e g io n  A
CON PT p-value
CpG 1 14.6 ± 1.3 (10) 15.9 ± 1.8 (9) 0.556
CpG 2 12.6 ± 1.7 (8) 20.2 ± 2.0 (9) 0 .0 1 2
CpG 3 - -
-
Average 14.0 ± 1.4 (10) 18.1 ± 1.9 (9) 0.092
Differences in mean DNA methylation between the CON and PT groups were 
analysed with an independent samples t-Test. Values represent percentages (%) 
± standard error of the mean (SEM).
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Figure 6.11 Comparison of the mean DNA methylation between the CON and PT
groups within the promoter of the TIMP1 gene. Bars represent mean (%) ±
standard error of the mean (SEM). CON, white bars and PT, shaded bars.*, p = 
0. 012.
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6.3.3 MMP11 CpG Methylation Status
When the methylation status was measured within 4 CpG sites of the MMPU  gene
promoter (Figure 6.9), the difference in methylation at one site between the CON
and PT groups reached statistical significance (p = 0.045) (Table 6.3). At this
CpG site, mean methylation in the PT samples (4.8 ± 0.4, n=10) was found to be
significantly higher than the mean methylation of the CON samples (3.6 ± 0.4,
n=10) (Table 6.3 and Figure 6.12). No data was obtained for the third CpG site 
pyrosequenced.
Table 6.3 Mean methylation percentages within CpG sites of the MMP11 gene 
promoter in Patellar tendinopathy (PT) cases and asymptomatic controls (CON).
M M P l l CON PT p-value
CpG 1 2.1 ± 0.4 (10) 2.4 ± 0.3 (10) 0.578
CpG 2 9.1 ± 0.7 (10) 9.2 ± 0.9 (10) 0.933
CpG 3 -
-
-
CpG 4 3.6 ± 0.4 (10) 4.8 ± 0.4 (10) 0.045
Average
m  A  — ________  •
4.9 ± 0.3 (10) 5.5 ± 0.5 (10) 0.381
Differences in mean DNA methylation between the CON and PT groups were 
analysed with an independent samples t-Test. Values represent percentages (%) 
± standard error of the mean (SEM).
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Figure 6.12 Comparison of the mean DNA methylation between the CON and PT 
groups within the promoter of the MMP11 gene. Bars represent mean (%) ± 
standard error of the mean (SEM). CON, white bars and PT, shaded bars.*, p =
0.045.
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6.4 CHAPTER SPECIFIC CONCLUSIONS
There was a significant difference (p = 0.016) in DNA methylation between the 
CON and PT group at CpG site 3 of the ADAMTS4 gene (Table 6.1). Specifically, 
mean DNA methylation was significantly higher in the PT group compared to the 
CON group (Figure 6.10). Higher expression levels of the ADAMTS4 gene have 
previously been detected in ruptured Achilles tendon compared with normal and 
tendinopathic tendon (Corps et al. 2008), showing that the ADAMT54 gene may 
have a role in tendon pathology. Our data, showing higher mean methylation at 
one CpG site, is in contrast to previous work into musculoskeletal conditions, 
where CpG sites as far as 800 bp upstream of the ADAMTS4 gene were 
demethylated in osteoarthritis samples (Roach et al. 2005). However, increased 
accumulation of the proteoglycan aggrecan has been observed in tendinopathy, 
along with a decrease in levels of ADAMTS4 (Smith et al. 2008). These findings 
highlight interest in the results from this study, as the increased DNA methylation 
observed within the ADAMTS4 gene promoter in the PT group may be resulting in 
a reduction in the levels of ADAMTS4 protein. As such, this could be causing a 
build-up of ADAMTS4 substrates, including aggrecan, disrupting the structural 
integrity of the tendon.
This study found that DNA methylation at one CpG site within the TIMP1 gene was 
significantly different (p = 0.012) between the CON and PT groups. Specifically, 
mean methylation in the PT samples (20.2 ± 2.0, n = 9) was found to be 
significantly higher than in the CON samples (12.6 ± 1.7, n=8). (Figure 6.11). 
Altered expression of the TIMP1 gene has been shown in ruptured compared with 
normal Achilles tendon (Jones et al. 2006) and epigenetic mechanisms such as 
CpG methylation may well have an important role in tendon pathology by affecting
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levels of gene expression. While an increase in TIMP1 gene expression has been
reported in ruptured compared with normal Achilles tendon (Jones et al. 2006),
the data from this study may infer that the increased DNA methylation is causing
a reduction in TIMP1 protein. This could lead to a build-up of substrates thatTIM Pl
would typically cleave and a subsequent disruption of tendon homeostasis, as is 
seen in tendon pathology.
This study also found a significant difference in DNA methylation at one CpG site 
within the MMP11 gene between the CON and PT groups (p = 0.045). Mean 
methylation in the PT samples (4.8 ± 0.4, n = 10) was found to be significantly 
higher than the CON samples (3.6 ± 0.4, n = 10). (Figure 6.12). It is postulated 
that these differences in DNA methylation may influence gene expression and the 
risk of tendon pathology. Indeed, although the mechanisms are not fully defined, 
differences in expression levels of the MMP11 gene have been reported in 
pathologic Achilles tendon (Jones et al. 2006). Increased expression of the MMP11 
gene was observed in both painful compared with normal tendon, as well as 
ruptured compared with normal tendon (Jones et al. 2006). Conversely, 
hypermethylation of a gene promoter is typically associated with reduced 
expression of that gene (Roach et al. 2005). This suggests that a reduction in 
MMP11 gene expression may in fact be apparent in the PT group, as a result of 
the increased DNA methylation measured at one CpG site. One may speculate that 
a reduction in MMP11 gene expression, followed by a subsequent reduction in 
MMP11 protein, could alter the tendon homeostasis and lead to an accumulation 
of proteoglycan substrates that it would usually cleave (Somerville et al. 2003).
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The preliminary results from this study suggest that methylation status of the 
ADAMTS4, TIMP1 and M M Pll genes may be important in relation to the risk of 
patellar tendinopathy. While significant differences in methylation status have 
been identified between the CON and PT groups, further work is needed to
establish the functional relevance of these findings and whether they may 
influence gene expression directly.
CHAPTER 7: DISUSSION
7.1 Copy Number and SNP Genotyping Studies
Chapter 3 focused on CNV within the COL5A1, COL4A1 and TNC genes. For the 
COL5A1 Hs00180523_cn assay, there was a significant difference in discrete CN 
between the AUS CON and ATP groups (p = 0.012). However, although significant, 
this analysis was underpowered given the sample size (CON, n = 69; ATP, n=44). 
Furthermore, this significance was not reported when the continuous CN data were 
analysed. Indeed, it has been speculated that CNV based on continuous calling 
can avoid the potential rounding errors encountered when pooling values into 
discrete groups (Park et al. 2012). As such, all analyses on copy number were 
undertaken on both the continuous and discrete data. There were no other 
significant differences in copy number for either the Hs00180523_cn or 
Hs02980647_cn assays within the COL5A1 gene. While it appears that CNV within 
the COL5A1 gene does not seem to play a role in the risk of ATP, Mokone et al. 
(2006) showed that the rsl2722 SNP within the 3' untranslated region (UTR) of 
COL5A1 gene was associated with ATP. It may be that CNV within other loci of the 
gene may be associated but have yet to be investigated. It is also conceivable 
that smaller-scale variants like the COL5A1 rsl2722 variant may play a more 
prominent role in the aetiology of ATP.
For the COL4A1 gene, although no significant differences were found for all 
analyses on the Hs02119212_cn assay, there was a significant difference in 
discrete CN for the Hs00739915_cn assay between the combined CON and ATP (p 
= 0.014) and combined CON and TEN (p = 0.033) groups. This is an interesting 
finding and given the sample sizes, the analysis was sufficiently powered to detect 
significance. The COL4A1 Hs00739915_cn assay spans intron 22 - exon 22 of the
gene. While the functional relevance of altered CN at this region is unknown, it 
may be that altered gene dosage may have an effect on the tendon and disrupt 
homeostasis of the ECM through a change in gene expression (Dear 2009; Yang 
et al. 2008). For example, it might be envisaged that an increase in COL4A1 
protein could lead to disorganisation of the collagen fibril and an imbalance in the 
other collagens, potentially leading to tendon pathology from the change in 
structural integrity. Furthermore, mutations within the COL4A1 gene have been 
shown to cause congenital muscular dystrophies in humans and mice (Labelle- 
Dumais et al. 2011). These heritable musculoskeletal conditions have serious 
health consequences including muscle weakness, myopathy, muscle necrosis and 
in severe cases, respiratory insufficiency (Labelle-Dumais et al. 2011). This shows 
the interest in investigating this gene in relation to other musculoskeletal 
conditions like ATP. In addition, altered expression levels of the COL4A1 gene have 
also been identified in human tendinopathy, with an increase in expression 
observed compared to normal tendon (Jelinsky et al. 2011). Nevertheless, when 
the copy number data were analysed for the COL4A1 Hs00739915_cn assay as 
continuous CN, the significance was not shown. This suggests that further 
replication of this study would be needed in additional samples and cohorts and 
highlights the importance of difference analysis methods in CNV studies.
The CNV data on the 77VC gene presented in chapter 3 shows that there was limited 
variation in the distribution of copy number (ie. CN < 2 or CN > 2) for the 
Hs00634176_cn assay within intron 23 - exon 23 across cases and controls of all 
cohorts. Namely, there was no significant different in copy number between the 
combined CON and ATP (p = 0.829), nor between the UK CON vs. ATP (p = 1.000) 
and AUS CON vs. ATP (p = 0.347). This was also the case for analyses concerning
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the CON vs. TEN and CON vs. RUP subgroups. Statistical analysis on the discrete 
CN data for the SA cohort was not possible, as all participants had discrete CN 
values of CN = 2. When these data were analysed as continuous CN, there was 
no significant differences (data not shown) and little variation between continuous 
CN values (SA CON, 1.97 ± 0.09; SA ATP, 1.97 ± 0.10; SA TEN, 1.97 ± 0.11; SA 
RUP, 1.98 ± 0.08). Only 1 UK control participant was reported to have a CN > 2 
at this locus. Similarly, only 2 AUS control participants and 3 AUS ATP participants 
had a CN < 2. As such, no significant differences were found for analyses on both 
the discrete and continuous CN data between cases controls of individual cohorts 
and when combined. While CNV is reported within the Database of Genomic 
Variants at this locus, we have observed little variation within the cohorts we 
investigated. There were also no significant differences in copy number for the 
Hs06903309_cn assay within intron 15 of the 77VC gene. Despite this, there was 
a higher frequency of participants with a CN > 2. Across all cohorts, a total of 12 
control and 12 ATP participants had a CN > 2. No control or ATP participants had 
a CN < 2 at this locus. The TNC gene was the first tendon related gene that was 
found to be associated with ATP (Mokone et al. 2005), however, it appears that 
CNV within the two loci investigated in the TNC gene are not risk factors for ATP. 
It is important to note that although CNV may be present within a gene, it does 
not necessarily result in a phenotypic consequence (Dear 2009). As CNV accounts 
for a large proportion of the structural variation within the genome, most of the 
variants have little or no phenotypic effect (Redon et al. 2006; Dear 2009). If all 
the CNV within the genome did have an effect, they would be classed as mutations 
and most individuals would be affected with certain disease traits. It seems that 
CNVs that have a deleterious or harmful effect on the genome are largely selected 
out of the population (Dear 2009). Nevertheless a large quantity of CNV still exists
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within the genome and research has shown the importance of this large-scale
variation in relation to complex diseases (Estivill and Armengol 2007).
Furthermore, as well as disease associated CNV, CNV may also offer a phenotypic
advantage and benefit to the genome in some way (Zhang et al. 2009; Hastings 
et al. 2009).
In chapter 4, CNV was investigated within the MMP3, MMP23B and ADAM8 genes. 
When the combined CON vs. ATP, CON vs. TEN and CON vs. RUP groups were 
compared, there were no significant differences in copy number for either loci 
investigated (intron 4-exon 4 and exon 7) within the MMP3 gene (assays 
Hs02276714_cn and Hs02908568_cn respectively). This lack of significance was 
also apparent when the UK and SA cohorts were analysed separately. However, 
when we measured CNV within exon 7 of the MMP3 gene (Hs02908568_cn assay) 
in the AUS cohort, there was a significant difference in copy number within the 
between the AUS CON and ATP group (p = 0.035) and between the AUS CON and 
TEN group (p = 0.035). While analysis of the continuous copy number data 
showed a lack of significance and the low sample size (CON, 87; ATP, 33; TEN, 
33) reduced the power of these analyses, this preliminary finding still warrants 
further investigation. The Database of Genomic Variants contained no current data 
on CNV within the MMP3 gene at the two exonic loci we investigated, although 
CNV is present within other regions of the gene. Despite this, we identified 
variation in copy number at both of these loci (intron 4-exon 4 and exon 7). As 
new CNVs are continuously being discovered and the extent of CNV within the 
genome is not yet fully defined, the predicted frequency of a given CNV derived 
from databases alone might incorporate a degree of error (Pinto et al. 2007; 
Grozeva et al. 2012). As such, a lack or reported CNV within a gene region does
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not rule it out as a plausible candidate for investigation. Indeed, we identified the 
presence of CNV in a region previously un-catalogued. Despite the preliminary 
findings on CNV within exon 7 of the MMP3 gene, it appears that small-scale 
genetic variants, namely SNPs, play a more prominent role in the risk of ATP. In 
2009, the rs679620, rs591058 and rs650108 SNPs within the MMP3 gene were all 
found to associate with the risk of Achilles tendinopathy (Raleigh et al. 2009). The 
rs679620 variant is a non-synonymous SNP that lies within exon 2 of the MMP3 
gene. This means that the rs679620 SNP has an effect of the protein sequence, 
due to a change in amino acid. Due to the functional effect of this variant, it is 
likely that this could disrupt the balance of MMP3 protein within the tendon and 
modify the risk of ATP.
Chapter 4 also investigated CNV within the MMP23B gene. We found no significant 
differences in copy number between the combined CON and ATP (p = 0.090), the 
CON and TEN (p = 0.387) or the CON and RUP (p = 0.436) groups within exon 1 
of the gene. In addition, there were no significant differences when the UK and 
SA cohorts were analysed separately. CNV within exon 23 of the ADAM8 gene was 
also not found to associate with ATP. No significant differences in copy number 
were found between the combined CON and ATP (p = 0.727), the CON and TEN 
(p = 0.707) or the CON and RUP (p = 1.000). When the UK, SA and AUS cohorts 
were analysed separately, the lack of significance was concordant within these 
groups. Both the assays within the MMP23B and ADAM8 gene lie within coding 
exonic regions, yet the functional relevance of CNV within these loci is not known. 
It appears that in ATP, they do not influence disease risk. In contrast to the lack 
of CNV reported in the Database of Genomic Variants for the MMP3 gene, the 
MMP23B and ADAM8 genes both contained CNV within the loci detected by the
assays. However, the majority of samples from our three cohorts gave a copy 
number of 2, with only a small number of individuals showing either a loss or gain 
in copy number. Interestingly, higher levels of MMP23 protein were detected in 
painful tendon compared with normal tendon (Jones et al. 2006; Schulze-Tanzil 
et al. 2011), showing that this gene is of interest in ATP. Nevertheless, it may be 
that CNV within other regions of the MMP23B gene (other than the region within 
exon 1 that we investigated here) may be responsible, or that other genetic 
variants may be involved. This may also be relevant for the ADAM8 gene, as 
despite the increased expression identified in ruptured Achilles tendon compared 
to controls (Jones et al. 2006), we found CNV within exon 23 of the gene to not 
be associated with ATP. Other genetic variants may be at play here, influencing 
the expression of these genes.
Chapter 5 detailed the investigations into the TNFRSF1A rs4149577 and CA5P3 
rsl049253 variants, as well as CNV within intron 11 - intron 12 of the CA5P8 
gene. Neither the SNP variants within the TNFRSF1A and CASP3 genes, nor CNV 
within the CASP8 gene, were associated with ATP in our combined cohort. This 
was also the case when the UK, SA and AUS cohorts were analysed separately 
and when the ATP group was subdivided to the distinct TEN and RUP groups. 
Importantly, this thesis only investigated a single SNP within the TNFRSF1A gene 
(rs4149577). Despite the lack of association reported at this locus, TNFR1 does 
have a functional role in apoptosis and has been shown to be expressed at 
significantly higher levels in tenocytes from Achilles tendinosis compared to 
controls (Gaida et al. 2012). Therefore it is possible that other genetic variants 
within the DNA sequence, not yet investigated, may influence the risk of ATP. 
Moreover, the TNFR5F1A rs4149577 variant is an intronic SNP that is in linkage
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disequilibrium (LD) with a number of other variants that have been associated 
with musculoskeletal and inflammatory diseases (www.ensembl.org) (Karaderi et 
al. 2012; Park et al. 2013; Swaminathan et al. 2010). Examples of these include 
the TNFRSF1A rsl800693 and rs4149578 variants, that have been associated with 
neuromyelitis optica and ankylosing spondylitis respectively (Karaderi et al. 2012; 
Park et al. 2013, Swaminathan et al. 2010). The second SNP variant to be covered 
in chapter 5 was the rsl049253 variant within the CASP3 gene. While there were 
no significant differences identified between the cases and controls, the CASP3 
rsl049253 variant has been associated with certain types of cancer (Guan et al. 
2013). Interestingly, the rsl049253 variant lies within the 3' UTR of the CASP3 
gene and the CC genotype of this variant has been shown to alter levels of CASP3 
mRNA expression (Guan et al. 2013). In addition, the location of the rsl049253 
variant is a known miRNA binding site, where miRNAs are able to bind to the 
mRNAs and regulate apoptosis (Guan et al. 2013). Regardless of the functional 
significance of this SNP, it seems that it is not a risk factor for the development of 
ATP.
As detailed within chapter 5, there was no significant difference in copy number 
within intron 11 - intron 12 of the CA5P8 gene between the combined CON and 
ATP group (p = 0.402), the UK CON vs. ATP (p = 0.155) group, the SA CON vs. 
ATP (p = 0.327) or the AUS CON vs. ATP group (p = 1.000). A lack of significance 
was also reported when the ATP groups were subdivided into TEN and RUP. SNP 
variants within the CA5P8 gene have previously been associated with Achilles 
tendinopathy (Nell et al. 2012), which is one reason why the CASP8 gene was 
selected for CNV investigation in this thesis. Furthermore, the CNV we investigated 
with the Hs02601709 cn assay overlaps the location of the rsl045485 SNP
investigated by Nell et al. (2012). It appears that the CASP8 rsl045485 variant 
may have a more profound impact on the development of ATP, compared with 
CNV at the locus we investigated. Indeed, while the functional effect of altered 
copy number within the locus we investigate is currently unknown, the CASP8 
rsl045485 variant is known to be a non-synonymous polymorphism that results 
in an amino acid change (September et al. 2012). This may affect interaction with 
other proteins (September et al. 2012) and may explain why this variant was 
associated with Achilles tendinopathy (Nell et al. 2012).
As touched upon in the chapter specific conclusions in this thesis and discussed in 
the introduction, CN may have a direct effect of altering gene dosage and the 
subsequent downstream expression level of a gene (Dear 2009). For the studies 
on the COL5A1 and COL4A1 genes, differences in CN were observed between the 
CON and ATP groups. This was noted for a single locus within each gene spanning 
intron 4 - exon 5 for the COL5A1 and intron 22 - exon 22 for the COL4A1. Similarly 
CN witnin exon 7 of the MMP3 gene was shown to be significantly different 
between the AUS ATP and AUS CON group. While these significant results were 
not reflected in the continuous CN data and were in small sample sizes, the 
differences identified in discrete CN in the COL5A1, COL4A1 and MMP3 genes 
between the ATP and CON groups suggests that altered copy number at these loci 
may modify the risk of ATP. Indeed, a disruption of the amount and types of 
collagen in tendon, as well as altered levels of regulatory enzymes like MMP3, are 
apparent in ATP (Jones et al., 2006).
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7.2 Pyrosequencing Studies
Chapter 6 described the pyrosequencing studies investigating DNA methylation 
status within the promoter regions of the ADAMTS4, TIMP1 and MMP11 genes. 
CpG site methylation was investigated in the promoter of the ADAMTS4 gene, at 
a location approximately 3 kb from the start site of the gene. The assay used 
measured the methylation status of 6 CpG sites. At one CpG site, DNA methylation 
between the CON and PT group was found to be significantly different (p = 0.016). 
Specifically, mean DNA methylation was significantly higher in the PT group 
compared to the CON group. Higher expression levels of the ADAMTS4 gene have 
previously been reported in ruptured Achilles tendon compared with normal and 
tendinopathic tendon (Corps et al. 2008) and it is reasonable to postulate that this 
may be the result of epigenetic mechanisms such as DNA methylation. While 
higher levels of DNA methylation (hypermethylation) is generally considered to 
silence gene expression (Raleigh 2012), it may be that the higher methylation 
status observed within this region 3 kb from the start of the gene, may have an 
indirect effect on gene expression through the disruption of transcription factor 
binding (Thirunavukkarasu et a!. 2006). For example, a number of transcription 
factors are known to bind within the promoter of the ADAMTS4 gene, including 
p53 and PPAR-gamma (peroxisome proliferator-activated receptor gamma) 
(www.genecards.org).
DNA methylation status was also investigated at 3 CpG sites within the TIMP1 
gene, in a region 8.8 kb from the start site of the gene. As such, DNA methylation 
status at one CpG site within the TIMP1 gene was found to be significantly different 
between the CON and PT groups (p = 0.012). Mean methylation in the PT samples 
was found to be significantly higher than in the CON samples. Interestingly,
altered expression of the TIMP1 gene has been shown in ruptured compared with 
normal Achilles tendon (Jones et al. 2006), suggesting that epigenetic 
mechanisms such as CpG methylation may well have an important role in tendon 
pathology. As with the AD AMTS 4 gene discussed above, altered DNA methylation 
may interfere with the binding of transcription factors within the promoter of the 
TIMP1 gene. This is supported by the presence of numerous binding sites within 
the TIMP1 gene promoter, where transcription factors such as Spl (specific protein 
1) and c-Fos (www.genecards.org).
Lastly, chapter 6 reported the DNA methylation status measured at 4 CpG sites 
within the promoter region of the MMP11 gene. These CpG sites were in a region 
approximately 30 bp from the start of the MMP11 gene. There was a weak but 
significant difference (p = 0.045) in DNA methylation at one CpG site within the 
MMP11 gene between the CON and PT groups. Mean methylation in the PT samples 
was found to be significantly higher than the CON samples. These differences in 
DNA methylation may have an influence on gene expression and the risk of tendon 
pathology, although functional studies would be necessary in order to prove this. 
Indeed, differences in expression levels of the MMP11 gene have been reported in 
pathologic Achilles tendon (Jones et al. 2006) and increased expression of the 
MMP11 gene was observed in both painful compared with normal tendon, as well 
as ruptured compared with normal tendon (Jones et al. 2006). If epigenetic 
mechanisms, such as DNA methylation, are responsible for such changes in gene 
expression, one may speculate that transcription factors may not be able to bind 
or access the genome as readily, due to increased CpG site methylation within the 
promoter of the gene. Nevertheless, further work would be needed to try to
establish this.
These preliminary investigations into DNA methylation status in patellar 
tendinopathy suggest that methylation status of CpG sites within the ADAMTS4, 
TIMP1 and MMP11 genes may be important in relation to the risk of this condition. 
It is plausible that the accumulation of the proteoglycan aggrecan observed in 
tendinopathy (Smith et al. 2008) may be explained by a reduction in ADAMTS4 
due to hypermethylation at CpG sites within the ADAMTS4 gene promoter. 
Similarly, the hypermethylation observed at a CpG site within the promoter of the 
TIMP1 gene could be causing a decrease in expression of the gene and elevated 
levels of substrates that TIMP1 would usually cleave. Furthermore, the increased 
DNA methylation reported in thesis, at a CpG site within the MMP11 gene, could 
be causing a reduction in MMP11 gene expression. This may result in lower levels 
of MMP11 protein, an accumulation of proteoglycan substrates that MMP11 would 
typically cleave (Somerville et al. 2003) and consequently disrupt the tendon 
homeostasis. Nevertheless, while significant differences in methylation status 
have been identified between the control and patellar tendinopathy participants, 
the functional relevance of these findings is currently unknown and can only be 
speculated. Additional research would be necessary to establish this.
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7.3 Limitations and Future Work
The research detailed in this thesis has advanced the understanding of the genetic 
risk factors for both Achilles and patellar tendon pathology, whilst also revealing 
a number of possible avenues for future research. The studies contained within 
this thesis have investigated novel genes, as well as genes previously associated 
with tendon pathology. The work has explored SNP variants, along with being the 
first to investigate the role of copy number variation in relation to ATP. In addition, 
the investigation of DNA methylation status by Pyrosequencing is an exciting new 
area researched in this thesis.
As described in the methods in Chapter 2, the SNP and CNV studies in this thesis 
were undertaken in a sample size sufficient to reach 80% power when cohorts 
were analysed separately, while >90% power was achieved when the UK, SA and 
AUS Caucasian cohorts were combined. However, a larger sample size would allow 
greater confidence in results, particularly for those where cohorts were stratified 
into subgroups for analyses. A larger sample size would also reduce the risk of 
false positive and false negative results. As the three cohorts investigated were 
all Caucasian, further work replicating these studies in other populations would 
also be advantageous.
The overview of participant characteristics for the UK, SA and AUS cohorts are 
detailed in the methods in Chapter 2 and mentioned in the results sections of 
Chapters 3, 4 and 5. There were some significant differences in participant 
characteristics reported between the CON and ATP cohorts. However, analyses 
showed that these differences were not found to interact with copy number or 
genotype in the CNV and SNP studies respectively.
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All participants for the ATP studies, both those with Achilles tendon pathology and 
the control subjects, self-reported as being physically active. Some participants 
were involved in physical activity and sports recreationally, while others 
participated in sports at a competitive or professional level. With this in mind, it 
is known that different sporting/physical activities, as well as the intensity and 
duration of exercise, affects an individual's risk of developing tendon pathology 
(Raleigh & Collins, 2012; Jarvinen et al. 2005; Christian et al. 2014). Further work 
with larger sample sizes may look at analyses where cohorts are stratified for 
activity level or sport.
Whilst the studies within this thesis on genomic copy number have generally 
revealed that CNV does not appear to be an important risk factor for ATP in the 
genes investigated, it does warrant further exploration in other genes. This work 
was the first to address the potential role of CNV in relation to ATP and has 
addressed a number of important issues including the most appropriate way of 
analysing and interpreting the copy number data. Copy number data can be 
reported as the raw continuous data to decimal places. This data is taken directly 
from the CopyCaller software prior to the calculation of discrete CN using the 
maximum-likelihood algorithm (Park et al. 2012). While it may appear to be more 
biologically relevant to analyse CN data based on whole integer gene copies, it 
may, in certain situations, mean that borderline CN calls are not accurately 
represented (Park et al. 2012; Plagnol 2009). Specifically, accuracy may be 
affected when determining values on the borderline between rounding up or down 
to a whole copy number value (Park et al. 2012; Plagnol 2009). However, a
distinct advantage of interpreting and analysing the continuous CN data is that a 
smaller sample size is required to reach statistical power.
To overcome any potential rounding errors, all CN data were analysed as both 
continuous and discrete CN values. Despite some minor discrepancies when the 
cohorts were stratified into smaller subgroups, we found concordance in our CN 
analyses and thus have confidence that the degree of error in CN calling was 
negligible. As discussed in the method (section 2.3.1), TaqMan probe based qPCR 
is a robust and accurate method for CNV determination. As with all methods, there 
are other ways of measuring and determining copy number within a sample 
(Walker et al. 2009; Machado et al. 2013; Fode et al. 2011). Whilst 
Pyrosequencing was used for measuring methylation status in this research, it 
may also be an appropriate method for analysing copy number (Fode et al. 2011). 
The Paralogue Ratio Test (PRT) is another method for the measurement of CN that 
may be of interest (Walker et al. 2009). However, as described elsewhere, the 
running costs of these methods and the analysis time required would be 
significantly greater (Walker et al. 2009; Fode et al. 2011). In addition, while 
models exist to analyse the combined effect of multiple SNPs as haplotypes, such 
models are not apparent for CNV analyses. Additional investigations into the effect 
of CNV on the risk of ATP may look to consider the combined effect of CNV at 
different loci, if plausible to do so.
The mapping of common CNV regions is a relatively new area in comparison to 
the vast knowledge of SNPs (Ionita-Laza et al. 2009). CNV discovery is an on-
going process, meaning the number and frequency of CNV catalogued within the 
human genome is liked to increase. This thesis examined the genetic association
Of candidate CNV regions with ATP, utilising the catalogued CNV data from the 
Database of Genomic Variants. Whilst at the time of research the MMP3 gene had 
no reported CNV within the two loci investigated in this work, it is likely that future 
mapping may highlight that CNV is present within this region and indeed much 
more of the genome. Indeed, the development of new technologies and better 
detection of CNVs is expected to advance CNV research (Ionita-Laza et al. 2009). 
Furthermore, despite there being no mapped CNV within the MMP3 gene at the 
loci in this thesis, this work identified differences in copy number in both the ATP 
cases and controls. Although not significantly different, the presence of 
participants with a CN < 2 or CN >2 suggests that there are CNV regions yet to 
be mapped in the MMP3 gene.
The epigenetic work reported in this thesis identified differences in DNA 
methylation status between the patellar tendinopathy (PT) and control groups at 
selected CpG sites in the promoter regions of the novel candidate genes ADAMTS4, 
MMP11 and TIMP1. Studying further CpG sites within these genes would be 
valuable, enabling a fuller analysis of the whole gene promoter of each gene. 
Additionally, investigation of DNA methylation status within a larger cohort would 
be beneficial for additional analyses.
This work investigated a range of genetic variants known to be involved in the 
maintenance of the tendon ECM. Certain genes had been previously associated 
with tendon pathology, while others were novel candidate genes. Future candidate 
genes worthy of investigation would be the scleraxis (SCX) gene and the 
tenomodulin (TeM) gene. Scleraxis (SCX) is a transcription factor involved in 
tenogenesis and tendon development (Killian et al. 2012). SCX can be detected in
192
progenitor tendon cells as well as mature tenocytes and is considered as a tendon 
marker (Shukunam i et al. 2006; Schweitzer et al. 2001). In teresting ly, increased 
expression of scleraxis has been shown in response to mechanical load, leading to 
changes in ECM production and structure of the tendon (Jones et al. 2013; Killian 
et al. 2012). Furtherm ore, SCX positively regulates tenom odulin ( TeM) gene 
expression (Shukunam i et al. 2006). TeM is a transm em brane protein expressed 
specifically in tendon and o ther connective tissues (Lejard et al. 2007) and a lack 
of TeM has been shown to affect tenocyte differentiation and collagen fibril 
structure (Docheva et al. 2005).
A variety o f d iffe ren t genetic variants have been investigated in this thesis, 
ranging from  small-scale SNPs, to larger genomic CNV, to  CpG site m ethylation. 
Future research uncovering the genetic risk factors for tendon pathology will likely 
continue to  centre on SNPs, given the interesting findings to date concerning these 
types of genetic variants. As more genetic variants are found to associate with 
ATP and others are excluded from  a role in the risk o f ATP, it is envisaged tha t a 
comprehensive and detailed understanding of the genetic predisposition of ATP 
will be unearthed. This may help to identify at risk individuals and enable 
preventative strategies to be implemented to  modify the ir in jury risk. 
Furthermore, the prelim inary findings w ithin this thesis on DNA methylation status 
within the ADAMTS4, MMP11 and TIMP1 genes highlights the interest in 
researching other form s of genetic variation in relation to ATP, namely epigenetic
mechanisms.
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7.4 Concluding Remarks
It is envisioned th a t the continued research and identification of novel genetic 
variants associated with ATP will help to develop a clinical risk model for this 
complex pathology, where a greater understanding is gained on an individual's 
risk of in jury. As such, preventative measures will be able to be implemented 
sooner, w ith the aim of reducing the risk o f ATP.
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APPENDIX II
Partic ipan t In fo rm ation  Sheet & Consent
PAR TIC IPAN T INFO RM ATION
Background
Thank you for showing an interest in this new study that is going to be conducted at 
The University of Northampton. The study is being carried out by Dr Stuart Raleigh 
who is a Reader and a researcher in Molecular Biology, Professor William Ribbans 
who is a consultant orthopaedic surgeon and Mr Louis El Khoury who is a researcher 
and PhD student. All three are based at the University of Northampton's School of 
Health and Professor Ribbans is also based at the County Clinic, Northampton. The 
contact details of the team are found towards the end of this leaflet. Please feel free to 
contact them at any time if you require any additional information.
What is the study about?
We are trying to establish whether certain individuals carry particular versions of genes 
(known as alleles) that may increase their risk of Achilles tendon problems. We are 
particularly interested to learn more about the types of Achilles tendon problems called 
Achilles tendinopathy (swollen, painful tendon) and Achilles tendon rupture. The study 
is about Achilles tendon problems in humans -  we never use animals -  and we would 
greatly value you as a volunteer.
Why are we interested?
We are interested because many people with relatively active lifestyles as well as 
professional athletes experience Achilles tendon problems during or after sports 
activities. This can sometimes lead to long term disability. In some cases the injury 
needs surgery and some individuals are reluctant, or have difficulty returning to a sport, 
or physical activity, they once enjoyed This research might eventually lead to a way of 
reducing the number of people who get tendon problems in the future or to better 
treatment for those already affected.
What’s involved if I participate?
We would like individuals to donate a small sample of their spit (saliva) for DNA 
analysis. We only want about 2 ml of your saliva (the same as one teaspoonful!) which 
can be taken from simply spitting into a tube. The procedure would take about 3 
minutes to perform. You don’t even have to attend a clinic. We can send you the tube 
to spit into. We would also like you to answer some background questions and details 
about your health and any exercise that you do. If you would like to take part, please 
complete, sign, and return the consent from in the paid post envelope and we will send 
you a questionnaire and a saliva collection tube. The total time taken to collect the 
saliva sample and complete the questionnaire is about 10-15 minutes.
What will happen to my saliva sample?
Your saliva sample will ONLY be used for Achilles tendon studies. Once we receive 
your sample, it will be labelled with a unique number only and stored in a secure freezer 
at the University of Northampton’s Park campus. We will isolate DNA from your saliva 
sample. We will then compare the genes between various groups of individuals to 
establish whether samples from people who have had Achilles tendon problems 
contain different versions compared to people who don’t have tendon problems. We 
would like to investigate many genes from your sample and in order for us to do this
we would like to retain your sample indefinitely. There may be occasions when we 
might want to send a small amount of your sample to scientists that we do joint studies 
with. This would only be done if they could help us with our study. However, if this does
happen the sample they receive will only have the number on it and it would not be 
possible for you to be identified.
Will my sample be used for studies investigating any other disease?
No. The genes that we are interested in analysing are only relevant to musculoskeletal 
soft tissue injuries (tendon injuries). It will not be possible for us to investigate other 
illnesses such as: cancer and cardiovascular diseases.
Will the information I provide be kept private?
Yes. We will not send any of your private contact details to any other party. Your 
personal contact details will only be seen by the three members of the study team. 
Indeed your personal contact details will be stored securely in a locked filing cabinet at 
the university and on a password protected computer. The data will not be on any 
networked computer drives. To make things even more secure your saliva sample and 
the DNA that we isolate from it will only be labelled with a number. It would not be 
possible for any person, other than the study team, to identify you from the number 
that your sample will be allocated.
How long will you be keeping my personal information?
We would like to retain you personal information for an indefinite amount of time. 
Nevertheless, if you want to end your participation in this project at any time we will 
immediately destroy your personal information as well as your DNA sample. However 
any data obtained from the analysis of your sample up until that point will remain part 
of the research and will be included in any published work.
Why do you need information about my previous medical history?
We need to ask these questions because certain ailments that you may have had in 
the past might be important to Achilles tendon studies. If we don’t have the data we 
could make a false conclusion in our study.
Why do you need to know about my lifestyle?
This is because it may be lifestyle factors that are most important in causing people to 
have Achilles problems Providing this information will help us to establish whether this 
is true or not.
Why do you need to know about my ethnicity?
This is because certain genetic factors might be different in people of different ethnicity. 
Having details about a person’s ethnicity can help us build a more accurate 
assessment of the role of genes in causing any Achilles tendon problems. Without 
details on ethnicity the data we generate might be flawed.
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Why do you need my name and contact details?
This is for two main reasons. Firstly we may want to invite you to be part of some future 
study and might send you a letter. Of course, it would be entirely up to you whether or 
not you replied to any future invites. You can always send us a request not contact you 
for any future studies. Secondly, very rarely, samples that are provided for a study can 
be accidently damaged during the laboratory procedure. If this does happen we would 
like to think that we could contact you again for a replacement sample. If we were not 
able to contact you then the valuable sample that you kindly donated would have been 
lost from the investigation and this might lead to less accurate scientific results.
What happens if I want to be involved but later change my mind?
You simply contact us and let us know. We will then immediately destroy any sample 
and information that you have donated to us.
Will I be able to obtain information about my own DNA sample?
The study that we are conducting is aimed at understanding how genetic factors affect 
the Achilles tendon by studying a group of people. It will be difficult to predict any risk 
on an individual basis. This is why this study is not designed to test individual genetic 
status. For this reason we do not plan to give back individual results to participants. If 
you require addition information about this, please contact us on the numbers or e- 
mails provided on the last page.
How can I obtain information about the progress of the research?
After roughly 18 months, information about the preliminary results of the study will be 
posted on the University of Northampton School of Health website. For more 
information please visit:
(www.northampton.ac.uk/info/20038/school-of-health)
What will happen to the data obtained from this study?
We would like to publish this in scientific journals. The publications would never reveal 
any participant identity or contact details.
What benefit do I get from being involved in this study?
Many scientific studies rely on sample donations from the general population. By taking 
part in this study you will help to further our understanding of why some people, 
particularly active sportspeople, develop Achilles tendon problems. Eventually the 
findings may help people to be treated for the condition. Furthermore, it might be 
possible that in the future we could identify those most at risk of developing the 
problem. If this is the case we could educate people about the suitability of sports that 
they do and advise them on their risk The finding may also be used to enhance our 
understanding of how human tendons work under stressed conditions.
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We thank you for reading the above information. If you feel that you would like to be 
involved then please complete and return the consent form on the next page. Please 
remember that if you have any questions then please contact the study team who will 
be very pleased to talk you through any aspect of this study.
Contact Details
Louis El Khoury
MX05
University of Northampton 
Boughton Green Road 
Northampton -  UK 
NN27AL
Tel: 01604 892512 
louis.elkhoury@northampton.ac.uk
Dr Stuart Raleigh
School of Health 
Kelmarsh Building 
Boughton Green Road 
Northampton -  UK 
NN27AL
Tel: 01640 892306 
stuart.raleiqh@northampton.ac.uk
Prof William Ribbans
The County Clinic 
57 Billing Road 
Northampton -  UK 
NN15DB
Tel: 01604 795414
wjribbans@uk-consultants.co.uk
THE UNIVERSITY OF
NORTHAMPTON
CONSENT FORM
If you would like to participate in this study then please complete the consent 
form below. If you have any further questions relating to the study, or if there is 
something that you wish to discuss with us then please contact us at the 
addresses provided above.
Please tick the box that corresponds to your choice.
I have read the study information sheet and understand 
what is involved.
Yes No
understand that my sample will be analysed 
anonymously and my contact details kept confidential. 
My contact details will only be used by the researcher if 
my sample is accidently damaged It would be up to me 
whether I provided another sample.
I understand that I can w ithdraw my participation at any 
time and that my sample and information would be 
destroyed upon my request.
I am willing to participate in this project.
I would be interested in receiving information about future 
studies. My agreement to this would mean my contact details 
would be retained securely and for this purpose alone.
Signed: Date:
Name (Print) 
Address
Phone Number E-mail
We appreciate your tim e and your w illingness to participate in this study.
Participant number (to be entered by the research team)

Achilles Tendon Datasheet - Controls
We greatly appreciate your interest in participating in this project. Please complete as 
much of this questionnaire as possible keeping in mind the following points:
1 This questionnaire is printed on both sides of every sheet. Please pay attention 
at answering the questions on the back of each sheet.
2. Throughout the questionnaire you might come across scientific terms followed 
by small numbers such as: ACL5 These terms are explained in the glossary on 
the last page of this questionnaire.
3. Please feel free to skip any question you are having difficulty with.
4 Please mail us back the questionnaire and a team member will contact you to 
go over any question you are having difficulty with.
5. If you have any concern about the aspect of this project please feel free to 
contact us on the numbers or e-mails below.
Rebecca Rickaby
Tel: 01604 892893 
rebecca.rickaby@northampton.ac.uk
Louis El Khoury
Tel: 01604 892512 
louis.elkhoury@northampton.ac.uk
Dr Stuart Raleigh
Tel: 01604 892306 
stuart.raleiqh@northampton.ac.uk
Prof William Ribbans
Tel: 01604 795414
wiribbans@uk-consultants.co.uk
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ACHILLES TENDON STUDY -  Control
We would greatly appreciate you providing us with your personal details. 
However if you prefer not to fill in this section, please proceed to the next page.
SECTION 1: PERSONAL DETAILS
Study 
Number
To be completed 
by research team 
so leave blank
Surname
Address
First Name
Contact
Telephone
Number
e-mail Occupation
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Date of birth D D / M M / Y e a r
Height
Cms:
Weight
(in
underwear)
Years and months
Ft and Ins:
Stone & Lbs:
Black/African
Gender 
BMl
To be
completed by 
the research 
team so leave 
blank.
White
male female
Asian
Ethnic group
Mixed Ancestry Chinese Other
Nationality
Country of 
Birth
Dominant
Hand Left Right
Yes (Current) Yes (Ex smoker)
Smoker
If yes, Number of years
No, never
If stopped, when
If yes, number per day
Do you know 
your blood 
group?
Yes A B AB O
No Rh Pos Rh Neg
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r
If you participate or have participated in different sports or physical activities 
please complete section 2 on Sporting and Recreational Detaifs aCt'V,t'eS’
SECTION 2: SPORTING AND RECREATIONAL DETAILS
Type of sport/ physical activity you 
have participated in
Current or past participation
Year started participation
Years involved in the sport
Years in competitive sport
Have you been involved in the sport at a 
professional level? If so, please state how 
larr
Level of Participation: 
e.g. Leisure/Club/Regional/International
Average hours of training per week 
- in the last 12 months
Type of sport/ physical activity you 
have participated in
Sport 1
Current Past
Sport 4
Sport 2
Current Past
Sport 5
Sport 3
Current Past
Sport 6
Current or past participation Current Past Current Past Current Past
Year started participation
Years involved in the sport
Years in competitive sport
Have you been involved in the sport at a 
professional level? If so, please state how 
many years.________________________
Level of Participation: 
e.g. Leisure/Club/Regional/International
Average hours of training per week 
- in the last 12 months
If you Run/Jog, please specify the distance crossed every week
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SECTION 3: GENERAL MEDICAL DETAILS
Do you suffer from any Connective Tissue and Rheumatological Diseases and Disorders’?
D Ankylosing Spondylitis
D Aspartylglycosaminuria (AGU)
D Behcet's Syndrome
D Crohn’s Disease
D Discoid Lupus Erythematosus
D Ehlers-Danlos syndrome (EDS)
D Eosinophilic Fascitis
D Giant Cell (Temporal) Arthritis
D Gout
D Hypersentive Vasculitis
D Lipid Storage Diseases
0  Marfan Syndrome 
D Menkes Kinky Hair Syndrome
D Mucopolysaccharidoses
D Myopathies and Dystrophies 
D Ochronosis (Homocystinuria)
D Osteoarthritis
D Osteogenesis imperfecta (01)
□ Polyarteritis Nodosa
D Polymyalgia Rheumatica
D Pseudogout
D Reactive Arthritis
D Reiter's Syndrome
D Relapsing Polychrondritis
D Rheumatoid Arthrits
D Scleroderma
D Sjogren’s Syndrome
D Systemic Lupus Erythematosus (SLE) 
D Systemic Sclerosis
D Polymyositis & Dermatomyositis D Wegener’s Granulomatosis
Has any member of your 
family (Blood relatives) 
suffered from any Achilles 
tendon injury/problem?
Do you suffer from elevated 
blood cholesterol?
Have you been diagnosed 
with any of the following 
diseases?
Yes □
□No
Unknown D
Yes D 
No D
If Yes, please specify the family member (eg 
Mother, Son) and type of injury
Rupture
Swelling
Other
o
o
0
Do any other members of 
your family suffer from 
elevated blood cholesterol?
Yes D No D 
Unknown D
D Diabetes mellitus
D Adrenal disorders
D Thyroid disorders
D Amyloidosis
D Renal disease
D Other endocrine and metabolic disease (Specify)
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Drug and Allergy History
[Have you ever used oral 
corticosteroids2 
[cortisone tablets)?
If yes, how long ago (or how many times, where applicable) 
did vou use the medication?'OU
Yes □ No □ 
Unknown D
months D 6 months
Have you ever been given an 
injection with corticosteroids?
Yes □ No □ 
Unknown D
D 3 months 
D 12 months
D 6 months 
D 24 or more months
I Have you ever been given an 
injection of corticosteroids in or 
| around a tendon?
Yes □ No □ 
Unknown D
D Once 
D 3 times
D Twice
D >3 times
Have you ever used anabolic 
steroids3?
Yes Q No D 
Unknown D
D 3 months 
D 12 months
D 6 months 
D 24 or more months
Have you ever used fluoroquinolone 
antibiotics?
(see list below)
Yes D No D 
Unknown D
D 3 months 
D 12 months
D 6 months
D 24 or more months
If yes, please select from the list below
D CIPROFLOXACIN
D CIPROXIN
□ LEVOFLOXACIN
□ TAVANIC
□ MOXIFLOXACIN
D AVELOX
D NALIDIXIC ACID
□ URIBEN
□ NORFLOXACIN
□ UTINOR
□ OFLOXACIN
D TARVID
What medication, if any, are you
currently using? (please list)
Do you suffer from any allergy? Yes D No D
(please list) Unknown D
SECTION 4: HISTORY OF LIGAMENT AND TENDON INJURIES/PROBLEMS
Have you ever had a ligament4 
injury/problem in the past?
If yes, please specify which 
ligaments?
(You may tick more than one block, 
please select either L (left) or R 
(right))
The Abreviated medical terms are 
explained in the glossary on the last page.
Yes D No D Unknown D
Knee (ACL)5
L R
Knee (PCL)7
L R
Wrist ligaments
To your knowledge, have any other 
members of your family suffered 
from any ligament injury/problem?
Have you ever injured a tendon9 in 
the past?
If yes, please specify which 
tendon?
(You may tick more than one block, 
please select either L (left) or R 
(right))
Yes D No D
Unknown D
D Sibling
D Son / daughter
D Other family member
and condition: Please choose ligament 
injury from the list above
Yes D No D Unknown D
L R
Foot and ankle:
Achilles tendon 0  0
Tibialis posterior 0  0
Plantar fascia 0  0
Knee: Patellar tendon 0  0
Elbow and wrist: Wrist extensor tendons 0  □
Subscapularis 0  0
Shoulder:
Supraspinatus 0  0
Infraspinatus D □
Teres minor □ 0
Other
225
0 Mother
0 Father 
D Sibling
If Yes, please specify the family member
To your knowledge, have any other Yes D No □
members of your family suffered
from any tendon injury/problem? ,, , n
Unknown D
D Son / daughter
D Other family
member:.............
Condition Please choose tendon injury from 
the list above
Have you ever suffered from any of 
the following injuries?
D Acute shoulder dislocation
D Chronic shoulder instability
D Chronic ankle instability
Thank you for taking time to complete this questionnaire. Your 
participation is greatly appreciated. Please go on to sign the 
consent document that you have been sent.
Please return your saliva sample, completed questionnaire and
consent form to us as described in the “participant information” 
sheet.
If you are unsure about any aspect of this project or require further 
information please contact the study team using the contact 
numbers, or emails, found on the front page of this questionnaire.
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Glossary
1. Rheumatologic disease A type of disease involving inflammation of
muscles, joints, and other tissues
2. Corticosteroid: a group of steroid hormones used to treat inflammation
3. Anabolic steroid a synthetic steroid hormone that resembles testosterone in
promoting the growth of muscle. Such hormones are used medicinally to treat
some forms of weight loss and, by some athletes and others to enhance
physical performance
4. Ligament. A short band of tough, flexible, fibrous connective tissue that
connects two bones or cartilages or holds together a joint
5. ACL: Anterior cruciate ligament
6 MCL: medial collateral ligament
7. PCL: Posterior cruciate ligament
8. LCL: Lateral collateral ligament
9. Tendon: A flexible but inelastic cord of strong fibrous collagen tissue
attaching a muscle to a bone
Achilles Tendon Datasheet - Cases
We greatly appreciate your interest in participating in this project. Please complete as 
much of this questionnaire as possible keeping in mind the following points:
6. This questionnaire is printed on both sides of every sheet. Please pay attention
at answering the questions on the back of each sheet.
7. Throughout the questionnaire you might come across scientific terms followed
by small numbers such as: ACL5. These terms are explained in the glossary on
the last page of this questionnaire.
8. Please feel free to skip any question you are having difficulty with.
9. Please mail us back the questionnaire and a team member will contact you to
go over any question you are having difficulty with.
10. If you have any concern about the aspect of this project please feel free to
contact us on the numbers or e-mails below.
ACHILLES TENDON DATASHEET -  Case
We would greatly appreciate you providing us with your personal details.
However if you prefer not to fill in this section, please proceed to the next 
page.
SECTION 1: PERSONAL DETAILS
Study
Number
To be  c o m p le te d  
by re s e a rc h  te a m  
so le a v e  b la n k
Surname First Name
Address
Contact
Telephone
Number
e-mail Occupation
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SECTION 2: SPORTING AND RECREATIONAL DETAILS
Type of sport(s) you have participated 
in
Current or past participation
Sport 1 Sport 2
Current Past
Sport 3
Current Past Current Past
Year started participation
Years involved in the sport
Years in competitive sport
Level of Participation:
e.g. Leisure/Club/Regional/International
Average hours of training per week 
-inthe last 12 months
Type of sport(s) you have participated 
in
Current or past participation
Have you been involved in the sport at a 
professional level? If so, please state how 
many years.
Sport 4
Current Past
Sport 5
Current Past
Sport 6
Current Past
Year started participation
Years involved in the sport
Years in competitive sport
Have you been involved in the sport at a 
professional level? If so, please state how 
many years.
Level of Participation:
e.g. Leisure/Club/Regional/International
Average hours of training per week 
- in the last 12 months
!f you Run/Jog, please specify the di crossed every week
SECTION 3: GENERAL MEDICAL DETAILS
DO you suffer from any Connective Tissue and Rheumatological Diseases and Disorders’?
D Ankylosing Spondylitis 
D Aspartylglycosaminuria (AGU) 
D Behcet's Syndrome 
D Crohn’s Disease 
D Discoid Lupus Erythematosus 
D Ehlers-Danlos syndrome (EDS) 
D Eosinophilic Fascitis 
D Giant Cell (Temporal) Arthritis 
D Gout
D Hypertensive Vasculitis 
D Lipid Storage Diseases
□ Marfan Syndrome 
D Menkes Kinky Hair Syndrome
D Mucopolysaccharidoses
D Myopathies and Dystrophies 
0 Ochronosis (Homocystinuria)
D Osteoarthritis 
D Osteogenesis imperfecta (01)
D Polyarteritis Nodosa 
D Polymyalgia Rheumatica 
D Polymyositis & Dermatomyositis
Have any other members of 
your family (Blood relatives) 
suffered from any Achilles 
tendon injury/problem?
□ Pseudogout 
D Reactive Arthritis
□  Reiter's Syndrome
D Relapsing Polychrondritis
D Rheumatoid Arthrits
D Scleroderma
D Sjogren's Syndrome
D Systemic Lupus Erythematosus 
(SLE)
D Systemic Sclerosis
D Wegener’s Granulomatosis
D No, I don't suffer of any of these 
diseases
Yes L
No [
Unknown D
If Yes, please specify the family member (eg 
Mother, Son) and type of injury
Rupture
Swelling
Other
Do you suffer from elevated 
blood cholesterol?
Have you been diagnosed 
with any of the following 
diseases?
No
Do any other members of 
your family suffer from 
elevated blood cholesterol?
Yes D No D
Unknown D
D Diabetes mellitus 
D Adrenal disorders 
D Thyroid disorders 
D Amyloidosis 
D Renal disease
D Other endocrine and metabolic disease (Specify)
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Drug and Allergy History If yes, how long ago (or how many times, where applicable) 
_dld you use the medication?
Have you e ve r used oral 
corticoste ro ids2
(cortisone tab le ts )?________________
Yes D  No D  
U nknow n D
D  3 months □  6 months 
D  12 months D  24 or more months
| Have you  e ve r been g iven  an 
injection w ith  co rticos te ro ids?
Yes 0  No D  
U nknow n D
D  3 months D  6 months 
D  12 months D  24 or more months
[H a ve  you e ve r been g iven  an 
injection o f co rticos te ro ids  in or 
| around a te n d o n ?
Yes □  No D  
U nknow n D
D  Once D  Twice 
D  3 times D  >3 times
Have you e ve r used anabo lic  
stero ids3?
Yes D  No D  
U nknow n D
D 3 months D 6 months 
D 12 months D 24 or more months
Have you e ve r used fluo roqu ino lone  
antib io tics?
(see list be low )________ ______________
Yes D  No D  
U nknow n D
D  3 months D  6 months 
D  12 months D  24 or more months
If yes, p lease  se lec t from  th e  lis t below:
D  CIPROFLOXACIN 
D  CIPROXIN 
D  LEVOFLOXACIN
D  TAVANIC
□ MOXIFLOXACIN
□ AVELOX
□ NALIDIXIC ACID 
D  URIBEN
D  NORFLOXACIN 
D  UTINOR
□ OFLOXACIN
□ TARVID
W hat m ed ica tion , if any, are you 
currently  us ing?  (p lease  list)
Do you su ffe r fro m  any a lle rgy?  
(p lease list)
Yes D  No D  
U nknow n D
I   H I o u I  I JU I  i i i
Have you  e ve r had  a ligam en t4 
in jury/prob lem  in th e  past?
If yes, p lease  sp e c ify  w h ich  
ligam ents?
(You m ay tick  m o re  th a n  one  block, 
please se lect e ith e r L (le ft) o r R 
(right))
The abbreviated medical terms are 
explained in the glossary on the last page.
Yes □ No D U nknow n □
L R L R
Knee (ACL)5 W Knee (PCL)7 □ D
Knee (MCL)6_________ □  0 Knee (LCL)8 □ □
Ankle lateral ligaments 0 0 Ankle medial ligaments □ D
Spinal ligaments □  □ Finger ligaments □ □
Shoulder ligaments D D Wrist ligaments D O
Elbow ligaments □ □ Other ligaments □ D
To you r know ledge , have  any o th e r | Yes D  No Q  
m em bers o f yo u r fa m ily  su ffe red  
from  any ligam en t in ju ry /p rob lem ?  | u n kn o w n  □
If Yes, p lease specify  the fam ily 
m em ber
D M other 
D Father 
□ S ib ling 
D Son / daughter 
D  O the r fam ily  m em ber
and condition Please choose ligament 
injury from the list above
Have you e ve r had a te n d o n 9 
in ju ry/p rob lem  in the  past? Yes D  No D  U nknow n D
L R
Foot and ankle:
Achilles tendon □ D
Tibialis posterior D D
Plantar fascia D D
Knee: Patellar tendon D D
E lbow  and wrist: Wrist extensor tendons D D
Subscapularis D D
Shoulder:
Supraspinatus D D
Infraspinatus D D
Teres minor D D
O th e r:................................................................................................
I 0 0 0 0 9
If yes, p lease  spec ify  w h ich  
tendon?
(You m ay tick  m ore  th a n  one  block, 
p lease se lect e ith e r L (le ft) o r R 
(right))
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To you r know ledge , have  any o the r 
m em bers o f y o u r fa m ily  su ffe red  
| from any tendon  in ju ry /p rob lem ?
Y e s □ No □ 
U nknow n D
If Yes, p lease specify the fam ily  m em ber 
D M other
0  Father
D  S ibling
0  Son / daughter
D  O ther fam ily  
m em ber:...........
Condition: Please choose tendon injury from 
the list above
Have you e ve r su ffe re d  from  any of 
the fo llow ing  in ju ries?
D  A cu te  shou lde r d is location  
D  C hron ic  shou lde r instab ility 
D  C h ron ic  ankle  instab ility
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Glossary
10 Rheumatologic disease A type  o f d isease invo lv ing in flam m ation of 
m usc les , jo in ts , and o ther tissues
11. Corticosteroid: a g roup  o f stero id  horm ones used to trea t in flam m ation
12. Anabolic steroid: a syn the tic  stero id  horm one that resem bles testosterone in
p rom o ting  the g row th  o f m uscle. Such horm ones are used m edic ina lly  to  treat
som e fo rm s of w e igh t loss and, by som e ath le tes and o thers to enhance 
phys ica l pe rfo rm ance
13. Ligament. A  sho rt band of tough, flex ib le , fib rous connective  tissue that 
co nnec ts  tw o bones or ca rtilages o r holds toge ther a jo in t
14. ACL: A n te rio r c ruc ia te  ligam ent
15. MCL: m edia l co lla te ra l ligam ent
16. PCL: P o ste rio r C ruc ia te  L igam ent
17. LCL: Latera l co lla te ra l ligam ent
18. Tendon A flex ib le  but ine las tic  cord  o f strong fib rous co llagen tissue 
a ttach ing  a m usc le  to  a bone
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SECTIONS 7, 8, 9 AND 10 TO BE FILLED OUT BY CLINICIAN
SECTION 7: ASSESSMENT OF ACHILLES TENDON INJURY BY CLINICIAN
Number (1
Symptoms > 6/12
Early morning pain over the Achilles area
YES
Early morning stiffness over the Achilles 
area
History of swelling over the Achilles area
Tenderness to palpation over the Achilles 
area
Palpable nodular thickening over the 
Achilles tendon
Positive Shift test:
Movement of painful/swollen area with 
DF/PF of ankle
NO
Other comments:
2 3 9
:CT!ON 8: DESCRIPTION OF ACHILLES TENDONTn JURY
Please com p le te  a sepa ra te  fo rm  fo r each  Tendon Injury Event Number;
upture:
ht Left
Full
P artia l 
Inse rtiona l avu ls ion
Tendii
N on -inse rtiona l
Insertiona l:
Peritendon itis
— ■ —-------------------  --------------- _
Tend inosis
P eritendon itis  +
Tend inos is
O ther
Unknown
H ag lund ’s
Latera l C alcaneal 
R idge
In tra-tend inous
ca lc ifica tion
A ch illes  Burs itis  - 
superfic ia l
A ch illes  Bursitis 
-deep
Tend inosis
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w. IMAGING w. n u n iL L c o  itN U O N  INJUR
Please complete a separate form for each Tendon Injury
Location
Event Number:
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a p p e n d i x  IV
Protocols
preplT-L2P
Quick reference guide:
Laboratory protocol for manual purification of DNA from 0.5 m l of sample
1 • Mlx the Mmple ln * *  DNA Genotek kit by inversion and gentle shaking for a few seconds.
2. Incubate the sample at 50'C In a water Incubator for a minimum of 1 hour or In an air Incubator
for a minimum of 2 hours.
3. Transfer 500 pL of the sample to a microcentrifuge tube.
4. Add 20 pL of PT-L2P and mix by vortexlng for a few seconds.
5. Incubate on Ice for 10 minutes.
6. Centrifuge at room temperature (RT) for 5 minutes at 15,000 x g.
7. Carefully transfer the majority of the clear supernatant with a pipette to a fresh microcentrifuge tube.
Discard the pellet
8. Add 600 pL of RT 95% to 100% ethanol to the clear supernatant. Mix gently by Inversion 10 times.
9. Let the sample stand at RT for 10 minutes to allow the DNA to fully precipitate.
10. Place the tube Into the centrifuge with a known orientation. Centrifuge at RT for 2 minutes at 15,000 x g.
11. Carefully pipette off the supernatant and discard It. Take care to avoid disturbing the DNA pellet
12. Add 250 pL of 70% ethanol and let stand at RT for 1 minute. Completely remove the ethanol,
without disturbing the pellet
13. Add 100 pL of TE solution and vortex the sample for at least 5 seconds.
14. Incubate overnight at RT or at 50*C for 1 hour vortexing occasionally.
15. Storage: In aliquots at -20*C for long-term storage (recommended) or at 4°C for up to 2 months.
DNAgenoTeK
wnw<Jn»g*not • iupport#dnag»not*kxom 5W M »b w «U W 0'l««
e  J0> 2 O'M in . • uM rS v y  <* 0#So<« T t c W o jn  •*

Standard curve for the ADAM8 Hs02429708_.cn (FAM) and Reference Assay RNase 
P (VIC). A linear trend  line was fit to the data to determ ine the PCR efficiency for 
each assay, p lotting cycle thresho ld (Ct) against DNA concentration (log 
concentration). E ffic iency (E) was calcu lated using the equation E = 10(' 1/m)- l ,  
where m is the slope of the linear trend line. Assays gave efficiencies of 95% and 
93%, for FAM and VIC  respective ly.
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Standard cu rve  fo r the CASP8 H s02601709_cn (FAM) and Reference Assay RNase 
P (VIC). A linear trend  line was fit to the data to determ ine the PCR efficiency for 
each assay, p lotting cycle thresho ld (Ct) against DNA concentration (log 
concentration). E ffic iency (E) was calcu lated using the equation E = 10(‘ 1/m)- l ,  
where m is the s lope o f the linear trend line. Assays gave efficiencies of 106% and 
104%, for FAM and VIC  respective ly.
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Standard cu rve  for the COL4A1 Hs00739915_cn (FAM) and Reference Assay 
RNase P (VIC). A linear trend line was fit to the data to determ ine the PCR 
efficiency for each assay, p lotting cycle threshold (Ct) against DNA concentration 
(log concentra tion). E ffic iency (E) was calcu lated using the equation E = 10(‘ 1/m)- 
1, where m is the slope of the linear trend line. Assays gave efficiencies of 104% 
and 98% , for FAM and V IC  respective ly.
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Standard curve for the COL4A1 Hs02119212_cn (FAM) and Reference Assay 
RNase P (VIC). A linear trend line was fit to the data to determine the PCR 
efficiency for each assay, plotting cycle threshold (Ct) against DNA concentration 
(log concentration). Efficiency (E) was calculated using the equation E = 10('1/m)- 
1, where m is the slope of the linear trend line. Assays gave efficiencies of 98% 
and 95%, for FAM and VIC respectively.
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Standard curve for the COL5A1 Hs00180523_cn (FAM) and Reference Assay 
RNase P (VIC). A linear trend line was fit to the data to determine the PCR 
efficiency for each assay, plotting cycle threshold (Ct) against DNA concentration 
(log concentration). Efficiency (E) was calculated using the equation E = 10('1/m)- 
1, where m is the slope of the linear trend line. Assays gave efficiencies of 108% 
and 105%, for FAM and VIC respectively.
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Standard curve for the COL5A1 Hs02980647_cn (FAM) and Reference Assay 
RNase P (VIC). A linear trend line was fit to the data to determine the PCR 
efficiency for each assay, plotting cycle threshold (Ct) against DNA concentration 
(log concentration). Efficiency (E) was calculated using the equation E = 10('1/m>- 
1, where m is the slope of the linear trend line. Assays gave efficiencies of 103% 
and 98%, for FAM and VIC respectively.
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33
DNA quantity (log concentration)
Figure V.7 MMP3 Hs02276714_cn
Standard curve for the MMP3 Hs02276714_cn (FAM) and Reference Assay RNase 
P (VIC). A linear trend line was fit to the data to determine the PCR efficiency for 
each assay, plotting cycle threshold (Ct) against DNA concentration (log 
concentration). Efficiency (E) was calculated using the equation E = 10('1/m)- l,  
where m is the slope of the linear trend line. Assays gave efficiencies of 96% and 
106%, for FAM and VIC respectively.
Standard curve for the MMP23B Hs07485808_cn (FAM) and Reference Assay 
RNase P (VIC). A linear trend line was fit to the data to determine the PCR 
efficiency for each assay, plotting cycle threshold (Ct) against DNA concentration 
(log concentration). Efficiency (E) was calculated using the equation E = 10('1/m)- 
1, where m is the slope of the linear trend line. Assays gave efficiencies of 87% 
and 90%, for FAM and VIC respectively.
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Standard curve for the TNC Hs00634176_cn (FAM) and Reference Assay RNase P 
(VIC). A linear trend line was fit to the data to determine the PCR efficiency for 
each assay, plotting cycle threshold (Ct) against DNA concentration (log 
concentration). Efficiency (E) was calculated using the equation E = io (-1/m>-l, 
where m is the slope of the linear trend line. Assays gave efficiencies of 82% and 
78%, for FAM and VIC respectively.
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Standard curve for the TNC Hs06903309_cn (FAM) and Reference Assay RNase P 
(VIC). A linear trend line was fit to the data to determine the PCR efficiency for 
each assay, plotting cycle threshold (Ct) against DNA concentration (log 
concentration). Efficiency (E) was calculated using the equation E = 10('1/m)- l, 
where m is the slope of the linear trend line. Assays gave efficiencies of 100% and 
102%, for FAM and VIC respectively.
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Copy Number Variation in the COL5A1 Gene and the Risk
of Achilles Tendon Pathology
^Ichae! P0^ humus2< Malcolm Collins2,3, Christopher j  Handley*, Jill Cook* and Stuart M Raleigh'
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S  o r ^ u m in lV s a e ^ e s  r,n<i F, h n ^  f  T f ,  f ? ? f ,CeS'  u ™ e r s ,t y  o f  Cape Town, >South African Medical Research Council, Cape Town, South Africa, *School 
o f  Human B iosciences and the M usculoskeletal Research Centre, La Trobe University, Melbourne, Victoria, Australia and »Centre o f Physical Activity and
Nutritional Research , School o f Exerc ise  and Nutrition Sciences, Deakin University
IN T R O D U C T IO N
AcfiU les tendon Patho logy is  a  m u lb facto n a l cond ition  w ith  n u m ero u s identified  n sk  facto rs ( l ) .  
R isk  fa c to rs  include tra in in g  e r ro rs , b io log ical age p rev io u s in ju ry  and g enetic  n s k  fa c to rs  | 2 ) .  
Desp«te being one o f th e  s tro n g e st tend o ns In  th e  h um an  body, th e  A ch illa s  tendon is  p rone to 
dam age and ru p tu re  ( 3 ) .  Fu rth e rm o re , due to  th e  in creased  s t re s s  on tend o ns d unng  physica l 
e xe rc ise , tendon m ju n e s  a re  m ore com m on in  both p ro fessio na l and re crea tio n a l a th le te s  ( 4 ). 
R esearch  to  date h as  a lso  show n a sso c ia tio n s  w ith  s in g le  nucleotide po lym orph ism s (S N P s) w ithin 
genes encoding pro terns w ith  fun ctio n a l ro les in  tend o n  biology ( 2 ) .  In  2 0 0 5 . a  g uan ine-thym ine 
( G T )  rep eat po lym orph ism  m th e  TNC  g ene  w a s  found to  a sso c ia te  w ith  ATP ( 5 ) .  La te r. SN Ps 
w ith in  the cand id ate  g en es C O L S A I , M M P3  and G D F -S  w ere  show n to asso c ia te  w ith  ATP ( 2 ) .  
H ow ever, p red isposition  to ce rta in  d ise a se s  m a y  a lso  be  asso c ia ted  w ith  copy n um b er variation  
(C N V ) 16) .  Copy n u m b er v a n a n ts  (C N V s ) a re  seg m en ts o f DNA g rea te r than  lk b  in  s i t e ,  which 
show  a lte red  copy n um b er w h e n  com pared  to a re fe ren ce  g enom e [ 7 J .  Th ese  stru ctu ra l changes 
can  occur in  d iffe ren t fo rm s , includ ing  in se rt io n s , dup lications and d e le tio ns ( 7 ) .  CN V h a s  ye t to 
be  investig a ted  In  re lation  to ATP, w h ich  is  th e  aim  of th is  study.
M ET H O D S
R e c ru itm e n t
A C au cas ian  population  co n sistin g  of a  So u th  A fn can  ( S A )  co hort ( 1 1 4  c lin ica lly  d iagnosed cases 
o f ATP and 9 6  co n tro ls ) and an A u stra lian  (A U S ) co hort (5 9  d in ic a lly  d iagnosed  ca se s  o f ATP and 
152 co n tro ls ) w e re  re c ru ite d  fo r  th is  case-con tro l g enetic  asso c ia tio n  study. Th e  R esea rch  E th ics  
C o m m ittees o f th e  Facu lty  o f  H ea lth  S c ie n ce s  at th e  U n ive rs ity  o f Cape Town, South  A fr ica , La 
Trobe U n ive rs ity , A u s tra lia , DeaWin U n ive rs ity . A u stra lia  and th e  U n ive rs ity  o f N ortham pton , United 
K ingdom  approved  th is  stu d y . Fo r th e  S A  co ho rt. DNA w a s  extracted  fro m  w hole blood u s in g  the 
procedure d escrib ed  b y  Lah in  and N u rn  berg  (8 )  and m odified by M okone e t a l .  ( 5 ) .  Fo r the 
A ustra lian  co ho rt. DNA w a s  ex tra c te d  fro m  w hole blood using  a  sequence extractio n  technique 
(R e x ig e n e  O N A k i t ,  Q iag en  P / L ,  V a le n c ia . C a lifo rn ia . U S A )  a s  p e r  th e  m a n u fa c tu re r 's  
recom m endations 
CNV selection  and PCR
Catalogued CN Vs w ere  identified  using  th e  D atab ase  o f G enom ic v a r ia n ts  (D G V ) (http // 
p ro jects  tcao  c a / v a n a b o n / ) hosted  b y  T h e  C e n tre  fo r App lied  G eno m ics , Toronto . Applied 
B io s y s te m s1"  f lu o re sc e n c e -b a se d  p re -d e s ig n e d  Taq M an * C opy  N u m b er A s s a y s  (Appl ied  
Ecosystem  s ’ * ,  Fo ste r O ty . C a lifo rn ia , U SA ) w ere  se lected  In  the cand idate gene C O L S A i  using 
T a q M a n *  C o p y  N u m b e r  A s s a y  S e a r c h  t o o l  ( A p p l i e d  B i o s y s t e m s ™ )  ( h t t o s  //  
&iQinf9 ,ap p i.ed b io SY < tem » .co m yq en p m e-d atab ase /C b P yn u m P er-yan a t.o n  h tm j )  S e e  F ig u re  1. 
PCR w as perfo rm ed  using  a  S tep O n eP lu s**  R ea l-T im e PC R  S yste m  (A pp lied  Eco system s’**). Each 
sam ple  w as run  in  q uad ru p lica te , co nta in ing  TaqM an* Copy N um ber A ss a y  and R eference  A ssay  
RN ase P, a lo ngside  n e g a tive  co n tro ls . Copy n um b ers w e re  ca lcu la ted  using  C o p yC a lle r*  So ftw are  
version  2 .0  (Applied  B *o system sTH) .  S e e  F ig u re  2 R esu lts  w e re  accepted  w ith  ca lling  confidence 
> 8 0 % .
S t a t is t ic a l  a n a ly s e s
D ata  w ere  an a lysed  u s in g  S P S S  v e rs io n  1 7 .0  (S P S S  S c ien ce  Inc .  C h icag o , IL ) .  A  ch i-squared  ( x a)
a n a ly s is  w as  used  to  d eterm ine a n y  s ig n ifican t d iffe ren ces in copy n um b er freq uencies In  ca se s
and contro ls ( P < 0 .0 S ) .
n ca ii a i J c n r l ft
GENES
ASSArs
’TTT7T * ^TTTTTTT TT TT T
G E N E  S T R U C T U R E
------------------ M
T T T T TT T T TTT
DGV3
F ig u re  1 . M s00180523_oi and Hs02980647 TtqMan* Copy Number Assays identified using TaqMan* 
Copy Number A ssay Search tool. Assays selected within eaons of the COLSAI gene In regions with 
reported CNV from the DGV7
LA T R O B E
■ K T n T v T r S  I  T  Y
A U S T R A L I A
R E S U L T S
Table 1 . General chan ctenstics of th# SA and AUS controls (CON) and ATP cases (ATP).
SA CON 
<"■96)
SA ATP
( " ■ 1 1 4 )
Age ( y e a n )  
G end er (%  male) 
W eight (kg) 
H e ight (cm )
B M I (kg/m 1)
37.1 *  10.0 (91 )  40 .2  *  12.3 (107) 
66.3 (9S) 7 3 .0 (1 1 1 )
175.4 *  9 .7  (93 )  175.9 *  8 .7  (103) 
72 .0  *  12.3 (95 )  80 .8  *  14.9 (106) 
23.3 *  2 8 (93) 26 0 *  3 9 (103)
AUS CON 
( w l S 2 )
38 5 *  11 .9  (149) 
39 .7 (151 )  
171.7 *  9.3 (150)
AUS ATP
( " ■ 5 9 )
40.3 *  14.1 (SB) 
67 8 (59)
173 8 *  9 .5 ( 5 7 )  
73 .3  *  13.9 (151 )  80 4 *  15.0 (59)
24 8 *  4 .0  (150) 26 6 *  4.1 (57)
Values arc means *  SO or frequency (% ) .  CON ege is  ege of recruitments, ATP age Is age of Initial Injury.
i  i IHiti!i , I  . ft
. . I ! ! ! ! 1i fititimiiH h u ht H H f  f I l f l t f H M t  l | |
F ig u re  2 .  Typical profile of copy number estimation in CopyCaller* Softwar# version 2 .0 (Applied 
Biosystem s**) In South A/ncan controls and ATP cases «
Table 2 . CO LSA I Copy number (CN) frequences in SA and AUS controls and ATP cases
Ht00180523.cn <2 CN ■ 2 CN >2 CN N P  value
SA CON 1 90 0 91
ATP 0 108 1 109 0.362
AUS CON 2 81 3 e6 1 •  R
ATP 0 50 0 so 0.221
SA A AUS CON 3 171 3 177 •
ATP 0 1S8 1 159 0.169
D IS C U S S IO N
T h is  IS the f irs t  Study to Investigate  the re lationsh ip  betw een CN V in  the C O LS A i gene and the 
r is k  o f ATP. R esu lts  ind icate  no association  betw een CN In  ATP ca se s  or contro ls. Th ere  w as no 
s ign ifican t d iffe ren ce  in  CN betw een CON and ATP. w ith  P  va lu es o f 0 .3 6 2  and 0 .2 2 1  in  SA  and 
A U S  re sp e ctive ly  Th e  com bined C au sasian  population also showed no sign ificant d ifference In CN 
in  CON and ATP ( P  -  0 .1 6 9 ) .  W h ilst th e  C O LS A i gene h as  know n SN P and CN V reg ions, stud ies 
to date  h ave  on ly show n asso cia tio ns w ith  SN Ps and th e  n sk  o f ATP ( 2 ) .  Th e  Investigation  of CNV 
and the n sk  fo r ATP is  a  new  area  of re se a rch . Fu rth e r ad van ces m a y  revea l asso cia tio ns In the 
fu tu re , a id ing the understand ing  o f th e  genetic b as is  to ATP. O u r stud ies a re  now  extend ing to a 
second  CNV region w ith in  the C O LS A I gene  (H s 0 2 9 8 0 6 4 7 _ c n ) .  S e e  F igu re  1.
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Variation within the CASP3 gene and the risk of 
Achilles tendinopathy in a British case-control cohort
Rg.becca Rickaby1, Louis El Khoury1, William J Ribbans1 and Stuart M Raleigh1
The Centre for Physical Activity and Chronic Disease, The Institute o f Health and Wellbeing, University o f Northampton, Northampton, UK
1. In t ro d u c t io n
AcM Ilcs tendon pathology (A T P ) is  a  degenerative  condition w ith  known 
fa c to r*1. E x c e s s iv e  ten o cyte  apoptosis has been  o b served  In  tend .r
3 . R esu lts
Table l a .  Genotype and a lle le  frequency d istribution o f CA SP3  r s l0 4 9 2 5 3  within 
(A TP/IN S/N O N ) and contro ls (C O N ).
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F ig u re  1 . S ch e m a tic  im age of C hrom osom e 4 show ing  the  location , s ize  and exonlc 
s tru ctu re  o f the  C A SP 3  g en e , along w ith  the  location o f C A SP 3  r s l0 4 9 2 5 3  C /T  In  the  3'- 
U TR  o f the  gene (C h r .4 :1 8 5 5 4 8 9 5 1 ).
2. M ethods
We recru ited  261 (1 3 0  ATP cases and 131 asym p to m atic  co n tro ls ) B ritish  C aucasian  
p artic ipan ts fo r th is  genetic associa tion  stu d y  ATP ca se s  w e re  d ln ica lly  d iagnosed with 
in sertio na l tend inopathy ( IN S ) , nonm sertional tend inopathy (N O N ), A ch illes tendon 
rupture  o r m ixed  pathology W ritten  Inform ed consent w a s  obtained and all partic ipants 
com pleted a  p h ys ica l activ ity /m ed ica l h is to ry / in ju ry  q uestio nnaire  The  stu d y  w as 
approved b y  the  R esea rch  E th ics  C om m ittee  o f the  U n ive rs ity  o f N ortham pton, U K . DNA 
w a s e x tra cted  from  2  m l  o f sa liva  co llected  using O RAG EN E-D N A co llection  kits 
(O G -5 0 0 ) and DNA purification  w as ca rried  out using  the  p rep IT-L2P  DNA extraction  kit 
(DNA G enotek In c ., O n tario , C a n a d a ).
TaqMan a s sa y  technology w a s used  to genotype all p a rtic ip an ts using  rea l-tim e PCR, 
w ith  10 ng o f  DNA and positive  and neg ative  contro ls Included in each  PCR run . The 
TaqMan G enotyp ing  A ssa y  conta ined  FAM and V IC  repo rte r dye labelled  probes, with 
ROX dye as  the  p ass ive  re fe ren ce  G enotypes w e re  au to m atica lly  ca lled  using StepO ne 
S o ftw a re , ve rs io n  2 .1  (A pp lied  B io syste m s, Fo ster Q ty , C a lifo rn ia , U SA ) (F ig u re  2 ) .
D ata w e re  an a lysed  using  IBM  S P S S  S ta t is t ic s , ve rs io n  20  (IB M  C o rp . A rm o nk , N Y). A 
Pearson 's ch i-squared  (X J )  or F ish e r's  exact test w a s u sed  to a n a ly se  d iffe ren ces In 
genotype and a lle le  freq u en cies fo r th e  r s l 0 4 9 2 5 3  v a n a n t. We com pared the  co llective  
ATP group ag a in st contro ls We a lso  conducted su b -an a lyses  for the  d ifferent typ es of 
tendinopathy. Rupture  and m ixed  patho logy cases w e re  exc luded  from  su b -an a lyses . 
Hardy-W einberg equ ilib rium  (H W E) w a s e stab lish ed  and p  < 0 0 5  w as considered  to be 
a  deviation  from  HWE
• Blue
Red
CASP3 
r t  1 0 4 9 2 S 3
CON
n -1 3 1
ATP
n « 1 3 0
IN S
n«*29
NON
n=47
TT
C T
CC
p-va lu e
6 2 .6  (82 )  
34 4 ( 4 5 )  
3 1 (4 )
61 .5  (8 0 ) 
33 .1 (4 3 )  
5 .4  (7 )  
0 .643
72 4 (2 1 )  
2 0 . 7 ( 6 )  
6  9 ( 2 )  
0 .218
55 .3  (2 6 )
38 .3  (1 8 )  
6  4 ( 3 )
0  456
MAF
p-va lu e
20 .2  (5 3 ) 2 1 .9  (5 7 )  
0  635
1 7 . 2 ( 1 0 )  
0 60S
25 .5  (2 4 )  
0 .284
HWE 0.461 0  700 0 .139 0.961
Table  l b .  Genotype and a lle le  frequency d istribution o f C A SP 3  r s l 0 4 9 2 5 3  w ithin m ale 
cases (A TP/IN S/N O N ) and m ale contro ls (C O N ).
CASP3
r * 1 0 4 9 2 5 3
Male CON
n * 8 2
Male ATP
n = 80
Male IN S
n = l S
Male NON
n « 2 7
TT
CT
CC
p-va lu e
68 3 ( 5 6 )  
30 .5  (2 5 ) 
1 2 ( 1 )
58 8 (4 7 )  
32 .5  (2 6 )  
8 8 ( 7 )  
0 .072
73 .3  (1 1 )  
1 3 . 3 ( 2 )  
1 3 . 3 ( 2 )  
0 . 0 3 6
5 5 .6  (15 )  
3 3 . 3 ( 9 )  
1 1 1 ( 3 )  
0 .0 6 4
MAF
p-va lu e
16 .5  (2 7 ) 2 5 .0  (4 0 )  
0 .0 5 8
20  0 (6 )  
0 .976
2 7 .8  (15 )  
0 .219
HWE 0 .326 0 .233 0 .0 2 4 0 .379
Values a re  exp ressed  as  a frequency (% )  w ith  num ber o f p artic ipan ts (n )  In 
p a ren th esis . M inor a lle le  frequency (M AF)  and Hardy-W einberg equilibrium  (H W E )  are 
show n.
4 . D iscuss ion
We found no sign ifican t d ifference In genotype (p  = 0  6 4 3 )  or a lle le  (p  ** 0 .6 3 5 )  
frequencies between the  ATP group and contro ls (Tab le  l a ) .  How ever, w e did find a 
genotyp ic association (p  *= 0 .0 3 6 )  between m ale in sertio na l tendinopathy ca se s  ( IN S )  
and m ale contro ls (C O N ) (T a b le  l b ) .  Sp ecifica lly , the  CC  genotype appeared to 
In crease  the  r isk  o f Insertional tendinopathy In m ales ( p »  0  0 4 5 ,  OR = 12 .46 ,  9 5 %  C l  
1 0 5 -1 4 7  4 6 ) .  Fu rth erm o re , C A SP 3  r s l 0 4 9 2 5 3  w a s not In HWE In the  m ale IN S  group 
(p  = 0 .0 2 4 ) .  Th ere  w ere  no sign ificant d ifferences betw een m ale ATP/NON and CON, 
nor w ith  fem ale  ATP/INS/NON and fem ale CON (d a ta  not sh o w n ). It it im portant that 
these  data  a re  v iew ed  w ith  caution due to  th e  re la tive ly  sm all sam p le  s ize , which m ight 
a lso  exp la in  the  deviation from  HW E observed  In  the  m ale IN S  group. Therefo re  
rep lication  in  a larger cohort would be n ecessa ry  to  in crease  confidence
O ur p re lim in ary  data  In fe r a  possib le ro le  fo r the r s l 049253  va rian t as  a r isk  factor for 
insertional tend inopathy In B ritish  m ales . A lthough additional research  is  needed, these  
re su lts  could fu rth e r Im p licate  the  Involvem ent o f the  apoptosis pathw ay In  the 
developm ent o f ATP and could Ju stify  the  inclusion o f th is va rian t In a r isk  assessm en t 
model for ATP. S u ch  m odels alone w ill not predict or d iagnose ATP, due to the 
m u ltifactona l n a tu re  o f th is  condition . N everthe less , in  com bination with the  alteration 
o f m odifiab le r isk  facto rs such  as  tra in ing , could hold potentia l In  lowering the  risk  of 
In ju ry '.
5 . A ck n o w le d g e m e n ts
T h is  re sea rch  w as supported  by a  g ran t to D r S tu a rt  M. Ra le igh  from  th e  R osetrees T rust and 
Th e  U n ive rs ity  o f N ortham pton . Th e  authors w ould  like to th an k  P ro fesso r M alcolm C o llin s and 
D r Mike Posthum us a t th e  U n ive rs ity  o f Cape Tow n's UCT/M RC R esearch  U n it fo r Exe rc ise  
Sc ience  and Sport M ediane for d iscussions concern ing th e  questionnaire  d esig n . Authors 
S .M .R .  and W .J .R .  h ave  filed  patents on the application of sp ecific  sequence va ria tio ns related 
to nsk a sse ssm e n t of A ch ille s tend inopathy and an terio r c ru c ia te  ligam ent in ju rie s  Attendance 
a t F E B S  EM BP P a n s  2 0 U  w as supported  b y  a  general tra ve l g ran t from  the B iochem ical Society 
to R .R .
6 . R e fe re n ce s
F ig u r e  2 .  Typ ical a lle lic  d iscrim inatio n  plot fo r C A SP 3  r s l0 4 9 2 5 3 .
1 C o lr a  M  R«lr<gfc CM ? « *  G *n * t* . tn k  U O o r* l a  " w w t a t t l iU i  w *  U 
S 4  I M - l « «
3 N « flE 4 * . v M U m I ,  Co o *  J . * • /  2012 T>» a iw p ta **  and
)  M a v r in a  M O  7000 T h «  c i «p cf*> M  N a n **  *07 71W
4 G u r X . U i Z l N H . K * 7013 A liw b o n a l < » ru ri i t  lh a m P 6 6 V ' p tandr>g • * •  o l C A 5 P  J  a W # r*  m fc d  t*»e« r>4mi 
M cond ltw rm r, m * l^ 'w u * i In p a to n ti * O i h m d  and ««cX  c a n c a  F A S C B  Jo a n a l. 27 1404-1412
5  S a p M rro a A V . P o MAu t t m  M C ottna M 7012 A p p lca u jn o f g m m a m * * • pcwartfcM V H aM m ar* and m ana^a-nani o l
A cM te i <androc«t*>y and a r f a r o  o w cu M  Ig a m a *  ru p fisa t R acan * P a fartf* o n  O N A&  G m  6  210-223
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